



## Supporting Information

### **Biosynthesis of Nodulisporic Acids: A Multifunctional Monooxygenase Delivers a Complex and Highly Branched Array**

*A. T. Richardson, R. C. Cameron, L. J. Stevenson, A. J. Singh, Y. Lukito, D. Berry, M. J. Nicholson\*, E. J. Parker\**

## SUPPORTING INFORMATION

## Table of Contents

<b>Table of Contents</b> .....	<b>2</b>
<b>General</b> .....	<b>4</b>
<b>Molecular Biology and Fungal Work</b> .....	<b>5</b>
Table S1: Fungal transformant list .....	6
Table S2: Components of DNA constructs used in this study .....	7
<b>Sequences</b> .....	<b>9</b>
Promoters used in this study .....	9
Coding sequences used in this study (gDNA) .....	11
Genes used in this study (cDNA) .....	16
Terminators used in this study .....	20
<b>LC-MS Analysis of Fungal Transformants</b> .....	<b>22</b>
<b>Identification of Nodulisporic Acids by Tandem Mass Spectrometry</b> .....	<b>43</b>
Figure S1. Proposed fragmentation of nodulisporic acids, NAD <sub>4</sub> and NAD <sub>4</sub> -OMe .....	43
Table S3: HR-ESI-MS <sup>2</sup> analysis of nodulisporic acids .....	45
<b>Isolation of Nodulisporic Acids</b> .....	<b>66</b>
Isolation of NAD <sub>4</sub> .....	67
Table S4. NMR Data for NAD <sub>4</sub> and NAD <sub>4</sub> -OMe, CDCl <sub>3</sub> .....	68
Isolation of NAD & NAD <sub>1</sub> .....	69
Table S5: NMR Data for NAD, CDCl <sub>3</sub> .....	70
Table S6: NMR Data for NAD <sub>1</sub> , CDCl <sub>3</sub> .....	71
Isolation of NAD <sub>2</sub> .....	72
Table S7: NMR Data for 18-23 alkene-NAD <sub>2</sub> , CDCl <sub>3</sub> .....	73
Isolation of DH-NAA <sub>4</sub> & DH-NAC <sub>4</sub> .....	74
Table S8: NMR Data for DH-NAA <sub>4</sub> , CDCl <sub>3</sub> .....	75
Table S9: NMR Data of DH-NAC <sub>4</sub> , CDCl <sub>3</sub> .....	76
Isolation of NAC .....	77
Table S10. NMR Data for NAC, CDCl <sub>3</sub> .....	78
Isolation of NAB <sub>4</sub> .....	79
Table S11: NMR Data for NAB <sub>4</sub> and its 2'-epimer, CDCl <sub>3</sub> .....	79
Isolation of NAA <sub>1</sub> and NAB .....	80
Table S12: NMR Data for NAA <sub>1</sub> , CD <sub>3</sub> OD .....	81
Table S13: NMR Data for NAB, CDCl <sub>3</sub> .....	82
Isolation of NAD <sub>6</sub> .....	83
Table S14: NMR Data for NAD <sub>6</sub> , (CD <sub>3</sub> ) <sub>2</sub> CO .....	84
Isolation of NAD <sub>5</sub> .....	85
Table S15: NMR Data for NAD <sub>5</sub> , (CD <sub>3</sub> ) <sub>2</sub> CO .....	86
<b>NMR Spectra</b> .....	<b>87</b>
NAD NMR Spectra .....	87
NAD <sub>1</sub> NMR Spectra .....	91

## SUPPORTING INFORMATION

NAD <sub>4</sub> NMR Spectra.....	96
NAD <sub>4</sub> -OMe NMR Spectra.....	102
NAD <sub>2</sub> NMR Spectra.....	107
NAC NMR Spectra.....	111
DH-NAC <sub>4</sub> NMR Spectra.....	115
NAB <sub>4</sub> NMR Spectra.....	119
DH-NAA <sub>4</sub> NMR Spectra.....	122
NAA <sub>1</sub> NMR Spectra.....	126
NAB NMR Spectra.....	131
NAD <sub>6</sub> NMR Spectra.....	135
NAD <sub>5</sub> NMR Spectra.....	139
<b><i>In Vivo</i> Feeding Studies.....</b>	<b>143</b>
Table S16. NodJ <i>in vivo</i> feeding studies.....	143
Figure S58. LC-MS analysis of <i>in vivo</i> feeding studies.....	144
Figure S59. NAD <sub>5/1</sub> feeding study.....	145
Non-enzymatic NAD <sub>6</sub> elimination.....	145
<b>Proposed NodJ P450 Monooxygenase Bifurcation Mechanism.....</b>	<b>146</b>
Figure S60. Proposed mechanism for NodJ.....	146
<b>Phylogenetic Classification of NodX.....</b>	<b>147</b>
Figure S61. Phylogenetic classification of NodX.....	147
<b>Nodulisporic Acid Biosynthesis Scheme.....</b>	<b>148</b>
Figure S62. Nodulisporic acid biosynthesis.....	148
<b>Author Contributions.....</b>	<b>149</b>
<b>References.....</b>	<b>149</b>

## SUPPORTING INFORMATION

**General**

**NMR spectroscopy** was conducted on a JEOL JNM-ECZ600R with a nitrogen cooled 5 mm SuperCOOL cryogenic probe (600 MHz for  $^1\text{H}$  nuclei and 150 MHz for  $^{13}\text{C}$  nuclei). The residual solvent peak was used as an internal reference for  $^1\text{H}$  [ $\delta_{\text{H}}$  3.31,  $\text{CD}_3\text{OD}$ ; 7.26,  $\text{CDCl}_3$ ; 2.05,  $(\text{CD}_3)_2\text{CO}$ ] and  $^{13}\text{C}$  [ $\delta_{\text{C}}$  49.00,  $\text{CD}_3\text{OD}$ ; 77.16,  $\text{CDCl}_3$ ; 29.84,  $(\text{CD}_3)_2\text{CO}$ ] chemical shifts.

**Flash chromatography** was carried out on a Buchi Reveleris X2 using Buchi FlashPure 20  $\mu\text{m}$  silica cartridges and a  $\text{CHCl}_3$ : MeOH gradient (1–100%).

**Semi-preparative HPLC** was carried out on an Agilent 1260 Infinity II HPLC system with DAD. In all cases the mobile phase was A:  $\text{H}_2\text{O}$ , B: MeCN both containing 0.1% formic acid. Purification was achieved using either a Phenomenex Luna C18 250  $\times$  10 mm 100  $\text{\AA}$  5  $\mu\text{m}$  column (column #1), or an Agilent Zorbax SB-C18 50  $\times$  9.4 mm 5  $\mu\text{m}$  column (column #2).

**Preparative HPLC** was performed on an Agilent 1260 Infinity II Preparative HPLC system, equipped with multi-wavelength and evaporative light-scattering detection, using A:  $\text{H}_2\text{O}$  and B: MeCN as the mobile phases both containing 0.1% formic acid. Purification was performed using Column #1 (see above).

**Reversed-Phase Prefractionation** HP-20 poly(styrene-divinylbenzene) (Supelco, Sigma) was used for metabolite capture and reversed-phase pre-fractionation. Acetone and MeOH were analytical grade or higher.  $\text{H}_2\text{O}$  was purified by reverse osmosis. Solvent compositions are reported as % v/v unless otherwise stated.

**Thin-Layer Chromatography (TLC)** was carried out using Merck KGaA Silicagel 60 F<sub>254</sub> plates and a mobile phase of  $\text{CHCl}_3$ :MeOH (9:1). Indole diterpenes were identified by staining with Ehrlich's reagent (*p*-dimethylaminobenzaldehyde).

**Liquid Chromatography-Mass Spectrometry (LC-MS)** was completed on an Agilent 1260 Infinity II LC-MS system with DAD and electrospray ionisation. A Phenomenex C18 Kinetex column (2.6  $\mu\text{m}$ , 100  $\text{\AA}$ , 50  $\times$  2.1 mm) equipped with a Phenomenex C18 guard cartridge and maintained at 40  $^\circ\text{C}$  was eluted with a mobile phase of A:  $\text{H}_2\text{O}$  and B: MeCN, both containing 0.1% formic acid. An injection volume of 10  $\mu\text{L}$  and flow rate of 0.4 mL/min were used. The gradient was as follows: 0–1 min 40% B, 1–5 min 40–60% B, 5–24 min 60–90% B, 24–25 min 90–100% B, 25–27 min 100% B.

**High-resolution mass spectrometric data and MS/MS spectra** were obtained with an Agilent 6530 Accurate Mass Q-TOF fitted with an electrospray ion source and equipped with an Agilent 1260 Infinity II LC system. Chromatography was carried out using an Agilent Accucore C18 2.0  $\mu\text{m}$  50  $\times$  2.1 mm column eluted with a mobile phase of A:  $\text{H}_2\text{O}$  and B: MeCN, both containing 0.1% formic acid. The flow rate was 0.3 mL/min and injection volume 5  $\mu\text{L}$ . The gradient used was as follows: 0–1 min 40% B, 1–30 min 40–100% B, 30–35 min 100% B. The mass spec parameters used were: positive ion mode, mass range 100–1000 Da, acquisition rate 2 scans/s, capillary temperature 300  $^\circ\text{C}$ , capillary voltage 3500 V, fragmentor voltage 175 V, drying gas flow 8 L/min, sheath gas temp 350  $^\circ\text{C}$ , sheath gas flow 11 L/min, and a nebulizer pressure of 35 psi. MS/MS data were acquired for selected masses using CID with an isolation width of  $M$  1.6 and collision energy of 30 eV.

## SUPPORTING INFORMATION

## Molecular Biology and Fungal Work

The following protocols were completed as described in van Dolleweerd *et al* 2018.<sup>[1]</sup>

- Molecular biology.
- Bacterial and fungal strains.
- Construction of DNA constructs using the MIDAS cloning system.
- Protocols for MIDAS Level-1 module cloning.
- Protocols for MIDAS Level-2 TU assembly.
- Protocols for MIDAS Level-3 multigene assembly.
- Media and reagents used for fungal work.
- Fungal Protocols – Protoplast Preparation.
- Fungal Protocols – Transformation of *P. paxilli*.

**Synthetic DNA MIDAS Level-1 constructs.** MIDAS Level-1 plasmids containing cDNA versions of NOD genes were synthesised, cloned into MIDAS Level-1 vector pML1, and sequence verified by Twist Biosciences.

**Indole diterpene production and extraction.** Fungal transformants were grown in 25 mL of CDYE medium (recipe below) with trace elements (recipe below) for 7 days at 28 °C in shaker cultures ( $\geq 200$  rpm), in 125 mL Erlenmeyer flasks capped with cotton wool. Mycelia were isolated from fermentation broths by filtration. IDTs were extracted from an 850 mg sample of mycelia via homogenisation with 500  $\mu$ L EtOAc in a bead beating apparatus (MPBio FastPrep24 5G bead beater grinder and lysis system, 40 s, 6m/s). The extract was recovered by centrifuging the homogenised sample at 17,000 rcf for 10 minutes and solvent removed in vacuo using a speedvac (Labconco Centrivap DNA concentrator). Extracts were resuspended in MeCN (150  $\mu$ L), filtered using 0.2  $\mu$ m syringe filters prior to LC-MS analysis

**Large scale fungal growths.** Fungal transformants were grown in a YEPGA starter culture (25 mL media in a 125 mL Erlenmeyer flask) for 15 h and subsequently used to inoculate (4% v/v) CDYE production cultures (400 mL media in a 2 L Erlenmeyer flask) which were grown for 7 days at 28 °C in shaker cultures ( $\geq 200$  rpm). Mycelia was isolated from the fermentation broths by vacuum filtration.

**CDYE media** with trace elements prepared as follows: Czapek dox (34 g/L, Oxoid, CM0095), yeast extract (5 g/L, Oxoid LP0021) and trace elements (5 mL/L).

**Trace elements** prepared as follows: FeSO<sub>4</sub>·7H<sub>2</sub>O (1.7 mM), ZnSO<sub>4</sub>·7H<sub>2</sub>O (1.73 mM), MnSO<sub>4</sub>·H<sub>2</sub>O (0.59 mM), CuSO<sub>4</sub>·5H<sub>2</sub>O (0.2 mM), CoCl<sub>2</sub>·6H<sub>2</sub>O (0.17 mM), HCl (0.8 M).

**YEPGA media** prepared as follows: Yeast extract (10 g/L, Oxoid LP0021), mycological peptone (20 g/L, Oxoid LP0040), glucose (20 g/L, Sigma Aldrich G8270), Agar (4 g/L, Invitrogen 30391-023), trace elements (20 mL/L), and adjusted to pH 6.0 using NaOH.

**RNAseq Methodology.** Crushed mycelial discs taken from colonies of *H. pulicidum* strain MF5954 (ATCC 74245) grown on YM agar (3 g/L yeast extract (Oxoid), 3 g/L malt extract, 10 g/L dextrose, 5 g/L peptone, 20 g/L agar) were used to inoculate a seed culture in a 250 mL Erlenmeyer flask containing 50 mL SL3 medium (50 g/L glucose, 10 g/L L-glutamic acid monosodium salt, 2 g/L Amicase® casein acid hydrolysate (Sigma), 3 g/L NH<sub>4</sub>Cl, 1 g/L K<sub>2</sub>HPO<sub>4</sub>, 2 g/L lactic acid, 20 g/L 2-(N-morpholino)ethanesulfonic acid, 0.5 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 1 g/L CaCO<sub>3</sub>, and 20 mL/L of a 50 $\times$  trace element solution (40 mg/L CoCl<sub>2</sub>·6H<sub>2</sub>O, 50 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O, 500 mg/L FeSO<sub>4</sub>·7H<sub>2</sub>O, 100 mg/L MnSO<sub>4</sub>·H<sub>2</sub>O, 500 mg/L ZnSO<sub>4</sub>·7H<sub>2</sub>O)). The seed culture was grown in total darkness on an orbital shaker at 220 RPM for 2 days at 29°C, then a 2 mL aliquot was used to inoculate a 250 mL Erlenmeyer flask containing 50 mL of LSFM medium (18.7 g/L glycerol, 40 g/L glucose, 5 g/L yeast autolysate (Sigma), 2 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 5 g/L soybean meal, 5 g/L tomato paste, 2 g/L sodium citrate, pH adjusted to 7.0) or FFL medium (70 g/L glucose, 100 g/L glycerol, 3 g/L NH<sub>4</sub>Cl, 10 g/L L-glutamic acid monosodium salt, 8 g/L Amicase® casein acid hydrolysate (Sigma), 0.7 g/L L-tryptophan, 1 g/L K<sub>2</sub>HPO<sub>4</sub>, 1 g/L CaCO<sub>3</sub>, 0.5 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 20 g/L 2-(N-morpholino)ethanesulfonic acid, 5 mL of 85% lactic acid solution, 20 mL of 50 $\times$  trace element solution, pH to 6.8). LSFM and FFL cultures were grown in total darkness on an orbital shaker at 220 RPM for 15 days at 29°C. *H. pulicidum* cultures were strained through cloth, isolated mycelia were placed in RNeasy® (Sigma-Aldrich), and samples were stored at -80°C. Total RNA was extracted from approximately 100 mg mycelia per sample using the RNeasy Plant Mini Kit (Qiagen), including the optional RLC buffer and on-column digestion with RNase-free DNase (Qiagen), as per the manufacturer's instructions. Sample RNA integrity was confirmed by analysis on a LabChip® GX Touch HT Nucleic

## SUPPORTING INFORMATION

Acid Analyzer (PerkinElmer). RNA samples were sent to Novogene (Singapore) for poly-A enriched cDNA library preparation using the NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (New England Biolabs) and 150 bp paired-end sequencing using a HiSeq X instrument (Illumina). Sequencing data generated for this project was submitted to NCBI and is available under Bioproject PRJNA770096. RNAseq reads were aligned to the *H. pulicidum* NOD cluster sequence (GenBank accession MG182145.1) using the Geneious mRNA mapper (Geneious R11.1, Biomatters, Auckland, New Zealand). These alignments identified errors in the originally-published<sup>[2]</sup> coding sequences for genes *nodD2*, *nodR*, *nodY1*, *nodY2*, and *nodZ*. Our RNAseq-verified coding sequences of all NOD genes are included below (pg 11-20), and have also been updated on GenBank.

Table S1: Fungal transformant list

Code*	IDT Genes	<i>P. paxilli</i> base strain	Genomic context	Plasmid one	Plasmid two
<i>Assignment of the 4-Series</i>					
RC63-5	G,C,M,B,W + D1	CY2 (ΔPAX)	-	pSK81 ( <i>paxG, nodM,B,C,W</i> )	pRC63 ( <i>nodD1</i> )
RC121-3 (Ia)	G,C,M,B,W,D1 + O	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	-
RC128-1 (IIa)	G,C,M,B,W,D1,O + D2	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pRC128 ( <i>nodD2</i> )
RC166-8 (IIIa)	G,C,M,B,W,D1,O, D2 + R	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pRC166 ( <i>nodD2,R</i> )
RC167-8 (IVa)	G,C,M,B,W,D1,O, D2,R + Z	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pRC167 ( <i>nodD2,R,Z</i> )
LS201-3 (Ib)	G,C,M,B,W,D1,O + Y2	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pLS201 ( <i>nodY2</i> )
LS202-9 (IIb)	G,C,M,B,W,D1,O, D2 + Y2	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pLS202 ( <i>nodD2, Y2</i> )
LS203-8 (IIIb)	G,C,M,B,W,D1,O, D2,R + Y2	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pLS203 ( <i>nodD2,R, Y2</i> )
RC173-5 (IVb)	G,C,M,B,W,D1,O, D2,R,Z + Y2	CY2 (ΔPAX)	-	pRC121 ( <i>paxG,nodM,B,C,W,D1,O</i> )	pRC173 ( <i>nodD2,R,Z, Y2</i> )
<i>Assignment of NodJ function</i>					
LS148-7 (V)	G,C,M,B,W,D1,O + J	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS148 ( <i>nodM,W,D1,O,J</i> )	-
LS146-1 (VI)	G,C,M,B,W,D1,O, D2,R,Z, Y2 + J	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS133 ( <i>nodM,W,D1,O</i> )	pLS146 ( <i>nodD2,R,Z, Y2,J</i> )
<i>Assignment of NodX function</i>					
LS196-4	G,C,M,B,W,D1,O + X	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS196 ( <i>nodM,W,D1,O,X</i> )	-
LS170-3 (VII)	G,C,M,B,W,D1,O, J + X	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS170 ( <i>nodM,W,D1,O,J,X</i> )	-
LS197-3	G,C,M,B,W,D1,O, D2,R,Z, Y2 + X	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS133 ( <i>nodM,W,D1,O</i> )	pLS197 ( <i>nodD2,R,Z, Y2,X</i> )
LS147-3 (VIII)	G,C,M,B,W,D1,O, D2,R,Z, Y2,J + X	PN2257 (Δ <i>paxM</i> )	<i>paxG,C,B</i>	pLS133 ( <i>nodM,W,D1,O</i> )	pLS147 ( <i>nodD2,R,Z, Y2,J,X</i> )
<i>In vivo feeding studies</i>					
LS29-1	J	CY2 (ΔPAX)	-	pLS29	-

\*Numeral in brackets refers to the trace number used to identify this transformant in Figure 3 of the manuscript.

## SUPPORTING INFORMATION

**Table S2:** Components of DNA constructs used in this study

Code	Promoter	Gene	gDNA/cDNA	Original MIDAS level 1 plasmid	Terminator
RC63	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
RC63	<i>P<sub>janD</sub></i>	<i>nodD1</i>	gDNA	pRC25	<i>T<sub>paxP</sub></i>
RC121	<i>P<sub>trpC</sub></i>	<i>neoR</i>	gDNA	pSK16	<i>T<sub>trpC</sub></i>
RC121	<i>P<sub>paxG</sub></i>	<i>paxG</i>	gDNA	pSK2	<i>T<sub>paxG</sub></i>
RC121	<i>P<sub>paxM</sub></i>	<i>nodM</i>	gDNA	pSK18	<i>T<sub>paxM</sub></i>
RC121	<i>P<sub>paxB</sub></i>	<i>nodB</i>	gDNA	pSK19	<i>T<sub>paxB</sub></i>
RC121	<i>P<sub>paxC</sub></i>	<i>nodC</i>	gDNA	pSK20	<i>T<sub>paxC</sub></i>
RC121	<i>P<sub>janD</sub></i>	<i>nodW</i>	gDNA	pKV45	<i>T<sub>trpC</sub></i>
RC121	<i>P<sub>janO</sub></i>	<i>nodD1</i>	gDNA	pRC25	<i>T<sub>paxB</sub></i>
RC121	<i>P<sub>janD</sub></i>	<i>nodO</i>	gDNA	pSK42	<i>T<sub>paxP</sub></i>
RC128	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
RC128	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
RC166	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
RC166	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
RC166	<i>P<sub>janO</sub></i>	<i>nodR</i>	gDNA	pKV58	<i>T<sub>paxG</sub></i>
RC167	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
RC167	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
RC167	<i>P<sub>janO</sub></i>	<i>nodR</i>	gDNA	pKV58	<i>T<sub>paxG</sub></i>
RC167	<i>P<sub>janO</sub></i>	<i>nodZ</i>	gDNA	pRC156	<i>T<sub>paxG</sub></i>
RC173	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
RC173	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
RC173	<i>P<sub>janO</sub></i>	<i>nodR</i>	gDNA	pKV58	<i>T<sub>paxG</sub></i>
RC173	<i>P<sub>janO</sub></i>	<i>nodZ</i>	gDNA	pRC156	<i>T<sub>paxG</sub></i>
RC173	<i>P<sub>janO</sub></i>	<i>nodY2</i>	gDNA	pKV49	<i>T<sub>paxG</sub></i>
LS201	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
LS201	<i>P<sub>janP</sub></i>	<i>nodY2</i>	cDNA	pLS58	<i>T<sub>paxP</sub></i>
LS202	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
LS202	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
LS202	<i>P<sub>aceB</sub></i>	<i>nodY2</i>	cDNA	pLS58	<i>T<sub>aceB</sub></i>
LS203	<i>P<sub>trpC</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>trpC</sub></i>
LS203	<i>P<sub>janD</sub></i>	<i>nodD2</i>	gDNA	pKV61	<i>T<sub>paxG</sub></i>
LS203	<i>P<sub>janO</sub></i>	<i>nodR</i>	gDNA	pKV58	<i>T<sub>paxG</sub></i>
LS203	<i>P<sub>janP</sub></i>	<i>nodY2</i>	cDNA	pLS58	<i>T<sub>paxP</sub></i>
LS148	<i>P<sub>janO</sub></i>	<i>neoR</i>	gDNA	pSK16	<i>T<sub>trpC</sub></i>
LS148	<i>P<sub>janO</sub></i>	<i>nodM</i>	cDNA	pLY52	<i>T<sub>trpC</sub></i>
LS148	<i>P<sub>janO</sub></i>	<i>nodW</i>	cDNA	pYL54	<i>T<sub>trpC</sub></i>
LS148	<i>P<sub>janO</sub></i>	<i>nodD1</i>	cDNA	pYL55	<i>T<sub>trpC</sub></i>
LS148	<i>P<sub>janO</sub></i>	<i>nodO</i>	cDNA	pYL56	<i>T<sub>trpC</sub></i>
LS148	<i>P<sub>aceB</sub></i>	<i>nodJ</i>	cDNA	pLS59	<i>T<sub>aceB</sub></i>
LS146	<i>P<sub>aceB</sub></i>	<i>natR</i>	gDNA	pRC1	<i>T<sub>aceB</sub></i>

## SUPPORTING INFORMATION

LS146	<i>PaceB</i>	<i>nodD2</i>	cDNA	pYL57	<i>TaceB</i>
LS146	<i>PaceB</i>	<i>nodR</i>	cDNA	pLS56	<i>TaceB</i>
LS146	<i>PaceB</i>	<i>nodZ</i>	cDNA	pLS57	<i>TaceB</i>
LS146	<i>PaceB</i>	<i>nodY2</i>	cDNA	pLS58	<i>TaceB</i>
LS146	<i>PaceB</i>	<i>nodJ</i>	cDNA	pLS59	<i>TaceB</i>
LS196	<i>PjanO</i>	<i>neoR</i>	gDNA	pSK16	<i>TtrpC</i>
LS196	<i>PjanO</i>	<i>nodM</i>	cDNA	pLY52	<i>TtrpC</i>
LS196	<i>PjanO</i>	<i>nodW</i>	cDNA	pYL54	<i>TtrpC</i>
LS196	<i>PjanO</i>	<i>nodD1</i>	cDNA	pYL55	<i>TtrpC</i>
LS196	<i>PjanO</i>	<i>nodO</i>	cDNA	pYL56	<i>TtrpC</i>
LS196	<i>PaceB</i>	<i>nodX</i>	cDNA	pLS50	<i>TaceB</i>
LS170	<i>PjanO</i>	<i>neoR</i>	gDNA	pSK16	<i>TtrpC</i>
LS170	<i>PjanO</i>	<i>nodM</i>	cDNA	pLY52	<i>TtrpC</i>
LS170	<i>PjanO</i>	<i>nodW</i>	cDNA	pYL54	<i>TtrpC</i>
LS170	<i>PjanO</i>	<i>nodD1</i>	cDNA	pYL55	<i>TtrpC</i>
LS170	<i>PjanO</i>	<i>nodO</i>	cDNA	pYL56	<i>TtrpC</i>
LS170	<i>PaceB</i>	<i>nodJ</i>	cDNA	pLS59	<i>TaceB</i>
LS170	<i>PaceB</i>	<i>nodY2</i>	cDNA	pLS58	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>natR</i>	gDNA	pRC1	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>nodD2</i>	cDNA	pYL57	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>nodR</i>	cDNA	pLS56	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>nodZ</i>	cDNA	pLS57	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>nodY2</i>	cDNA	pLS58	<i>TaceB</i>
LS197	<i>PaceB</i>	<i>nodX</i>	cDNA	pLS50	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>natR</i>	gDNA	pRC1	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodD2</i>	cDNA	pYL57	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodR</i>	cDNA	pLS56	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodZ</i>	cDNA	pLS57	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodY2</i>	cDNA	pLS58	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodJ</i>	cDNA	pLS59	<i>TaceB</i>
LS147	<i>PaceB</i>	<i>nodX</i>	cDNA	pLS50	<i>TaceB</i>
LS29	<i>PjanO</i>	<i>nodJ</i>	gDNA	pKV47	<i>TpaxG</i>



## SUPPORTING INFORMATION

## Sequences

## Promoters used in this study

>*P<sub>trpC</sub>*

GAATTCATGCCAGTTGTTCCCAGTGATCTTCGTTTTCGAAGATGGACACTCCCAATTTGTGCAAGTTATTCGGC  
 CTACCTGGCTGTGGCCGAGGCGCGTTATCATGACCGTCGCTGTTCAAAGATAAGGCGAGAAGTTTTCGGGGC  
 TGCTTGACGATATGGCTTCGTTCCAGACAGATATAGTTCCCGGAGTCGCAGGCGTCTATTCTTCTCCGAAAC  
 AACTCGGCTGCACTGTTTCCATCACCAGGCTCTGGCGTTGAGGATGTCAGCGAAACTCGGCCCGGCAAGTG  
 ACACCCGAAAAGTATCGACTCCGGCTGCCGTTTCAAGCTAGTGGCTTCCTCATCAGCGAGTCGGCCAAGC  
 AGACGTGAAGCAGGACGGGTTTGCATTCCAAGACCGTGATCCGAAGCGCGTTGATTTCAATCCCAGC  
 CTTTTCGCTCAACCAAAGAGCATCGGCTTTGATTTCTTCAGGTCATACGAGGCTTGTGCAATGGTCTgCGCA  
 TGGATCGCTGCTGTTCTCCTATCAAACCTCGGATTTTGTCTTAGGGGATGGCGTAGGAAAAGACGCTGCCGCG  
 GTTCAGAAACCTCGATGCTATCAGGATGTGACAAAACGACTCGAAAACCCGGGATTTCATCGGTGATGCT  
 TTCGGGATCGCAAGCGTAAAGAAAGACTCTCTTCCAAGACCTAGAAGTATAGCAAATCAGCAGCAGACCAT  
 CAATGTATAGCGAATGCGCCATACAAAAGCTGAACGTCCCCGGAGAAGCACTTGTCCAGGGACGGGAAAT  
 AGGCTTCCGGAACGGGAGCCATTGGCAGCACAGCTATATCATTCTAAGTAAACAAATGTAATGAGCAAGCG  
 GACGGAGTGCTGAAACCTCCGTATGCCTGAAGCCGACGAAAGCGCGTTGGATTAGAGGTGACAGAAGAT  
 GATATTGAAGGAGCACTTTTTGGGCTTGGCTGGAGCTAGTGGAGGTCAACAATGAATGCCTATTTTTGGTTTA  
 GTCGTCCAGGCGGTGAGCACAAAATTTGTGTCGTTTGACAAGATGGTTCATTTAGGCAACTGGTCAGATCAG  
 CCCCACTTGTAGCAGTAGCGGCGGCGCTCGAAGTGTGACTCTTATTAGCAGACAGGAACGAGGACATTATT  
 ATCATCTGCTGCTTGGTGCACGATAACTTGGTGCCTTTGTCAAGCAAGGTAAGTGAACGACCCGGTCATACC  
 TTCTTAAGTTCGCCCTTCTCCCTTTATTTAGATTCAATCTGACTTACCTATTCTACCCAAGCATCGAT

>*P<sub>janD</sub>*

CTTACCCGTCCTTTTTCTCAACGAAAACCTCAGAGATCGGGCTTAAATAGATGTCAAGGGCACGAGGAAGGC  
 TGTAGGGGGTTCAAGTAATGCTTATTAACAGAAAAGAAAAAGAAACTGAAGTACTTGCATTCAGCCAGCAAAT  
 TTGTTTGAGTGGTATTCCAAGGAAGTGAAGATAGTGGGCAAGGCGAAGTGATATAGGTATTTAAGTGTTT  
 ATGAGCCCTACTGGCCAAGGAGATTCTCCTATCAGCTACCTATTGACCCCAAAAACATAAGGTAAAATTACG  
 CAATAAGGAAAACCTGAACACCTCCTAGGTGCTGCACAGCTCTGGACCTGTCTCACCTCTACCTCATCGGTAAA  
 GACTCGATTCTCTAGATCAGCTCTCGTGTTCATGTTGATTGCAACGTTTTCACTGCAGTCCACATTAGCCCATG  
 CAGACGCAATCTCAATCACTATGTTTCTGCATTGCAGCTATAGTTTATGCACTCGAATATCAGATGTAATTTA  
 GCTACGTGTCACTTGGCATAGAAAAGAAATGCAGATTCTCGGCGCAGGTAGCCCATCAAACCTATTTCCGCCT  
 CGCATAACGCTATGAGCTAGTAATTGGCATATGCATTCCGGCAGATTGGGCTTCACTCAACGTGTAACCCTA  
 CAGGATTCTTATCAGTGGCTTGAAGGTAATTGATAGATCACAGGGGCCACCCGACATTCTGATTGCGTAT  
 AGAGTCTATACATCCGGCTGACTGTAGTTCTTCGACTTTTCATCCTCGGAAAAGTGGGGTAATACGACAT  
 GCATGATACCGTTGACCAGATACCAGATGTCAATCATGGTCTTTGATCTTCATCAATAGATACTGTAATTTG  
 TCAACATCACTCACCTTCTTTCTCATATAAATCTGATTAGTCGTGGGGTGCCTCAGCGAGCACCTTGTTTG  
 ACCAAACCTAATCTTCCACTTCATCAAGCTCAAGATCATCTTAACT

>*P<sub>paxG</sub>*

ATTCACGACCTGTGACTAGTCAAGGTTATCAATTTTAAAACCTTACTGGGTGTTGTGTTGAATACTATGCACGA  
 GATCTGGCACGTATAATCTATGGAGTTTACTTCCGTACACAGAATTACATCTCGCTTTGTGAATACGAATCAC  
 CCAGTCATGGATGTATTACAACGCAACCATAATCGTTGCATCATGTCATCCATGTTTCGCACGCCTTGTCTATA  
 ATACGGAGTTCTCAAGTGGGGCAGAGGGATTTATTTTCGAGAATTTGAAACATGACTGTACCGCAGTTGTA  
 ATTATAGAGAGTTATTTAACTGGGGTAGTTGGGAACGGATTTTATAGCGGCATAAATCAATACAAGGATCCGGT  
 GTCGTTTACTCTCGAACCTACCCATACCCCGGAATTTCTTTCATCGCAATTTTGAATCCTACTCTGCAAAA  
 TAGAAAAGAATTTCTTCCAGTCCCATTTCTTTCATCATAGGGTTATAAAAATAGTGCTCTTGAATTCAGGTTCA  
 CGCCAGAGAAAACCTTCATCAAGTTCGACGCC

>*P<sub>paxM</sub>*

GTTGTTGGCATGGGAGTAGGATGGATCATAAACTACATCGGAATGGTCTACATCTCGTTCAAACATGAACTT  
 ACGGAATGTCGATTATGCCCTCTGTTGCAACATCGCGTGGGAACTGGTCTACTGTCTGGTCTTTCCCTCGA  
 AAAGCCCGGTGGAGAGGGGTGATTCTGGATGGGCCTCCTCATCAACTTTGGTGTGATGTACGCAGCAATA  
 ACGTTTTTCATCCCGAGAGTGGGGCCATGCGCCGCTTGTGAGCGCAATATTTCTTGTATTTTTTCGTCGCG  
 ACCATGGGCTTTCTCTGCGCATGTTGCATTGGCCCTTGAATCGGGCCTGCGCTGGCATATTCATGGG

## SUPPORTING INFORMATION

GGCCGTCATTTGTCAACTTCTTCTAAGCGTTGGTGGATTGAGTCAACTGTTGTGTCGAGGCAGTACGCGTGG  
 CGCATCCTATACTCTATGGTATGTCTGATCTCATTTTCATGCCCGATGAATCGGAATTTCTCCCAAAGTGAC  
 AGAAATACAAGTACTCATCTTCTGTACTATAGGGCTTCCCGCTTCTTAGGATCAACATGTACAGTTGGGTTTG  
 CCGGCTTACGTTGGATGTATTGGTCGGAAGCATTCCGGTTGGCTGAATAGTCCTTTGGTACTGTGGAGTCTTG  
 TGGTGTTTTTATCAATCGATGGGTTTTATGGAATTTGTTTCTGGTACGTCGACCGTAACGAAAAGTCACTTGG  
 CATAAGCGGGCCGAAAAAAGCAAATTTGATCGGCAGTTGAGGGTGAAACATGTAAGTACTAGCTTATTCTGCATAC  
 AATGCATTATCTATGGAGGGATGAGAAAAAGTAAAATGAAATTGAAGAAAAGAAAAGAAAATTAGAAACAAAA  
 ATACACGTTTACTTTTTGAAATAACCTTGAAACTAAGATCCGAAAAAAGAAATCTTTTCTTCATGCATTTCTG  
 CCAGTGCTAGATTGAAATTGAAGAAAAGTACATACGATGTACTTTGCTTACGATACGCGTAACGTGCATGTCC  
 AAGGCGACCCAATCCATGATATAATTGGCACGTTTTAGTAGTAAGCAATGATCATTTGTGGCTGACACTATGC  
 AATCTGTATCATATGATATTAGTATGCAAAGGTTGATTCTGAGTTTGAATTTCAACCACTGTTTCATCGTTCCCTC  
 ATTGTTAACCTTATTCATATTTACCTTTTGCTTTATTCTTTTCATGTATCTTTAAGATTCAGAAACC

>*PpaxB*

GGAGAGAATCGAAAGAGTATTCATGTTGACTTGGAACAGAGAATTTGGTATTGACTAACGTATTCTCGAGTTC  
 TCTCAAGGAAAGGAAAAATGAAATGAGTCGAGTAGCTCTGCTTGGTAGGCTGTTGAGATTCGGCGCAATACA  
 TCCCCTCCATATAATAAGTAATGCAAGGAGTATACTTTCCAGGTGTCCAATCGGCGGCTGCAGCTATCACA  
 ATTAGAAAAAGCAGTGGGATTCATCGCGTTCAGCATTTCGCCCCACAATTGTCAGCTTTCAGGCGTGATCC  
 CAAAAGTGATACATGTTACTAAATTTACGGATTGACCTCATTACAGCGATGTCTACGATGAGCAACGAGGTAGT  
 AGTATCAAGAGGGGCTGTCGGTACCTTAATAATTCCGGTTTCTCCGTGATGCAGATATCAAACATATGCAGTA  
 GTAATTAATCTTTTATTTTTCTTCATACCAGCCCCTGTAATGACAACATCACGCCTAAATAGGTTAAGCGCAG  
 CAACGCCTCAAGATCCTTCATGCAGTGAGAAAAATAAGAATTATAATTAATTAATAAAAAAGAGGGGAAAGTAAC  
 GAACTTTTTGCCCTGATCCACATCGACGCCTCGATTTTCCAGGCGCACCGTACTCAAATCGGCTTTCATTCC  
 TTTGAGCCATTTTCTTCACTTGGCAGTAAGCCTAAACTCTGCCTATCCAAAGACAGCTAATTGTTGCGACGCA  
 GTTCGTCTGAATTCATGGCAAGAATGACTGCATACTAGCTTTCGTTGGCGAAATAGACTAGTTTAGATCTTG  
 CAGGATCTCCTCGTGGACTGCATCTACAGAGATTTCCGGGAGTGTCCATCTCCCGCTGCGGGCTAACCGAT  
 GAGATAATGCAGTTTCATTAACAATTCAATATTTCCATTTTCATCCACAGGGCATAAATAGACGTACATTTAGCC  
 GTTAATACGCATCATGGTCAAATCCTTCAATCTATAGCTATTCAACGAGTGACTCTAATTTCTTTTTCCACGT  
 CAACCTTAGAAACT

>*PpaxC*

ACAACAAAAAGATCAGCCAATGGCTTAATCGCCTGGTACTCCGGAGGAGCTTGGGAAACATCAAACCGTCC  
 CATAGTTTCTAAGGTTGACGTGGGAAAAAGAAATTAGAGTCACTCGTTGAATAGCTATAGATTGAAGGATTTG  
 ACCATGATGCGTATTAACGGCTAAATGTACGTCTATTTATGCCCTGTGGATGAAATGGGAATATTGAATTGTT  
 AATGAAACTGCATTATCTCATCGGTTAGCCCGCAGCGGGAGATGGACACTCCCGGAAATCTCTGTAGATGCA  
 GTCCACGAGGAGATCCTGCAAGATCTAAACTAGTCTATTTCCGCAACGAAAGCTAGTATGCAGTCATTCTTG  
 CCATGGAATTCAGACGAACTGCGTCGCAACAATTAGCTGTCTTTGGATAGGCAGAGTTTAGGCTTACTGCCA  
 AGTGAAGAAAATGGCTCAAAGGAATGAAAGCCGATTTGAGTACGGTGCGCCTGAAAATCGAGGCGTGCAT  
 GTGGATCAGGGCAAAGTTCGTTACTTTCCCTCTTTTTTAATTAATATTATAATTCTTATTTTTCTCACTGCAT  
 GAAGGATCTTGAGGCGTTGCTGCGCTTAACCTATTTAGGCGTGATGTTGTCATTACAGGGGGCTGGTATGAAG  
 AAAAAATAAAAGATTAATTACTACTGCATAGTTTGATATCTGCATCACGGAGAAACCGGAATTATTAAGGTAC  
 CGACAGCCCCTCTTGATACTACTACCTCGTTGCTCATCGTAGACATCGCTGAATGAGGTCAATCCGTAATTT  
 AGTAACATGTATCACTTTTGGGATCACGCCTGAAAGCTGACAATTGTGGGGCGAAAATGCTGAACGCGATGA  
 ATCCCACTGCTTTTTCTAATTGTGATAGCTGCAGCCGCGGATTGGACACCTGGGAAAGTATACTCCTTGCAAT  
 ACTTATTATATGGAGGGGATGATTGCGCCGAATCTCAACAGCCTACCAAGCAGAGCTACTCGACTCATTTTC  
 ATTTTTCTTTCTTGGAGAGAACTCGAGAATACGTTAGTCAATACCAAATTTCTCTGTTCCAAGTCAACATGAAT  
 ACTCTTTTCGATTCTCTCAACACAGCCTTTAGGGGTGATGGTCCCATTTT

>*PjanO*

AGTTAAAGATGATCTTGAGCTTGATGAAGTGGAAGATTAGGTTTGGTCAAACAAGGTGCTCGCTGAGTGCA  
 CCCACGACTAATCAGATTTATATGAGAAAGAAGGGTGAGTGATGTTGACAAATTACAGTATCTATTGATGAA  
 GATCAAAGGACCATGATTGACATCTGGTATCTGGTCAACGGTATCATGCATGTCGATTACCCCACTTTTCGCA  
 GGATGAAAAGTCAAGAAGTACAGTCAGCCCGGATGTATAGCAGCTCTATACGCAAATCAGAATGTGCGGT  
 GGGCCCTGTGATCTATCAATTACCTTGAAGCCATGATAAGAATCCGACTCCTGTGCAGGAAAATAGGAC  
 GAGATTCATACAGCTAGTGGTATTGTGATTCCATACCGTACAGAACGTGTAGGGTTACACGTTGAGTGAAG  
 CCCAATCTGCCCGAATGCATATGCCAATTACTAGCTCATAGCGTTATGCGAGGCGGAAATAGTTTGTGGG  
 TACCTGCGCCGAGAATCTGCATTTCTTTTCTATGCCAAGTGACACGTAGCTAAATTACATCTGATATTCGAGT  
 GCATAAATATAGCTGCAATGCAGGAAACATAGTGATTGAGATTGCGTCTGCATGGGCTAATGTGGACTGCA  
 GTGAAACGTTGCAATCAACATGAACACGAGAGCTGATCTAGAGAATCGAGTCTTTACCGATGAGGTAGAGGT  
 GAGACAGGTCCAGAGCTGTGCAGCACCTAGGAGGTGTTTCAGTTTCTTATTGCGTAATTTTACCTTATGTTTT

## SUPPORTING INFORMATION

TGGGGTCAATAGGTAGCTGATAGGAGAATCTCCTTGGCCAGTAGGGCTCATGAACACTTAAATACCTATATC  
 ACTTCGCCTTGCCCACTATCTTTTCACTTCCTTGGGAATACCACTCAAACAATTTGCTGGCTGAATGCAAGTA  
 CTTTCAAGTTTCTTTTTTCTTTCTGTTAATAAGCATTACTTGAACCCCTACAGCCTTCTCTGTCGCCCTTGACATC  
 TATTTAAGCCCGATCTCTGAGTTTTCGTTGAGAAAAAAGGACGGGTAAG

>*PjanP*

GACTTCGGTTTTCCATTGGCAGTGCTCGTGTCTATACTCAGGAAGACTTGACCGTGACCGTCTAGTTAGTTTT  
 CTTTTCGATACCGTGCAAAAAAAGAAGAGCCGGGCAGTGCAAAATAGCTTCTACTCGGTCCCTAGAAAC  
 GTTTGTCTGGATGGATAGACTTCGTTTTCTTTTCTTCTATTGCCTCGCTCCCAAAGGTACAATAATTTACGTATA  
 TTGAGTCCAGTATTTATGGTCAGACCTATACGCGTACATACCTTCAGTAAATTTAGAGTACACTTCTGGCCA  
 AGTCATTTCTGATATTCCACCGTAGTGTCCAATGGTACCTGGGTCTTTCAATCAATCTTACCCCTCTATGATG  
 CATGGTAGTAAAACCCCTTTAAGTACCGTAAACTTTTGAAAATTCATAATGCAATGATTATGCAATGTGGG  
 GCTATCACGGTCTGGCCGGAGACTATATTGTGGTAATGATACGACATGCAGAATACCAAAGCCAGGCACGAT  
 GGAACAGTGAATACATACAGGTCATCCAGGCGCAACGAGGTTTCCAGGTGTGGACCTACTCCACTTTAA  
 GCTAACCCCGGTGTGCTCAGTAATAAAATTCGTAATAACTCCAGTATACATTATTTAACTCGTTATAAATCTTT  
 TACAACACTATTATCTCTACTAATAGTTTTATTATCATTTCGATAGAGGTCTTTAGGGTTTTCTAGTACTCTATA  
 AGCCTAAAATATTATTTTTGTACTAGTTGATTATATTATTTTAAAGACTTATTTCACTACTTTTAGACTAG  
 AGTAAGAATAAAATATCTTAATTACAGTGATAATATTATATATCACAGACCCTGTATTTCTTTGTTTTAAATA  
 CAAGCCGACCGGTAAGATACGCCCTGTAATAAACACGGGACTGGGTGGGTCGTTAGGAAAAGTCCCACA  
 CCTGGGTTAAGCTCGTTGGCACCTGGATGACCTGTACTCTGGATGGAACATGCTTTTTGTCCAAAGATGTTCT  
 GCAGAAATGGCTCATATGCTCAATATAACAGATCATGCATAATGGCAACCGATAAGAACTAAAAACAAGCCA  
 ATCATATTGAAAATTACATAAAATCTAAAGCTACATCCACGGTGCCTAAATTTATGTCTCAGGCACCCCTCGTAT  
 AGCCATGGATAGGGTATGATTCCAGTTACCCTGTGAAAAGCCGCAAGTCTGAAAATGTTTCCAAAAATGT  
 GATAACCAGCTCACTAGCCCTTGAATTTGTTTGCTTCTACACCATCCACTTCTATCTTGCTTTCTGCTGC  
 ATTCCACAGGACA

>*PaceB*

CTCGGGAGGCCAGGACTGGGCTGGCACCCCGAAGACACATTTCTGGCAGATTTGCAATGAGGCTCATGG  
 CGTAGAAGTGATCTTGATATGAATTCCAGTGATGGAGAGGACGATGCGTAGGAAGACAAAATCGGCTTCAAT  
 ATCCAACAGCAGCACTTTCTTCAAGAATTCACCTCCGTATATCAGCGGGCCGCACTAGCACCCGCTGCTCC  
 TCGCGCCATTCTGGATATATCGGGAACCCTCTAAAAATCCACATTTTTGCCTATCTACTGTACTAACATGGGT  
 GCTACCTCGTTCAGGCGTGCCCGATACAGCGATTTGCAGTGGTCAACGTCAGCCGGTCTTCAGCCGTAGCG  
 GTCAAGGATGACGAATGATCTAATTTGTGGGGCTCCGAAAGTATACTTAGTGGTATCAGTATGCTAATCAAGT  
 ATTTCCCTCGTTAATGTCTGCTTTCTCATCACAAGTGCATGCAGGCGTGGCATCCCATGGCAAAAAAGC  
 AAGATGCATCCTCATATCCTGCAGGCTTATCTAAATCACGGATGTGACAGTATCAGTGTCCCGTGTGGTATG  
 AGCTCATCCCGCTGGAATTGCAAAAAACAGTATTCATTTTGAATTACAATACATACTAACTCCATTACCTT  
 AGTGACCCTAATGCATGGCCTGCATTTTTAATATAATTTATTATGAAATGGGTTTCACTGTTATTGAATACTTA  
 CCCATAGCTACATGGCAATCGGAAAGCACTTACTCTCAGGGCTAATCAGAAACGGTCACTCTCGCGCGATCC  
 CTCATCCTTTACGCAAACCATAAATAGGCAGGCGCTTGAGAGGCCCTTAGTCCTGGACTCAACAGTATACGAC  
 TCCTTCTGCACTTACGTGGATACGCCATCAATGTGAGAC

**Coding sequences used in this study (gDNA)**>*paxG\_gDNA*

ATGTCCTACATCCTTGCAAGCTCTGAACTTCGTTTCGTCGAGGAATATCTCATCTTAATTATTGGGGAGCTT  
 CACACTCATTATCTGCTGATAATTACTGGGAATCAAACCTCCAAGGATCCCAAGACTCCTGAGTGATTCCAG  
 CAAAGCACCAAGCACGATTAGAACAGTACAGGTGCTAGAAGATGACGTTGACGATATTGCTATTCAGTATAA  
 CAAGGTCAGTTCTGTCATTGCTCTTGGGATTCCTTGTGTTTCATTATACCAATCGTTTGTCTTCTTAGATT  
 GTTCGTGGACCTCTAGACTATCTTCTAGCGATTCCGGGAAAAGACATCCGAAGCAAGCTGATCGACTCCTTC  
 AACATATGGCTCCAGCTTCCAGAGGAGAAGTTGTCTATTGTGAAAGATATAATAAACTTACTTACACTGCAT  
 CCTTCTGTGAGATTTCCAACCCAGCGCTCCTGTTCTATTCTAACATCATGGTGATTATAGTATCGATGATA  
 TTCAAGATGCATCACGGCTCCGGAGAGGAAAGCCTGTGGCTCATGATGTATACGGTGTAGCACAAACTATCA  
 ACTCAGCCAATATGCCTACTATCTCCAACAAGCAAGATTGAAAGAGATTGGTGACCCCGCGCCTTCGAAA  
 TATTTACAAGGTCAGTCTAGATCTACATCTTGGCCAGGGCATGGACCTATATTGGCGTGATATGGTGGTTT  
 GTCCGACCGAGGAGGAATACACCCGGATGGTTATGTACAAAACCTGGAGGTCTTTTCAACCTGGCCCTCGATT  
 TGATGCGTATCCAATCCCGCAAGAATACGTAAGTTTCTAATCCATAACGGTCACTTCGCAGCAATGCTAATTA  
 GTATTTTACAGTGACTTTTCTAACTTGTGCGAGCTATTGGGTGTTATATTCCAAATTCGTGATGACTATATGAA  
 TCTGCAGAGCGGACTCTATGCTGAGAAAAAAGGGCTGATGGAAGATTTGACGGAGGGGAAGTTCTCCTATC  
 CTATCATACACAGCATCCGTGCATCTCCAGAGAGCTCCGAGCTTCTCGATATTCTAAAGCAACGCACAGAGG

## SUPPORTING INFORMATION

ACGAAGCAGTCAAATCCGGGCTGTGAAGATCATGGAGTCGACGGGGAGCTTCCAATATACTAGGGAAACC  
CTAAGTCGACTTAGTGCGGAGGCTCGTGGCTATGTAAAGAAGCTGGAGACTTCTTAGGGCCCAATCCTGG  
AATTCATAAGATTCTCGATCTACTTGAAGTGGAGTACCCTACTAATGAGAAAGGAAGAGTTTAA

**>nodM\_gDNA**

ATGTCTACCCCTGAGTTC AAGGTGATAATCGTTGGCGGCTCCCTTGC GGGTCTAACATTGGCCATTGCCTC  
CTCCGCGCCGGAATTTCCACATCGTTCTTGAGAGGCGTAGTGTAATCGCACCCAGAGGAAGGTGCCTCAAT  
AGGGATTCTTCTAATGGCGCTCGTGTCTTGATCAACTAGGCATCTATGAACATATTCAAGACACTACTGAG  
CCATTGAGTACAGCTCATATACGATATCCAGATGGTTCTATTTTCAGCAGTCGCTATCCCGAGATCATAAAAG  
AAAGGTGAGCACTCCCATGAACATATGCCTATCGTTTGC GCAATGGCTGACCCAGCATGGCCGTTCTGAG  
GTTTGGGTATCCGATAGCCTTTTTACCCCGGAGGAGACTTTTGGAGATTCTCTATACATCGTACCCTGACCAT  
TCTAACATCTATACCAACAAGAATGTGATCAAGGTGCAAAGCCATGATAATCAAGTTTCTGTCTTGACAGAGG  
ATGGAAATACATATCGAGGGGATCTTGTGGTGGGCGCCGACGGTGTCAACAGTCGAGTTCTATCTGAAATTT  
GGAAATTAGCAGGTAATCCCTCTCTCACGAAACGGGAAGGAAGAGGTCAGTCGAGATCTTATAATATTGCA  
TAGCGACTCATAACAGACGTTGATAATAAAGTTAGGAAGGACCATCGAGTACGCTTGTGTGTTTGGGATATCC  
TCGCCAATCTCAGACCTCAAGCCCGGCGAGCAGGTTAACGCGTTCTACGACGGACTCACAATCGTCACGAT  
CCATGGTAGAAACGGAGAGATATTCTGGTTTTTATCAAGAACTCTCGCGTCGCTATATCTATCCCGATCTC  
ATCAGATTACAGCAGAAAGACGCAGAAGGGATCTGTGAAGAAGCCAAGTCACTAACTGTCTGGAAGGTGTT  
ACATTCGGTGACATTTGGGAAAGAAGAGAAACAGCATCATTGACCGTTTTGGATGAGTTCTTGCATCACACTT  
GGAGTTGGGACAGATCGTTTTGTGTGGCGACAGTATCCACAAGGTATATGCCTCCTATGGTCTGAAGCAC  
ATTAAGGGGTTGGCTAACGCTGTATATAGATGACTCCAAATTTGGCCAGGGTGC GAATACTGCTATCGAG  
GATTCTGCCGCTCTAGCCAATCTACTGCACAGTTTGTCAAGGAGAAACGAGCCGAAAAGCCGACTGACTCA  
GATATACACTGCTTCTGAGGCAGTTCAAATCACAGCGTCTTCGACGCGTT CAGAAGATATATAAAATGTCAA  
GGTTTGTACGCGGCTTCAAGCGCGCGATGGGTTGTTGAATACTCTTCTGGGACGCCATTACGCCCATATG  
CAGCAGATCTTCCAGCTAAGATTGCCTCTGGATGCATCGCTGGTGCGGAAGTTCTGGATTACCTCCCATTAC  
CCAAGGTAAGTGGGCGGGCTGGAATAGGGGCCATCGTAGATCTACCATGTACATCCTGCTAGGATTACA  
GGGTATTACCTCTGCTCTGGCGATGGTAGTGTACTCCATATTAGAGACATCGCTTCATAG

**>nodB\_gDNA**

ATGGATGGATTTCGATCGTTCCAATGCACCCGTTGAATATCAGCGCGTCAATGGATTTTCGGACATCTTCGTC  
TTCGGAATGGGCGTTTGTGGCTCATAAACTACGCCGGCATGATCTACACCTCGCTCCAGGAACAGACTTAC  
AGCATGGCACCCTGGCTCTTTGCTGCAACTTTGCTTGGGAAATGGTATATGGTCTTATCTACCCTTCAAAA  
GCCGCATCGAGCAAGGTGTGTTCTAGCTGGACTGGTAGTCAATCTCGGAGTCATGTACACCCGCGATCAGG  
TTTGCGCCGAATGAATGGGCCCATGCGCTCTTGTGATGAACAACATCACACTCATTTTCGCACTAGGTGTC  
TTGGGCTCCTTGACGGGCCATCTAGCCCTAGCAGCAGAGATTGGGCCAGCACTTGGATATTCTTGGGGTGC  
AGTGGCTTGCCAGCTACTGCTAAGCGTCGGGGGTTCTGCCAGCTTCTAGGGAGAAGTAGTAGTCGTGGAG  
CTTCATATACCTTATGGTAGGTAATCCATCTTCTTGTCCGAAGTTATGCAACAGAAGTTTGGGACATATAAA  
TAACAAGGTATAGGTTATCTCGCTTATAGGATCCGGTTGTGTGGTTGGTTTTGCCATATTGAGGTACATGTA  
CTGGTCGGAGGCATTCAACTGGCTCAATAGTCTCTGGTACTATGGAGCCTCGGTGTATTCAATTGCGGTAGA  
CAGCCTCTATGGAATTTGTCTGTGGAATGTGAAGAAATACGAACATGGCCAAGAACGAAGCAATGCGCGGA  
AGGCTCAATAA

**>nodC\_gDNA**

ATGTCCTTAGGTTTACAGTGCTTGGCGGCAGTGTTGTTTTCGGCTTTGTTTTCACTTGGGGTCATCCTAGTTC  
ATCTTCCATGGCGCGCCTTGAAGTCAAAGGACCCGCGTGAGCGAATATTAGGTTTCGCCCAAAGAAGTGGTT  
CCAACATGCCCTTACGAATATATTGAAATATATACGGGCGTCATCATTGGGCGCCCTTTGTGGCCAAAGTTA  
GCACCGAATCTCAAAGAAAGTGATTACAGACAGGTACACAATGGTACTTGAATCATGGACTGCATACACCTA  
TGCCTGATTATGGTCGATGATGTACGTTTCTATTATACGCCTCTTGTGGTGATAGAGGTGAGAGTTGTA  
AATAACTAACCCGGACTCTCAGATTACAGATGACAGCGACTATCGTAAAGGCCGCCAGCGGCCCATATCAT  
CTATGGCCGTTTCGGAGACAGCTAACCGTGCTTATCTTCTGTGTCAGTCAGATTATAAACAAGACAACCTCAGGA  
CTTCCCGCGGCTCGCCCGTGGGTACACAGAGTTTGGCAGAGATTCTAGAGGGCCAGGACATCTCGCTG  
GTTTGGCGACGTGACGGCCTCACTAGCTTTCCAAAAGCTCACGACGAGCGCGTATTGCTTATCGGTGCAT  
GTCATCTTTGAAGACTGGCGCGCTTTTTAGGTTGCTAGGGAGGCTTGTCTTGGAAAATCGTTCCATGGATGA  
CACATTGAGTCAGGTTGGGTAAGTGAAGTGTATCCATCCTGAACTCGACCCCTTTCACAGTGGCGGAAGCCA  
ATGCTAAAACGTCTAGATACTATTACAATTACAAAATGACTGCAAAAATGTTTTCTCATCCGAGTACGCAA  
GGCAAAAGTACTTTAGCTGAGGACTTACGGAACCGAGAGCTGACGTATCCTATCATCTTGGCCCTCAATGA  
GCCTGAAGGATTTTATATTGAGAAAGCCTTTGAGTCTGGCTCCCCTCGTGACATACAAAATGCAATCGGTGT  
AATACAGAGTGAAAACGTATACCGTGCTTGTGGACGAGTTGAAACAATATGAATCGAACGTCAGAGAGTG  
GTTACACTATGGGGTAGAAAGGAGAAAAGTCTGATCTTACGCATTGA

## SUPPORTING INFORMATION

**>nodW\_gDNA**

ATGACTTTAGCTATTTTAGGCATCAGTTGCCTGGCAGCCGTCCTATCTCATACTATTTTATTCATCCGAGGAG  
 AGTGGGACAAGCACGCCCGGTCCTGTTCCATTGCTTCATTACTTGCCCCATTGCGCTCATATGCTCGTTGT  
 TGGCAGTGGGATTATATGGGATCACTTTTATGTTTCATCCAAGTTTGGCTATGCTATATCTCTTCTATCTGTCTT  
 TCAATCATTATATATCGGTTTCTTCTGCATCCCTTAAGAGATTTCCCGGCAAGGTATCCGCCAGGCTGAGCA  
 CGTTGAGATGGATGAAAACAGCAGCCGTAGATAGAAAATGGCACCTTGAAGTACAGAATATGCATAGTGTCT  
 ATGGCGATTTTCGTCCGAATTAGTAAGTTCTAGCCTATTTCCAACCTCTGCCATAAACTCGAAGTTGATAGACTA  
 TGTGTCAGGGCCTCGTGAGATATCCGTCAACAACCTTCAATGCCATTTCGCGATTTGGCCAAGTGTGCCAGGG  
 GTCCATTCTACGACGTGAATTATCCCCACAAGTCCCTTCAATGACAAGGGACAGGAATTTCCACCTCCGAC  
 GGAAGAAAATTTGGCAAAGGCCTTCAGTCTAATGGTGAAGTATCACACAACCCTGGCGTGGGCGATTTCATG  
 CTGATAGAGCATAACAGCTATGCTAGCTCATGAAGGCCATGTCCGGCAATGTTGCCAAGAACTCATGGGCTAT  
 CTCTCATCTAGAGGAGGTCAACCGGTAGAAGTAACTGAATTGATGCAAAGAGTCACATTTGAATCAATGGGT  
 TGGCTTGTATTTGAAAGGCCTTCAACATGATTCAAAAAGGCCTTTTCGCATCCCGGCTTCACGCAACTGAGG  
 TCTGTCAAGCAACTAGGGGGGTTACTTCTGTGGGCGCCTTGGACGTTGATCCTTCTCCGCAATCTACCGTTC  
 TTGAGGTCCAAGGCAACAAGTTGGCTACAGTGGTGTCTCACAGGAGGTAGTGAAAGGAAGCAAGTAGGTAA  
 TACTTAATTACATACTAATCAGGATACCTGACTGACGCACAGTGGAGAATCCAACATGACTCACGATCTATT  
 CAGCCATCTCTTAGACGACGAGTCTAAAGATACGGATGACCTCGTCTATGATTCTGAGCTGGCTGTCTGTGGC  
 CGGTAGCGACTCTACAGCATCGACCCTTACTGCCATCTTGTCTTCTGGCAACCCATCCAGACAAGCAGGC  
 AATTCTTCAAAAAGAGGTTGATGACATGAATATAGGTGGACTGCCTATGCCAACCTCCACCCTAGTCAATATG  
 CCTTACCTCAACAGTTGCATCAACGAAGCACTCCGTTTATATCCAGCAGTGATGAGCGGCTCGCAGCGGGA  
 GTCCGGTCTGGTGGAGTGATCCTTGATGGCCAGTTTATACCAGAGCATATGCTCGTATCCATGCCCACTTA  
 CACGATACACAGGGGTTAGTATCGATTTCGATACAGTCATCCTTTGAGCTTAATTTTAACTCTGCCGTCTTTAG  
 ATAAGAGAAAATTTTCGTGAGGCCAGATGAGTTCATCCCGGAGCGATGGACGAGCCAATCACACTTGACTCTCA  
 ACCCAGATGCATTCATCCCTTTCTGTGGGTGTGTACGGATGCCTCGGTAACCTTTTCGCGATGATGGAGA  
 TCGGTATGGTAATTTCTCTATAATGTCAAGATTCAATCTGAGACTTCTGCCTGGGCGGCCGATGAGCCATG  
 AAGCCTCTGCGCCAGCATAACGATTGCTATATAATTCATATAACCAGCGTTTTCTCTTGTTTTGAACCCCGGGC  
 TGAAATATCTGGGCATAA

**>nodD1\_gDNA**

ATGGATGCTGCTTCAACTCTTACGCATGCACCGGTATCTCAGCCATGGCAGTCCCTAGCTCAAGGGTTGGG  
 GTTCGTCAATGAGCATGAAGGGTACTGGTGGTCTAAGCTTGGACCTCCTCTCGGTAAAATGATGAACTGGGC  
 TCGATACTCGACATCGGAACAGTACAGAGTCCTAGCATTCTTTACAAAATATCTTCTCCCTGCCTGCGGCC  
 AAAGCCTGGTGATGATGGTGAAGTCTTCTGGAAGTTTTTCATCAGCTATGATTACACGCCCATTCAGCTCAG  
 TCTCAATTTTCACAATGGCAAATGACGCTGCGCACCGCGAACATAACCAATTAGCGATAAATCGGGAACCGC  
 AGACGACCCAATCAACCAACAAGCTTCGGTAGACGCCATAATCCGCCAGGAACGAGTGTGGCCATCCAGG  
 ATCTACGTTGGTTCAACCACTTTGCATCCCAGTACTTCTTCGACAAGGACACGGCAGCCTCTCTAAAGACCA  
 AGGTGATAAGCTCCGAGTCCAGCAGGGAGTTCAGTGTATGCTGAGCCACGACTTTCCTGAGCGTGATGTC  
 CAATGCAAAGTGGCTTTCTGCCCGCTTTGAAAGCCGTCGCTACAGGTCTTTCCAACAAGGAGATCATCTGG  
 GATTGATTCTAGGGCTCGGAGATGACATCATCCCATACAAGCGAGCGCTTGTCTGCTTGAACAGTACACA  
 TCGTCCGAAAATGCAGCGAAAGCAGGAGTGGCAGCTGTATTCTTCGCTTTTCGATACGGTGTAAAAGATAAT  
 TACAAGAGCTCTCGTATCAAGATCTACTACCTCACAAACACGGACAGCCTTCAACTCTATGGTCGACATCTACA  
 CACTTGGAGGCCTGCTAAAAGGGCCTGATATCCAAAAGGAGTAGAGGCCCTTGAAGTGCTCTGGAAAGCC  
 GTCCTCAACGTCCCCGAGGGGTGGCCCGATGATAAAGATCTACCCATGAATCCACACCGTTGTGCGGCAGT  
 AATCTTCAATTTTGAAGTGTGGCCAGGAGCAGAGTTTCCGAGTCCCAAGGCCTATCTCCAGCCCATTTA  
 TGGCCGGCCTGATTTGGAGATAGCTGATGGTATGGACTACTTCTTCAAGCAGCAAGGGTTGGATGGGGTAT  
 ATGGTTCTTACAAGGAGAATTTGAAGTGCTTGTACGACCTCCTCACCTCACTCACATCTACCAAGCTATG  
 GCTAATAGATCAGAAGTACGAACCTCACAGAACCAACTCACAGCCCTCCACCATGATATTTCTTTTTCAATCAA  
 AAGGTCCAATGCCTACGTTACGGTGTACTACAAGCCCGAGCTATCTCTAGATACCGAGTAG

**>nodO\_gDNA**

ATGGAGGTTTCTCAAGTGAACAACCTCCCCATTCTATGGAGAACGAGTCCCTCCCTCAAACGACTATGAAAAT  
 GCAAGATGCAGAGTGTTCATGGCAGGCAGCCTGAGCACTTCCCCCTTGCAATAGTCAAGGCAAACAAGGT  
 CGAGCATATTGTAGCCCGCGTGAACCTGGCAGCAGAAGTACGACGCTGTATCGCCGTTCTGTTCCGGCGGCC  
 ACAGCCTCTCTTGTGGACTATACGCCATGGGGCGATCCTTATTGACCTCGAAGATTATCAGCACTTGAGCT  
 ATGACGACGAGATCCATGAAGTGAAGCTTACCCAGTACACTTGGTGCAGGACCTACTTACGTTCTTTGCGA  
 AGAAAAGAGGTTCTTTCCCGTAGGTCACTCTGGAGACATTGGCTTAGGTGGCTATCTCCTTCAGGGCGGAA  
 TTGGGCTCAATTTCTCGGGTATGAACGTTGACCCTACATACTCAGTAGCTTTTGAATACTGACGATATCTTAG  
 GGATATGGGTATGCCTGTGAATACATTACCGGGCTTGTATATCATCACCGCTGATGGTGAATCAAGCATTGT  
 GATAAGACGGAAAACCTGACCTATACTGGGCTGCTCGTGGAGCTGGACCGGGTAAGTTCTCAAAGCTGT  
 CTGTACCAGTGTGAAGAGTTCTAATAAAGCAGAATTCCTGCAATCGTTATACGGTTCTTCTGAAGACGTG

## SUPPORTING INFORMATION

CCCCCTTTGCCGGTGTGTAAGCGGAGTAGATACGTCTGGCCGGCGGCCATGTATGGGAAGGTTTTTAAGT  
 GGCTTGAAGAGGTAAGTTTAAATCCCAAGGATCTAGGACGGCAGGGGTTAATCTGATCCGCGTCTTTACAGCT  
 ATTGAATTCCTTGAGCGAGGACGTGAGATTGCCGTTTTCGGGTTTGTATTGCCCGACTCAACCAGCCAGG  
 CTTAGTCCTCCATGCAACAGCATTGTTGGTACTAGCGAGAATGTCCGGGAAAAGCTCACGCCTATCATCAA  
 AAATCATCCTCCAGGGACTTTCTTGGCTGAAGATTTCTGAGCACCACCTCCCGAAGACTACGACTTAGG  
 TAAGGATACCATGCCGCGGGGCGCTCGCTATTTTACCGACAGCGTCTTTCTCAAGCCCCGGTATCGACTTCGT  
 CGCAACCTGCAAAGGAATGTTTACGGAGCTCAAACATCCCCGTGCATTGGCGTACTGGCAACCGATGAAGA  
 CCAATATTGATCGCATCCTTCCCGATATGGCGATGAGCATCCATAGTCATCATTACGTGTCACTACTTGCCAT  
 CTATGAAGACCCAGTGAGGACCAACAGCAAATATCCTGGATCATAGATCGTATGAAAAGTCTTGAGCCGGC  
 AATCCTGGGAACCTTTCATAGGGGATGCACACCCAGTGGAAGGCCATCTAATTATTGGTCCGAGGAAGCTGA  
 AGAACGGGTGATCACTATTGGGCGGAAGTGGGACCCTAGTAGTAGAATTCGGGGTATTGTGTTGAGCGATG  
 CCTAA

**>nodD2\_gDNA**

ATGGACTCTACCGGGAGACAGCCTCTCAGCCAGGACGGGCAGCCATGGCAAGCTCTTGCCTCTGGCTTGG  
 GATTTCCAGATGAAGACCAGAAGTATTGGTGGTCAGTCATGGCGCCCCTATTAGGGGAACTGATGAAATGG  
 GCCAACTATCCTGTTGATAAACAGTATCTTGTCTTTCGCTTCTGCCATGAATACATACTTCCATTTTGGCGAC  
 CTCGTCCAACGGCCGAAGGCGGTATCTTCTGGCCACGTTGATCACCAAGGATGGTACTCCGTTTCGAGCCG  
 AGCCTTAACCTTACAAAAATAAAGCCACTCTACGAGTTGGATATGCGCCTGCATGCGAGCTTTCAGGAAGC  
 AATGACGACCCTATCAATCAACGAGCCCAATTGCGGCATTGGAGCACCAAAAGAGAGTCCACCACAGCA  
 GAATCTCAAATGGGTGGATAATTTCAAGAAAGCATGGTTCATCGATAATGACGACGACGAGTAGCCTTGAAGGC  
 ACGCGTACATAACGAGCTCTTTGAACAGGCAGCCGTCCAATGCTTGATAGGTTATGTGTTTTCCGACTACAC  
 GCAGGTCAAGGTTGCCATGAGTCTCTTTGGAAGTCAGTCCAGACAGGCCAGCAAATTTCCGCGAGTGATCT  
 GGGACACCTTTCCGAGCTTGGTGACGATGCTTCCAGTTACCTAGATTGCCTATCAGTGCTAGAGGAGTATA  
 CTGAGTCTAAACAGGCCAACTAGCACAAAGTACAGCCTTCCCTTCGTCATTTTCGATGTGAATCTGAAGGGG  
 ACTACCAGCAGTCGCGACTTAAGGTATACTATGCTACACCATGCACTGCATTGACACGATGGTCCAGGTTT  
 TCACTTTGGGCGGAAGGCTCAAGGGCCCTGAAGTTGACCATGCGATTGAATGCCTTCGTGTCCTATGGCCC  
 AGCGTGCTTGCAGTTCCTGAAAACCATCCGGACGACCAAGACTGCCTCGACGGTACCACCTGTAGCAGT  
 GACCCAGTTTAACTTCGAGCTTGCCCGGGAGCGAAACTGCCTGTTCCCCAGATCTATCTCCGACTAACTT  
 TTACGGTCGTGATGAATTGAAATTGCGGAGGGCCTAGAGGGATTTTTCAAGACTCTTGGCTGGAGTGAGC  
 CTTTCCATGCCTATAAACAGAATTACATTGCAACATGGTTAGTCTATCGCCTTTCTCTCGCTCATTGCCCTGAT  
 CCAATGAAGTATTTTACTCACACGATGTAGTGCCACGCCCGAAGGGAAATGGAAGCGATCCAACACGACG  
 TATCATTCTCGTTCAAGGACTCAAGCCCATATGTGTCGGTTTATTATAAACAGAGCTCTCGGTCCTATCCTC  
 ACCGTCGTAG

**>nodR\_gDNA**

ATGTTTGATATTGATTTTGGCATTCTATTTCCAATTTCTGGGAACAATCCCCTATCTTTCTGGCTGTTGGGCT  
 AATATTCGCATTTGCGACCTTATCTCCGTGGCTCCGTTCCGGGGAACGCCTGATCAATGGTCGCGAAGGCTT  
 CGAAATACTGTGGACGAATGCGAAGAAGCGATATCAAACGAAGGGGCGATCTGTTATGGAGGCAGGCTTTT  
 CAAAGGTAGGATACATCATTGTCTCAAATGAAAGACATCAAATCGTGCCGGGTATATGTGCTGATACTTG  
 GAGATAGTACAACGATTCTTTCTACATGATGACGGATAGTGGTACCGAAATGGTCTACACCCGAGATACGT  
 CGACGAGATCCGGAACGACCCAAGGTTGGACTTTACAGATATATGAAAACCTGTAATAGAATTCCGATCCATTT  
 TCTATATATCCGGGCTGACGTCTACGTACGCGAGGTCTACATGGGCTCAGACAGAAAGGTGGCGAGATAA  
 ACCGAGATCTTATCCAACCAAATGACTAGATCTGTGGGTAAGGGGTTGTCGTCCTCTAGAGAATGCAGGC  
 AAAGGGAAGGACAAGAGTAACTAATGCCCATCCTTGTATAGGTAGGCTCATTGGGTCCATATCGGCTGAAA  
 TCGAGGACGCCCTTACAATCGATGGGAAGAAGGCGAAGGTGAATATGAAGAGTACCTTCTAGTGCTTCCC  
 CCTGCTGAAATGCATACAGAATGGCATGAGATTGTATTGCTCTCCGTAATGATCCCGGTTGTTGCGCAAGGA  
 GTATCCAAAATGTTTGTGCGGAGATCCATTGTGCCGTAACAAGGATTGGATAGGTATGATCTTAAGGCATACAA  
 GGAGTGTCCAGACAGCACTGCGGTCCCTTCGATTGTGGCCTTACTTTCTTAGACCACTTGCAGCCAGATTTT  
 TGCCAACCTGTGACAAGTCACTGCAGAAATAGAAGAGGCCAGGCGCATCATCAATCCAGTACTTGAGAAG  
 AAGCGTGCCGAGAAGCTCGCAATGATTGAGGAGGAGAAAACCTCCAGAGGCCAACCACTACATGGATTG  
 GTTAGAAGAATCCGACAAGGATGAATCTATGACCCAGTTGTTGCTCAGCTGAAGATTTCCATGGCAGCTAT  
 ACACGCTACCTCGGACCTTATCGCAGACAATTTTACGCTATGTGACAGGCCAGAGCTAGTCAAGGAACT  
 GCGAGCCGAAGCTGTGTCTGTTATAGGAGCGTACGGCTGGGGGAAGGAAGCAATCTACAACCTGAAGCTGA  
 TGGACAGCGTCTGAAGGAGACTCAACGCCTAAAACCTATGCAAATCAGTAAGCGCCGGTGGCCCGGTGTG  
 GACTTGCTATCGCTAATCGCTTTGCTTTGCTTGTCTCTAGACTTGACGCGACTAGCTCTAGATCGCATAAA  
 ACTTTCCGATGGCACGGTTATCCCTAGGGGCTCCAAAGTTCTTATCTCCTGCCACAACATGTGGGATTGCAA  
 CGTCTACCCCAACGCAAACAGTATGACGGTCATCGCTTCTATAAACTTCGGCAGCGCGCTGGAATGGAGA  
 ATTCCGCACAGCTATCAACACCTAGTCCGGATCATCTGGGCTTCGGACTGGGAATGTATGCCTGTCCCGGTA  
 GGCATATCGCATCGACCGTTATGAAAGTCACACTATGCCATATCCTCCTGAAGTATGACTTCGAATTGGCGG

## SUPPORTING INFORMATION

AGGGCTGCACCCCTAGAGTGATTGAATATGGTAGTTTCTTGTTAGCTGATCCAACGGCGAGAGTTTCTATCA  
GACGGCGGAAAGAAGAGATTCAACTGTAA

**>nodZ\_gDNA**

ATGATAACAGCATCCACTTCCGTGTTTGGTGGCTTAATCCTTGCCTTTATCTTCTCACTTTTTATATAAGAATAA  
GAAGACCCGTATCCCAGCAGAAATCGACCGCGTAAGGACGGGAGGTTTCTAGCACACATTAGAGCCTTTG  
GGTGCAGGTTAGGTACGCGAGTTGATGATATTCGCAATGGATATAATAAGGTTAGTTGCTCCTATAGCTGCT  
CACAACAAATACTCAACACATGATATCTCAATACGCAGTTCAACAAAAACGGTAAGCCGTTTGTGATCCAGGA  
TTCTACCTTTATCCCACAGGTCGTCATACCACCTCAATACCTGGGATGGTTGAAGGAGCAACCAGAGAAGGC  
TCTTTCTGCAGAAACCGTGAGGCTAGAACAGCTTGGACTTCGCTATTTGGTCCCTAGCTCAGATCCCAGAT  
GGTCCATTTGTTGACAGACGTCGTGTGTCGCTATCTTACCCGCAATTTTCAAAGAGTACAAGAGCGTTTATAT  
GAGGAGCTCCATATGAGTACGGATGAAATCATGGGGCTGGAGGCAACTGAGTGGCGTCAGATTTGTCTCCA  
TGAAGCGATGGAAACGATTCTTCGAAGGATGATTAGTTGCGTCCTGATTGGACTCCCATGGTGTGCGAGATGA  
GGAATGCTTAAAATCGTGGACCGGATTTCTTCACTGCATGGCCATTGCAGGAAGTATTCTAGGGGCAGTAAC  
ACCTTGGTTCCTACGGCCACTCCTCGGACTACTGCTCAAGCCGCCCGTTGGCTATATGCGCAGAAGATCAC  
TGCGTTATCTTACTCCGATCTTACTGAAAGATGGAAAAAATTGAGAAGCATGAGAAGAGCTCACTGACGA  
CGCGTGAGCTGCCGGATGACTTCGTAACATGGTGTATTGAGGAGGTACGGAATGGTAATATGAAAGAAAA  
CACGATGCTCTTAGCCTTGCCTCGGAATTTCTATTCTTTGTGAGTCACTCTACGCGTTGGTATCATGGTTTCC  
CATATTCAATACGCGATGCGATGGATCGAGGCTCTAACGAGAACGCGAGTCGATCGCATTCTTTGACGCGCCT  
ATAGGAGCTGCAGAAGTCAACATGCTCGATCTTCTAAGTCCGGATCCCACAATAGGTTACTGGGAAAAGCTT  
GTGGAAGAAGCCACTACTGCATTGAGAACAGACGAGGACTGGATTCATGCAGGCACTGTGTCAAAATTGGC  
ATACACGGACAGCGCAATCAGGGAGTCTCTACGCCGAAACCCTTTCAGCATCCGAAACGTGACCCGAGAGG  
TGATAGGAAAAGATGGGCTAACACTGCCATCCGGTACGCGTCTGCCACAGGGCACTTGGATCACGACCGCT  
CTCGCCAATATACATCATGATGCAAGATTTTACTCAAATCCCACCGAATACCAGCCTTTCCGTTTTGTGGCCA  
GAGAAGCGTTTACACAGAGGGGAAAGAGGGTAGCGAAAAGGTTTTACAGCCCTCTGAAGCTATCTTGACG  
AGCACAATTGATGAAAGGCTCTTGACATTCGGATATGGGCGTCGAGCATGGTACGAAATCCAACGTCTCTCT  
AGAGTCTCAAACCTTTATATCCTGTCTCCAGTCAACCTACCTAGGTACTAATGCTTTTGCAATTACTGTAGC  
CCCGGCCGATGGTTGCTTACACATACTGAAAATGTTGATCGCGTATATCACGATCAATTATGACATACAG  
CCCTTGACGGGACCGCCGAAAAAAGTCAAATTCGCAGATTTACCCGTGCCATCGCCGAGTATCAAATCATT  
GTGCGCCGGAAGAATCTCGCTTACCTTAGGCAACGTGAGCGTTGA

**>nodY2\_gDNA**

ATGGCGCCTGATAGACTTGGTCCCAGGGCACAGCACGCCCAATTCCAGTGGCATCTCAGTTATCGTGGT  
CGGCCTTGGAAATTGCTGGCCTAACAGCTGCAATTGAGTGCCACCGGAAGGGCCATTAGTCATTGCCTTCG  
AGCGAATGAAGGATGTGCAACCCTTTGGTGAAGTTGGCTTCAATCCCCATATTGGTTACTCCGCCAACCTA  
GTAAAGGCGATAGCATCATCATCGGCAGCAACGGCGGCCGATTTTTCGGCAATGGGGCCGCGGTGAGGT  
ACGCAATGCTATGCAAGCCTGGCGATATACGCCTACCCATGCCGACATTTACGATACCGCCGGAAGATTCAT  
GGCCCAGTCTGAGATTCCCAAAGCTGCGGATGACATGTACTTCACTCTTTCGAGGCAGACTAGCGAAGACCT  
TCTACGAACACGCACAAAGCCTCGGCATTGATATGAGGATGGGGTTCGAAAGTGACTGAATTTTGGGAAGAC  
AGCAATCGGGCTGGAATCGTTGTGGAAGGAGAGAGGTTTGGAGCCGACTGTGTTATTTGCGCTGATGGCAT  
ACACAGCAAGTCTCGCTCCTTGTTCACCTTCTTAAACGCTCAACCATTTTCGTTCTGGTTTCTTATTTTCAGG  
GGGAAAGCGGACGCTAATGCGATTATTGCCGATCCCGATGCGAAATGGATCCTTGACCAGACAGAGAACAC  
CGATCAGTTCAAAGTGGTTCTGGGGAAGGAGATCTGTGTTGTCATAATTACCTGCGGGCTAGGCCGTGCGAGT  
GGTCTGCAGTGCTATGCATAGGGTGAGCAATACCTATCTCCAGATACCAATAATATATAGCAGGTAGGCTT  
TGGACTATATCTTCTGTTCTGCTCACACAAGACTGCCCCAGGACCTAAATGAAGCGGAACAGTCGTGGTCCG  
ACCCATGCCAACCCTGGATGATCTATTGGACGCCATCAAAGACTGGCCGTGCAGGCGCCAGATCGAACCAAT  
CGTTCGGAAGATATCCGAAGACCAGTTCATCGACTATCCCCTTCTAACTGTGTCTCCACTGGACACGTGGGT  
ATCCAGCACGGGCGGATGATTCTAATAGGAGATGCTGCTCATCCATTCTTCCGACTTCCGGACAAGGAG  
GCGCACAAGCCATGGAGGATGCAGCTGTGCTTGCATTTGCCTCGAGTTGGCAGGGAAAGGAAACATCCCC  
CTGGCTCTTTCATGCAACAGAAAAGATCAGGTCTAGTTTCCCGGCCCTTCGGGCTACTCTCCCTTTCCATTTTA  
TCCGTTTTCTTACTTTTCGTAATAACACGTAACCTCCAGAAAGAGCCGAGCTTCAGTCTCCAACATAACAG  
GACGTATTCAGAAGGGTTCAACTAGCACCGCTGCGGAAATCCAAAGACAGCTATGTCTGTTCCAAATGT  
TCCAGTAATGGATTGGATCTGGCATCACTGCTGCCAGTCCCTACGCATATGATGAGTTTCGACAAGGTAGCGGA  
GGCGATTCAAAGCGGGAGTGAATACATTCCACATAATCTTCCAGAAGATGGTACGTAG

**>nodJ\_gDNA**

ATGGAACTTATCGTTATTATCATAACTCTCGCTTTTTGCATCCTGCTGTACGGTACTCGATGGAGAGCTGCTC  
TCGACCCCGCGAGCCCCGTTTGGATATCCCCTACGGTACCACTCATCGGGCACATACTTGGTATCGCGACT  
GACGGCTTTGGGTATTTTTCCAAGCTCAAGTATGGTTAAGACTTCTACATGTTGCTTAGTTGAAGCGAGGAAG  
ATATGCTGTATATAGTACATAGACTAACGGTGTAGATAGTGACAAATATGGACTTCCCGCCTTCTCGCTCCAG

## SUPPORTING INFORMATION

ATGCCACTATCAAGGCTTTATGTGATCACGTCTAGCGAGCTAGTCCC GGCTATTCAAAGACAGTCCCAGAAT  
 ATACGATTTCGATACGTTTCGAATTTACACTGGCCGCAGAACGTGTAGGTGGTGTGTCAGTGGGCCTGGACTTAAA  
 TTGCTTAAAGGTAGTATCGTGGATGAGCTACAACATGCTATGCATCACGCACTTATAGGACATGGCTTGGAT  
 GCCATGAATCTTTCCATGATCGAGGCTATAAAGCCCTCAATAGACGAACTCCAAAGCCAGAAACAAGCGGCA  
 TTCGACTTATTTGCATGGTGTAAACGTTCTATCACAAATGGCGAGCACAGACTCGGTTTACGGTCCCTATGAATC  
 CATTCCGATCCATAGAAGTTGAAAGGGCTTTTTGGTAGGTCAAAGCACAGAATAGAACCCCAATGCTGTGTA  
 AGAATTGCTGAGCTCATACGTGGTGTAGGGATTTCGCGTCAATATGAATATGATAATCCTCAATGTCCTTCC  
 CTTTCTCACAGCACGAAAGTCCCTAGATGATCGTCGTAAGGTTGTGGACGCTCTAACAGAGTATTACAACCT  
 GGGAGGCCACGAAAACCTCCTCGGAAATGACGTATGGTTCGATGGGAGGTCCAATATAACAAGGGAATCACCA  
 CACAAGATATAGCTCGAATGGAAATTGTTAACGCGATAGGTGTCCTATCGAATACTGCGCCTTCCACATTTTG  
 GACCCTTTTCGAAATTTACTCACGCCCGAGTTTGCTGAGGGATCTTCGACAAGAGCTCGTGGCTTCTGCTGT  
 GTACACGCATCCAGGTACCGATGGAGGGATAGTTCGTAATGCTATGATCTCAGCGCTGTACGCGCCAAGTGCA  
 GTTTGCTTCTCGGTACCTTTCAGGAGGTCCTCCGTATGAGGTCTAATGCTATAGTCACGCGCATGGTCCATG  
 AGGATACCATCCTCAACGAGCGAGTTCATTCAAGAAGGGTCCGTGATCGTATCCCTGCAAGATGTGTTA  
 ATCGCGAAAAGTCAGTATGGGGCGAAACAGGGGATAGCTTCGACGCATATCGATATCTCGGCCAGGGGAAG  
 AGTGGGACATCGCGAAGTGGCCGTAACGTCACACGCGTTGCGTTCAGTCTTTCGGGACAGCACCTAACAT  
 CTGTCCTGGGCGCCACTTCGCATCTGGGGAGATATTAGCGGTAGTAGCCATGGTGAATTTACGGTTTGACAT  
 GGAGCCCCTGCTCGGAGAGTGGATTCTCCCAAGGCCAACGTGAAAACACTTGCAAGTTCATACAGACAC  
 CGGCAGGGGAGTTCATGGTGACTCTCAGAGAGAGAAAGGAATCAAGGATGACAAATGGGATTTACGGGTC  
 ACAGAAGGCGACTCGAAGTTTCCACTGCTAGTTGGGTAA

**>natR**

ATGACCACTCTTGACGACACGGCTTACCGGTACCGCACCAAGTGTCCC GGGGGACGCCGAGGCCATCGAGG  
 CACTGGATGGGTCTTACCACCGACACCGTCTTCCGCGTCACCGCCACCGGGGACGGCTTACCCTGCG  
 GGAGGTGCCGGTGGACCCGCCCTGACCAAGGTGTTCCCGACGACGAAAGCGACGACGAATCGGACGC  
 CGGGGAGGATGGCGACCCGGACTCCCGGACGTTTCGTCGCGTACGGGGACGACGGCGACCTGGCGGGCTT  
 CGTGTTGTCTCGTACTCCGGCTGGAACCGCCGGCTGACCGTCGAGGACATCGAGGTCCGCCCCGGAGCAC  
 CGTGGGCACGGGGTCCGGAGAGCGTTGATGGGGCTCGCGACTGAGTTCGCTCGCGAGCGAGGCGCCGGG  
 CACTCTGGCTGGAGTCCACCAACGTCAACGCACCGGCGATCCACGCGTACCGGCGGATGGGGTTACCC  
 TCTGCGCCTGGACACCGCCCTGTACGACGGCACCGCCTCGGACGGCGAGCAGGCGCTCTACATGAGCAT  
 GCCCTGCCCTGA

**>neoR**

ATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTG  
 GGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGGCGCCGGTTCTT  
 TTTGTCAAGACCGACCTGTCCGGTGCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGG  
 CCACGACGGGCGTTTCTTGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATT  
 GGGCGAAGTGCCGGGGCAGGATCTCCTGTATCTCACCTTGTCTCCTGCCGAGAAAGTATCCATCATGGCTG  
 ATGCAATGCGGCGGCTGCATACGCTTGTATCCGGCTACCTGCCATTGACCACCAAGCGAAACATCGCATC  
 GAGCGAGCACGTAACGATGGAAGCCGGTCTTGTGATCAGGATGATCTGGACGAAGAGCATCAGGGGC  
 TCGCGCCAGCCGAACTGTTCCGCAAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCA  
 TGGCGATGCCTGCTTGCCAATATCATGGTGGAAAATGGCCGTTTTCTGGATTATCGACTGTGGCCGGC  
 TGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAA  
 TGGGCTGACCGCTTCTCGTGCTTTACGGTATCGCCGCTCCCGATTGCGAGCGCATCGCCTTCTATCGCCT  
 TCTTGACGAGTTCTTCTGAG

**Genes used in this study (cDNA)****>nodM\_cDNA**

ATGTCTACCCCTGAGTTC AAGGTGATAATCGTTGGCGGCTCCCTTGC GGGTCTAACATTGGCCATTGCCTC  
 CTCCGCGCCGGAATTTCCACATCGTTCTTGGAGCGCCGTAGTGTAAATCGCACCCAGAGGAAGGTGCCTCAAT  
 AGGGATTCTTCTAATGGCGCTCGTGTCTTGGATCAACTAGGCATCTATGAACATATTCAAGACACTACTGAG  
 CCATTGAGTACAGCTCATATACGATATCCAGATGGGTTCTATTTACAGAGTCTGCTATCCCGAGATCATAAAG  
 AAAGGTTTGGGTATCCGATAGCCTTTCTCCCCCGGAGGAGACTTTTGGAGATTCTCTATACATCGTACCCTG  
 ACCATTCTAACATCTATAACCAACAAGAATGTGATCAAGGTGCAAAGCCATGATAATCAAGTTTCTGTCTTGAC  
 AGAGGATGGAAATACATATCGAGGGGATCTTGTGGTGGGCGCCGACGGTGTCAACAGTTCGAGTTCTATCTG  
 AAATTTGGAAACTGGCAGGTAATCCCTCTCTCACGAAACGGGAAGGAAGAGGAAGGACCATCGAGTACGCT  
 TGTGTGTTTGGGATATCCTCGCCAATCTCAGACCTCAAGCCC GGCGAGCAGGTTAACGCGTTCTACGACGG  
 ACTCACAATCGTCACGATCCATGGTAGAAACGGAGAGATATTCTGGTTTTTTATCAAGAACTCTCGCGTCGC



## SUPPORTING INFORMATION

TATATCTATCCCGATCTCATCAGACTGCAGCAGAAAGACGCAGAAGGGATCTGTGAAGAAGCCAAGTCACTA  
 ACTGTCTGGAAAGGTGTTACATTCGGTGACATTTGGGAAAGAAGAGAAACAGCATCATTGACCGTTTTGGAT  
 GAGTTCTTGCATCACACTTGGAGTTGGGACAGATCGTTTTGTGTGGGCGACAGTATCCACAAGATGACTCCA  
 AATTTTGGCCAGGGTGCGAATACTGCTATCGAGGATTCTGCCGCTCTAGCCAATCTACTGCACAGTTTGATC  
 AAGGAGAAACGAGCCGAAAAGCCGACTGACTCAGATATATCACTGCTTCTGAGGCAGTTCAAATCACAGCGT  
 CTTTCGACGCGTTTCAAGAAGATATATAAAATGTCAAGGTTTGTACGCGGCTTCAAGCGCGCGACGGTTGTTG  
 AATACTCTTCTGGGACGCCATTACGCCCCATATGCAGCAGATCTTCCAGCTAAGATTGCCTCTGGATGCATT  
 GCTGGTGCGAAGTTCTGGATTACCTCCCACTTCCCAAGGTAAGTGGGGCGGGCTGGAATAGGGGCCATC  
 GTAGATCTACCATGTACATCCTGCTAGGATTCACAGGGGTATTACCTCTGCTCTGGCCATGGTAGTGTTGC  
 TCCATATTAGAGACATTGCTTCATAG

**>nodW\_cDNA**

ATGACTCTCGCTATTCTGGGCATCAGTTGCCTGGCAGCCGTCTATCTCATACTATTCTGTTTCATCCGAGGA  
 GAGTGGGACAAGCACGCCCGTCTGTTCCATTGCTTCATTACTTGCCCCATTGCGCTCATATGCTCGTTG  
 TTGGCAGTGGGATTATATGGGATCACTTTTATGTTTCATCCAAGTTTGGCTATGCTATATCTTCTATCTGTCT  
 TTCAATCATTATATATCGTTGTTTCTGCATCCCTTGAGAGATTTCCCGGCAAGGTATCCGCCAGGCTGAG  
 CACGTTGAGATGGATGAAAACAGCAGCCGTAGATAGAAAATGGCACCTTGAAGTACAGAATATGCATAGTGT  
 CTATGGCGATTTTCGTCGAATTAGGCCTCGTGAGATATCCGTCAACAACCTTCAATGCCATTCGCGATTTGGC  
 CAAGTGTGCCAGGGGTCCATTCTACGACGTGAATTATCCCCACAAGTCCCTTCAAATGACAAGGGACAGGAA  
 TTTCCACCTCCGACGGAAGAAAATTTGGCAAAGGCCTTCAGTCCATGCTATGCTAGCTCATGAAGGCCA  
 TGTCGGCAATGTTGCCAAGAAGTCAATGGGCTATCTCTCATCTAGAGGAGGTCAACCGGTAGAAGTAACTGA  
 ATTGATGCAAAGAGTCACATTTGAATCAATGGGTTGGCTTGATTTGGAAAGGCCTTCAACATGATTCAAAAA  
 GGCCTTTCGCATCCCGGCTTACGCAACTGAGGTCTGTCAAGCAACTAGGGGGGCTCCTTCTGTGGGCGCC  
 TTGGACGTTGATCCTTCTCCGCAATCTACCGTTCCTTGAGGTCCAAGGCAACAAGTTGGCTACAGTGGTGCTC  
 ACAGGAGGTAGTGGAAAGGAAGCAAATCCAATGACTCACGATCTATTACGCCATCTCCTGGACGACGA  
 GTCTAAAGATACGGATGACCTCGTCTATGATTCTGAGCTGGCTGTCTGGCCGGTAGCGACTCTACAGCATC  
 GACCCTTACTGCCATCTTGTTCCTTCTGGCAACCCATCCAGACAAGCAGGCAATTTCTCAAAAAGAGGTTGAT  
 GACATGAATATAGGTGGACTGCCTATGCCAACCTCCACCCTAGTCAATATGCCTTCAACAGTTGCATC  
 AACGAAGCACTCCGTCTTTATCCAGCAGTGTAGCGGCTCGCAGCGGAAACCGGTCCCTGGTGGAGTGTAT  
 CCTTGATGGCCAGTTTATACCAGAGCATATGCTCGTATCCATGCCCACTTACACGATACAGGGGATAAGAG  
 AAATTTCTGTCAGGCCAGATGAGTTCATCCCGGAGCGCTGGACGAGCCAATCACACTTGACTCTCAACCCAG  
 ATGCATTCATCCCTTCTCTGTGGGTGTGTACGGATGCCTCGGTAAACCTTTCGCCATGATGGAGATGCGTA  
 TGGTAATTTCTCTATAATGTCAAGATTCAATCTGAGACTTCTGCCTGGGCGGCCGATGAGCCATGAAGCCT  
 CTGCGCCAGCATACGATTGCTATATAATTCAATATACCAGCGTTTTCTTGTGTTTTGAACCCCGGGCTGGAA  
 TATCTGGGCATAA

**>nodD1\_cDNA**

ATGGATGCTGCTTCAACTCTTACGCATGCACCGGTATCTCAGCCATGGCAGTCCCTAGCTCAAGGGTTGGG  
 GTTCGTCAATGAGCATGAAGGGTACTGGTGGTCTAAGCTTGGACCTCCTCTCGGTAAAATGATGAACTGGGC  
 TCGATACTCGACATCGGAACAGTACAGAGTCTTAGCATTCTTTACAAATATCTTCTCCCTGCCTGCGGCC  
 AAAGCCTGGTGTATGATGGTGTGAGCTGTTCTGGAAGGTTTTTCATCAGCTATGATTACACGCCCATTCAGCTCAG  
 TCTCAATTTTACAATGGCAAATGACGCTGCGCACCGCGAACATACCAATTAGCGATAAATCGGGAACCGC  
 AGACGACCCAATCAACCAACAAGCTTCGGTAGACGCCATAATCCGCCAGGAACGAGTGTGGCCATCCCAGG  
 ATCTACGTTGGTTCAACCACTTTGCATCCCAGTACTTCTTCGACAAGGACACGGCAGCCTCTCTAAAGACCA  
 AGGTGCGATAAGCTCCGAGTCCAGCAGGGAGTTCAGTGTATGCTGAGCCACGACTTTCCTGAGCGTGTATGC  
 CAATGCAAAGTGGCTTTCTGCCCCTTTGGAAAGCCGTGCTACAGGTCTTTCCAACAAGGAGATCATCTGG  
 GATTGATTCTAGGGCTCGGAGATGACATCATCCCATACAAGCGAGCGCTTGTCTGCTTGAACAGTACACA  
 TCGTCCGAAAATGCAGCGAAAGCAGGAGTGCAGCCTGTATTCTTCGCTTTCGATACGGTGTAAAAGATAAT  
 TACAAGAGCTCTCGTATCAAGATCTACTACCTCACAAACACGGACAGCCTTCAACTCTATGGTCGACATCTACA  
 CACTTGGAGGCTGCTAAAAGGGCCTGATATCCAAAAGGAGTAGAGGGCCCTTGAAGTGTCTGGAAGGCC  
 GTCCTCAACGTCGCCAGGGGTGGCCCGATGATAAAGATCTACCCATGAATCCACACCGTTGTGCGGAGT  
 AATCTTCAATTTTGTGAGTGTGGCCAGGAGCAGAGTTTTCCGACTCCCAAGGCCTATCTCCGACCTTATTA  
 TGGCCGCTGATTTGGAGATAGCTGATGGTATGGACTACTTCTTCAAGCAGCAAGGGTTGGATGGGGTAT  
 ATGGTTCTTACAAGGAGAAGTATTTGAAGTGCTTACGAACTCACAGAACCAACTCACAGCCCTCCACCATGA  
 TATTTCTTTTTTCAATCAAAGGGTCCAATGCCTACGTTACGGTGTACTACAAGCCCGAGCTATCTCTAGATACC  
 GAGTAG

**>nodO\_cDNA**

ATGGAGGTTTCTCAAGTGAACACTCCCCATTCTATGGAGAACGAGTCCCTCCCTCAAACGACTATGAAAAT  
 GCAAGATGCAGAGTGTTCATGGCAGGCAGCCTGAGCACTTCCCCCTTGAATAGTCAAGGCCAAACAAGGT

## SUPPORTING INFORMATION

CGAGCATATTGTAGCCGCCGTGAAACTGGCAGCAGAACTAGACGCCTGTATCGCCGTTTCGTTCCGGGCGGCC  
 ACAGCCTCTCTTGTGGACTATACGCCATGGGGCGATCCTTATTGACCTCGAAGATTATCAGCACTTGAGCT  
 ATGACGACGAGATCCATGAAGTGCAAGCTTACCCAGTACACTTGGTGCGGACCTACTTACGTTCCCTTGCGA  
 AGAAAAAGAGGTTCTTTCCCGTAGGTCACTCTGGAGACATTGGCTTAGGTGGCTATCTCCTTCAGGGCGGAA  
 TTGGGCTCAATTCTCGGGGATATGGGTATGCCTGTGAATACATTACCGGGCTTGATATCATCACCCTGATG  
 GTGAAATCAAGCATTGTGATAAGACGGAAAACTCTGACCTATACTGGGCTGCTCGTGAGCTGGACCGGAA  
 TTCCCTGCAATCGTTATACGGTTCTTCCCTGAAGACGTGCCCCCTCTTGCCGGTGTGTAAGCGGAGTAGATAC  
 GTCTGGCCGGCGGCCATGTATGGGAAGGTTTTTAAGTGGCTTGAAGAGCTATTGAATTCCTTGAGCGAGGA  
 CGTCGAGATTGCCGTTTTCGGGTTTGTATTGCCCGACTCAACCAGCCAGGCTTAGTCCCTCCATGCAACAGC  
 ATTTGGTGACTCTAGCGAGAATGTCCGGGAAAAGCTCACGCCTATCATCAAAAATCATCCTCCAGGGACTTT  
 CTTGGCTGAAGATTTCTGTGAGCACCCTTCCCGAAGACTACGACCTTGGTAAGGATACCATGCCGCGGG  
 GCGCTCGCTATTTTACCGACAGCGTCTTTCTCAAGCCCGGTATCGACTTCGTCGCAACCTGCAAAGGAATGT  
 TTACGGAGCTCAAACATCCCGTGCATTGGCGTACTGGCAACCGATGAAGACCAATATTGATCGCATCCTTC  
 CCGATATGGCCATGAGCATCCATAGTCATCATTACGTGTCACTACTTGCATCTATGAAGACCCCAAGTGAGG  
 ACCAACAGCAAATATCCTGGATCATAGATCGTATGAAAAGTCTTGAGCCGGCAATCCTGGGAACTTTCATAG  
 GGGATGCACACCCAGTGGAAGGCCATCTAATTATTGGTCCGAGGAAGCTGAAGAACGGGTGATCACTATT  
 GGGCGAAGTGGGACCCTAGTAGTAGAATTCGGGGTATTGTGTTGAGCGACGCCTAA

**>nodD2\_cDNA**

ATGGACTCTACCGGGAGACAGCCTCTCAGCCAGGACGGGCAGCCATGGCAAGCTCTTGCCTCTGGCTTGG  
 GATTTCCAGATGAAGACCAGAAGTATTGGTGGTCAGTCATGGCGCCCTACTCGGGGAACTGATGAAATGG  
 GCCAACTATCCTGTTGATAAACAGTATCTTGTCTTGCCTTCTGCCATGAATACATACTTCCATTTTGCAGC  
 CTCGTCCAACGGCCGAAGGCGGTATCTTCTGGCCACGTTGATCACCAGGATGGTACTCCGTTCCGAGCCG  
 AGCCTTAACCTTACAAAAATAAAGCCACTCTACGAGTTGGATATGCGCCTGCATGCGAGCTTTCAGGAAGC  
 AATGACGACCCTATCAATCAACGAGCCCAATTGCGGCATTGGAGCACCAAAAGAGAGTCTTACCACAGCA  
 GAATCTCAAATGGGTGGATAATTTCAAGAAAGCATGGTTCATCGATAATGACGACGCAGTAGCCTTGAAGGC  
 ACGCGTACATAACGAGCTCTTTGAACAGGCGAGCCGTCCTAATGCTTGATAGGTTATGTGTTTTCCGACTACAC  
 GCAGGTCAAAGTTGCCATGAGTCTCTTTGGAAGTCAGTCCAGACAGGCCAGCAAATTTCCGAGTGATCT  
 GGGACACCTTTCCGACGCTTGGCGACGATGCTTCCAGTTACCTAGATTGCCTATCAGTGTAGAGGATATA  
 CTGAGTCTAAACAGGCCAACTAGCACAAAGTACAGCCTTCCCTTCGTCATTTTCGATGTGAATCTGAAGGGGG  
 ACTACCAGCAGTCGCGACTTAAGGTATACTATGCTACACCATGCACTGCATTCGACACGATGGTCCAGGTTT  
 TCACTTTGGGCGGAAGGCTCAAGGGCCCTGAAGTTGACCATGCGATTGAATGCCTTCGTGTCTATGGCC  
 AGCGTGCTTGCAGTTCCTGAAAACCATCCGGACGACCAAGACTTGCCTCGACGGTACCACTCTGTAGCAGT  
 GACCCAGTTTAACTTCGAGCTCTGGCCGGGAGCGAACTGCCTGTTCCCGAGATCTATCTCCCGACTAACTT  
 TTACGGTCGTGATGAATTGGAAATTGCGGAGGGCCTAGAGGGATTTTTCAAGACTCTTGGCTGGAGTGAGC  
 CTTTCCATGCCTATAAACAGAATTACATTGCAACATGTGCCACGCCCGAAGGGAAATGGAAAGCGATCCAAC  
 ACGACGTATCATTCTCGTTCAAGGACTCAAGCCCATATGTGTCCGTTTATTATAAACAGAGCTCTCGGTCT  
 ATCCTCACCGTCGTAG

**>nodR\_cDNA**

ATGTTTGATATTGATTTTGGCATTCTATTTCCAATTTCTGGAACAATCCCCTATCTTTCTGGCTGTTGGGCT  
 AATATTCGCATTTGCGACCTTATCTCCGTGGCTCCGTTCCGGGGAACGCCTGATCAATGGTCGCGAAGGCTT  
 CGAAATACTGTGGACGAATGCGAAGAAGCGATATCAAACGAAGGGGCGATCTGTTATGGAGGCAGGCTTTT  
 CAAAGTACAACGATTCTTTCTACATGATGACGGATAGTGGTACCGAAATGGTCTACACCCGAGATACGTCCG  
 ACGAGATCCGGAACGACCCAAGGTTGGACTTTCACAGATATATGAAAACCTGTCCTACATGGGCTCAGACAGA  
 AAGGTGGCGAGATAAACCAGATCTTATCCAAACCAATTGACTAGATCTGTGGGTAGGCTCATTGGGTCCA  
 TATCGGCTGAAATCGAGGACGCCCTTACAATCGATGGGAAGAAGGCGAAGAATGGCATGAGATTGTATTG  
 CTCTCCGTAATGATCCCGGTTGTTGCGCAAGGAGTATCCAAAATGTTTGTCCGAGATCCATTGTCCGTAAC  
 AAGGATTGGATAGGTATGATCTTAAGGCATACAAGGAGTGTCCAGACAGCACTGCGGTCCCTTCGATTGTGG  
 CCTACTTTCTTAGACCACTTGCAGCCAGATTTCTGCCAACCTGTGACAAAGTCACTGCAGAAATAGAAGAG  
 GCCAGGCGCATATCAATCCAGTACTTGAAGAAGAAGCTGCCGAGAAGCTCGAATGATTCAGAAGGGAGAG  
 AAAACCTCCAGAGCCCAACACTACATGGATTGTTGTAAGAATCCGACAAGGATGAATTTCTATGACCCGAT  
 TGTGCTCAGCTGAAGATTTCCATGGCAGCTATACACGCTACCTCGGACCTTATCGCAGACAATTTTCAG  
 CCTATGTGACAGCCAGAGCTAGTCAAGGAACTGCGAGCCGAAGCTGTGTCTGTTATAGGAGCGTACGGCT  
 GGGGGAAGGAAGCAATCTACAACCTGAAGCTGATGGACAGCGTCTGAAGGAAACGCAACGCCTAAAACCT  
 ATGCAAATCAACTTGACGCGACTAGCTCTAGATCGCATAAAAACCTTTCCGATGGCACGGTTATCCCTAGGGGC  
 TCCAAAGTTCTTATCTCCTGCCACAACATGTGGGATTGCAACGTCTACCCCAACGCAACCAGTATGACGGT  
 CACCGCTTCTATAAACTTCGGCAGCGCGCTGGAATGGAGAATTCCGCACAGCTATCAACACCTAGTCCGGAT  
 CATCTGGGCTTCGGACTGGGAATGTATGCCTGTCCCGGTAGGCATATCGCATCGACCGTTATGAAAGTCAC



## SUPPORTING INFORMATION

TCTCACAGCACGAAAGTCCCTAGATGATCGTCGTAAGGTTGTGGACGCTCTAACAGAGTATTACAACCTGGG  
 AGGCCACGAAAACCTCCTCGGAAATGACGTATGGTCGATGGGAGGTCCAATATAACAAGGGAATCACCCACAC  
 AAGATATAGCTCGAATGGAAATTGTTAACGCGATAGGTGTCCTATCGAATACTGCGCCTCCACATTTTGGAC  
 CCTTTTCGAAATTTACTCACGCCCCGAGTTTGTGAGGGATCTTCGACAAGAGCTCGTGGCTTCTGCTGTGTA  
 CACGCATCCAGGTACCGATGGAGGGATAGTTCGTACTATTGATCTCAGCGCTGTACGCGCCAAGTGCAGTT  
 TGCTTCTCGGTACCTTTTCAGGAGGTCCTCCGTATGAGGTCTAATGCTATAGTACGCGCATGGTCCATGAGG  
 ATACCATCCTCAACGAGCGAGTTCTATTCAAGAAGGGGTCCGTGATCGTGATCCCTGCAAGATGTGTTAATC  
 GCGAAAAGTCAGTATGGGGCGAAACAGGGGATAGCTTCGACGCATATCGATATCTCGGCCAGGGGAAGAG  
 TGGACATCCCGAAGTGGCCGTAACGTCACACGCGTTGCGTTCCAGTCTTTCCGGACAGCACCTAACATCT  
 GTCCTGGGCGCCACTTCGCATCTGGGGAGATATTAGCGGTAGTAGCCATGGTGATTTTACGGTTTGACATG  
 GAGCCCGTGCTCGGAGAGTGGATTCTCCCAAGGCCAACGTGAAAACACTTGCAAGTTCCATACAGACACC  
 AGCAGGGGAGTTCATGGTGACTCTCAGAGAGAGAAAGGAATCAAGGATGACAAATGGGATTTCAAGGTCA  
 CAGAAGGCGACTCGAAGTTTCCACTGCTAGTTGGGTAA

**>nodX\_cDNA**

ATGGAGTCAAGTGCGGATAATACAGTTCCCAAGCAAGCGGAATCTGTATTCATACGCGAAATTCTAGAGAAT  
 CCGCTAATGCCAAATCTTCCCCCTGAGCTGGCCGAAATCGCCAAATTTGTCTCCTTCGAGGGAAACGTCAAG  
 CCTAGCATTCTGTTAACTGGAGGCTCGCAGAGAGCATCTCAGCTTTGAAAGCCTTTGAAGCAACGTTCCCTG  
 AATTATCTGGCCCATCGGAAGTATGGTGTACGCCCTAGCAATGTCTCAATAAACACAGACCACGCAACCTTG  
 TTCTCATGTCCCCCATGCTCACCCAAATCGAGGATAGAGGAGAAGTCCGTCTTTTCTCGCCATTTGATACA  
 CTGACAGCAGAACTTTTTCCGAACCGAGATAAACACCCGCGCCAACGCATCTCTACAACGGGCATTGATTACC  
 AATATCTATAAAACAAAGGATGGCCGTTTCTACCATACACACGGGGGAATGAATCCAGAGCCCACCCTACAG  
 GCACTAGGGTTGCCCGTCGAAGGCGAGGTTCAAGACACTTCTGAGGTCGTAACCGACAGGATCCAACAAAG  
 ACTCTCAAAGTATGACGCCACACATCTAGACCATTTGCTAAATGAAGAACACCCGCCAAGCCGGTACCATTGT  
 CTACAGCTCCGCTGAGTACTTTGCCAGCGAGCACGGCCAGAAAAATGGCAAGGTGGGACTGTATGAGGTCA  
 TTAGAGATCCAAATTTCTCAGCCAGCAGCCTGGTGGCTGATCATCCTAACGCTCCATCGAGCCCCAAGA  
 GGCCGCTGGCCGGGCTGAAGGTGGTGGACTTAACGCGCGCTATAGCGGGTCCGACGATAACACGAAGTCT  
 TGCCGAGATGGGGGCTAGTGAATGCGTGTACTTTCCCAAGACATCACGGACATGTCGGTGTACACCAAG  
 ACTTGAATTGGGGCAAATGGAACACTCATGGCTACGGTTGGATGTCGAATCTGACCGCCAAAAGCTGAGGGAC  
 TTGATATTGGATGCAGATGTGGTTGTAGATAGCTATCGGCCAGGTGTGATGAAACGTTTTGGCTTTGGCTAC  
 GACGAGGTGTTCAATCTGGTGCGGGACCGCAGTCGTGGTATTATTTACGTCAGGGAGAAGTGTATGGTTG  
 GTATGGACCCTGGAGCCATAGAAGCGGCTGGCAGCAGATTAGCGACGCGTGCTGCGGGATTTCTACTTCGT  
 ACGGCCATGCTATGGGTCTTGAAGAGCCTGTAACCTCCTGCTCTGTTCAATTCTGATTATTGTACCGGAATATG  
 CGGGTCCACGGCTGTCTTGGACGCCCTTGTCCAAAGAGCCGAGAAAGGGGGAAGCTACAGGGTTGATGTA  
 TCAATCAACTATTACAATCAATGGCTTGTTCGATCAGTCGGGACATACGACGAGCATACTGGACTGACCTG  
 TTCCGCCGTCACGACGCACCTGTTTTCAGACACTACCACTCCATGCAATACATGCTGCCTAAGCTGCTAACG  
 GCATTGTACAAATTCGACGGCGAGATTCTTTTCAAAGGGAATTTTTCCGGCCATTCCGGTCCGGCGCGTTG  
 AACACGACGTTTCATACAAGTAAGGCCTATCGCTCGATTCAAGGACGACGCGATTGAACTCAAGTATAATGTG  
 GGCACGAGAGGGAACGGAGTGCATGCGCCAACCTGGCCGGCAGATCTACGCCGTGAGATTGTGAGAGATG  
 AGGATGAGCAGGGGTCCGGATTCAGGTCAGGGTCAGGGTTAGGGTCAGGGTCCATTGCAGATTAG

**Terminators used in this study****>TpaxG**

TCACTCCCGAGCAATATTGCTAAAATAAAGTGGGTCCGGTATCGTTTTACCGAATGAAAATGTCGCATTTCCA  
 CTTTAAAGAGGTAAACCTCGGCATTTTTCTTGTGTCACTTGGTTAAAAGCACTATCCGTATATCTAACAACACAT  
 CAAGCTCACGAACCTGAAAATAGTTCATAGAATAACTTGAACCTCAACGACAATATTGATAAATGCTACTAATA  
 TTTGGAGCATAAACTCTGCATTTTTCAGAGTATCGTTAAGTCCATGTCATTTAATTTTATGACCGCCAAGGTTAA  
 CTAATGAATGGTGAAGTTCGATACCAACTTCTTGCCTTCCAAACATTTGAATGATCGCGGTCCGAGGTACATTTG  
 CTTCACTATTGCGAGTTCTATGCAAAAATTCGATAAATGAAAATATGGGTTGAAAACGCTTGGAAAATATT  
 TCATTATAAAGGAATCTCTATCTCCGCGATACAGCGATCCTGGAAGAGAAATGCAGCAGCATTGA

**>TpaxC**

TTGGCCTTGTGAAATATGGGACTACGAAGTGAATCAGAAGTGAATATTGAGTATTTGAGTCTAGATAGTTTAC  
 AATTTTACTTGAATTACCAAATTTGCAGAATTCTACCAAGCTAGACTACATGCGGGGTGATCCTTCTTAG  
 ACTCATGTCTGCAGTTCAGTATAACGAGGATGCCTTCTATAGGATATTGAATCTACGTTGAAGTATTCCTT  
 ATAGAGGTTGCAAAGTGGCCAGCAACATCTGATATCCGACATGACAGAGAT

**>TpaxM**

## SUPPORTING INFORMATION

ACCATTGGAGCAATTTTTGGTTTTCTTTCTTTCCAGTGTCTAGCTGTTGATTGTCACCTATCTTGCTTTCAAG  
 AACATCACTAGATTTGAGTTCAATTAGTACTATATCGTTAAGCCGCTTTGTTTTAAACCGTCTTCAGGCTCCC  
 TGCGAGAGCATTCAAGCGATCTCAAATGGGCAGCGAATACTCACAGCTTGAGTAAGCCATACTATGAAAATT  
 CCATACACTATCCATACCTACTTTTTCTACGAAATATTTCTACTGCAGAGGGGTACTCTGACTGACCAGTACG  
 ATGGAAGATAGAACTTTGAAATTGACAATCGACATTCCTTACCACCTTCTACTACACTGGGTCAACTCCGA  
 AAACGAAATTTCTATATTAATGTGGCAAATCAAGGCCGGACAGTGTCTCATAATATATAAGCAATGTTCCAAG  
 GTTAGTATCATAATGCAAGTCCTAATCCACCTCTACGACAGAAGAATTACCTGGGTGGCCGTAGACCCACAA  
 GCAATCGAGTCCAGCCAGCGAACTTGGTAATTTCTGTCAGCTGTAATGGATGTCAGTTACACCGATGAAAGAT  
 CCAATTTCTCCTAGCTATAATTCCTCGTCTTTTTGGGCCATGTTTCATTCTATCGGGGATTTAAGAAGGGAG  
 ATCTCACCAGGCTATTGTATCAGATGCCCATTTGTTTTGCAACTCTATTCTCGGAAATCGGCCAATTAGCAAAA  
 CAGTTAACTGAAGTAAGCCAAAA

>*TpaxB*

GGTTAACAATGAGGAACGATGAACAGTGGTTGAAATTCAACTCAGAATCAACCTTTGCATACTAATATCATA  
 TGATACAGATTGCATAGTGTGAGCCACAAATGATCATTGCTTACTACTAAAACGTGCCAATTATATCATGGATT  
 GGGTGCCTTTGGACATGCACGTTACGCGTATCGTAAGCAAAGTACATCGTATGTACTTTTCTCAATTTCAAT  
 CTAGCACTGGCAGAAATGCATGAAGAAAAGATTTCTTTTTTTCGGATCTTAGTTTCCAAGGTTATTTCAAAAAGT  
 AAACGTGTATTTTTGTTTCTAATTTTCTTTTCTTTTCTTCAATTTCAATTTACTTTTTCTCATCCCTCCATAGATA  
 ATGCATTGTATGCAGAATAAGCTAGTTACATGTTTCACCCTCAACTGCCGA

>*TpaxP*

ATAGGGATACGTTGCCGGTCGCTTTGTTGTCTTTGAACGCAGTGGTGGGCAGTGGACGTTCACTGGAGAT  
 AGATTTTACATCTTAGAATGAATTGAATTATGCTTTCTGTTTATTAATCCTCAGGAATGTCTTCTATTCTCTGTA  
 ACAGTGAGTCGGATCAGAATACCTGAGTGCATTAACCTTGTGGCATCCTTTTCTGGTTCTTCTGTAAGGGA  
 CATTGCCTTGAGATTGAATGGCCGCCCTCGCAAAATTGTAATCCATGCTC

>*TpaxQ*

TCTAGTTTCAAATTCGCTGGGTTGGAGTAATCATTTTAAACAATTGATGAAAGCCCAATCGCAAGTCCTACAGC  
 TCATTATCGTGCAAGCAGCTGGCTCACCCACCTCTGGGGTTGAGTGGCGAACTATGTGAGACTAAGGAG  
 CCCCAGTCTGCTAGTGTTTAACTGCCCATTTTTTTCATGCCACTTTTACATCTTGCCTTATTGTGGCGCAG  
 TCTAGAGTTGCAAATTTGAGATACTTGGTAAGCGAGCAGGAGAGATACCATGCGCCTCAGATACTGTTTCA  
 TTTTATTGATAGTAGTAGAGTTAGCTAGACTGGCGAGTCTTCTTCTGGAACACTACAGGATAGTCCAGATTCTGA  
 GTAGTAACAAACAATAAGCTCGTAGTAGTACATGTTGAGAAAGCCTTGAAATTTTGATACTATGGTTGCTTGA  
 ATAAGGCGATCCGATTCCACGGATGTCAAATTTATCGAGTGAATCTATTTCAAATTTCCCT

>*TtrpC*

GATCCACTTAACGTTACTGAAATCATCAAACAGCTTGACGAATCTGGATATAAGATCGTTGGTGTGCGATGTCA  
 GCTCCGGAGTTGAGACAAATGGTGTTCAGGATCTCGATAAGATACGTTTCAATTTGTCCAAGCAGCAAAGAGTG  
 CCTTCTAGTGATTTAATAGCTCCATGTCAAACAAGAATAAAACGCGTTTCCGGTTTACCTCTTCCAGATACAGC  
 TCATCTGCAATGCATTAATGCATTGGACCTCGCAACCCTAGTACGCCCTTCCAGGCTCCGGCGAAGCAGAAGA  
 ATAGCTTAGCAGAGTCTATTTTCAATTTTTCGGCAGACGAGATCAAGCAGATCAACGGTCGTCAACAGACCTAC  
 GAGACTGAGGAATCCGCTCTTGGCTCCACGCGACTATATATTTGTCTCTAATTGACTTTGACATGCTCCTCT  
 TCTTTACTCTGATAGCTTACTATGAAAATTCGGTCACCAGCCCTGGGTTCCGAAAGATAATTGCACTGTTT  
 CTTCTTGAACCTCAAGCCTACAGGACACACATTCATCGTAGGTATAAACCTCGAAAATCATTCTACTAAG  
 ATGGGTATACAATAGTAACCATGGTTGCCTAGTGAATGCTCCGTAACACCCAATACGCCGGCCGAAACTTTT  
 TTACAACCTCTCCTATGAGTCGTTTACCAGAATGCACAGGTACACTTGTTTAGAGGTAATCCTTCTTTCTAGA

>*TaceB*

GCTTTACACTGCGGTGATACAGAGATAGATGAGAAAAGTATCTTAAAAATAAACTATTGAGCGGATGAAGAA  
 AAAGTAAACATTTGTATGGTTGACCAACGCGAAATGTAACGTTAGGTACGCAACTCTGCAGGAAAATATATG  
 GGTGAGTGAACCTACAGTCTTAAACCTTGGCGAAACCAGGGTTTGGATTTCCAGTCGGCGTCCGTCCA  
 AATGCAAATGGTGTGATTTTACAGACACCTTTTTTTTTGCGCTCCACTTTAGCTCGTGAATCGGAGGTAGAT  
 CGCCATCAGAGAGCGTGCAGACTCTGCGTGACACGCGAGTTGGATTCAATTAAGTACTGCTAGCTTCTATAG  
 GGCTGTGTGCTTGAATCTCCCGTCCAACCGTGCAAG

SUPPORTING INFORMATION

---

**LC-MS Analysis of Fungal Transformants**

The analysis of fungal transformants by LC-MS was conducted as described above (pg 4–5). For each of the transformants in this study extracted ion chromatograms (EICs) for key nodulisporic acid products have been reported. In each case the peak representing the metabolite of interest has been marked with an asterisk after confirmation by HR-ESI-MS<sup>2</sup> (Table S3, and pgs 43–65), or isolation and NMR analysis (pg 66–142). When no asterisk is shown the metabolite was either not produced, was below the limit of detection for the instrument, and/or was not confirmed by HR-ESI-MS<sup>2</sup>.








## SUPPORTING INFORMATION


Strain: RC128  
Metabolite: DH-NAC<sub>4</sub>\*  
LC-MS Trace: EIC (654.4 M)



## SUPPORTING INFORMATION

Strain: RC166  
Metabolite: DH-NAB<sub>4</sub>\*  
LC-MS Trace: EIC (652.4 M)

## MSD1\_652




## SUPPORTING INFORMATION

Strain: RC167

Metabolite: DH-NAA<sub>4</sub>\*

LC-MS Trace: EIC (666.4 M)




## SUPPORTING INFORMATION

Strain: LS201

Metabolite: NAD<sub>4</sub><sup>+</sup>

LC-MS Trace: EIC (586.4 M)




## SUPPORTING INFORMATION

Strain: LS201

Metabolite: 24-hydroxy-NAD<sub>4</sub> (*metabolite not observed*)

LC-MS Trace: EIC (602.4 M)

## MSD1\_602




## SUPPORTING INFORMATION

Strain: LS202

Metabolite: NAC<sub>4</sub>\*


LC-MS Trace: EIC (670.4 M)



## SUPPORTING INFORMATION

Strain: LS203  
Metabolite: NAB<sub>4</sub>\*  
LC-MS Trace: EIC (668.4 M)


## MSD1\_668



## SUPPORTING INFORMATION

Strain: RC173  
Metabolite: NAA<sub>4</sub>\*  
LC-MS Trace: EIC (682.4 M)

## MSD1\_682






## SUPPORTING INFORMATION

Strain: LS148

Metabolite: NAD\*

LC-MS Trace: EIC (584.4 M)


## MSD1\_584



## SUPPORTING INFORMATION

Strain: LS148  
Metabolite: NAD<sub>1</sub>\*  
LC-MS Trace: EIC (600.4 M)

## MSD1\_600




## SUPPORTING INFORMATION

Strain: LS146

Metabolite: NAA\*

LC-MS Trace: EIC (680.4 M)




## SUPPORTING INFORMATION

Strain: LS146

Metabolite: NAA<sub>1</sub>\*

LC-MS Trace: EIC (696.4 M)




## SUPPORTING INFORMATION

Strain: LS196

Metabolite: NAD<sub>4</sub><sup>+</sup>

LC-MS Trace: EIC (586.4 M)

## MSD1\_586




## SUPPORTING INFORMATION

Strain: LS196

Metabolite: 3<sup>h</sup>-hydroxy-NAD<sub>4</sub> (*Metabolite not observed*)

LC-MS Trace: EIC (604.4 M)




## SUPPORTING INFORMATION

Strain: LS170

Metabolite: NAD<sub>2</sub>\*

LC-MS Trace: EIC (618.3 M)




## SUPPORTING INFORMATION

Strain: LS197

Metabolite: NAA<sub>4</sub>\*

LC-MS Trace: EIC (682.4 M)

## MSD1\_682






## SUPPORTING INFORMATION

Strain: LS197

Metabolite: 3<sup>rd</sup>-hydroxy-NAA<sub>4</sub> (Metabolite not observed)

LC-MS Trace: EIC (700.4 M)




## SUPPORTING INFORMATION

Strain: LS147

Metabolite: NAA<sub>2</sub>\*

LC-MS Trace: EIC (714.4 M)

## MSD1\_714




## SUPPORTING INFORMATION

## Identification of Nodulisporic Acids by Tandem Mass Spectrometry

Nodulisporic acids were identified primarily by HR-ESI-MS<sup>2</sup> using a method and information gained from the analysis of purified nodulisporic acids and their precursors. These included examples from each of the major series and at each biosynthetic step Emindole SB, NAF, NAE, NAD<sub>4</sub>, NAD<sub>4</sub>-OMe, NAD, NAD<sub>1</sub>, NAD<sub>2</sub>, DH-NAC<sub>4</sub>, NAC, NAB<sub>4</sub>, NAB, DH-NAA<sub>4</sub>, and NAA<sub>1</sub>. Comparison of HR-ESI-MS<sup>2</sup> spectra collected from these compounds allowed for fragmentation patterns to be rationalised and the information utilised to predict, and subsequently identify, MS<sup>2</sup> spectra of nodulisporic acids present in fungal transformants.

Both emindole SB and NAF have only one major fragment, 130 *M*, which is characteristic of the indole moiety having lost the terpenoid portion of the molecule. NAE also has only one major fragment, 266 *M*, which is consistent with a diprenyl indole moiety. No 130 *M* fragment was observed for NAE suggesting these prenyl groups are less readily lost than the original diterpene skeleton. For NAD<sub>4</sub> a more complex fragmentation pattern was observed. Loss of the terpene skeleton and retention of the western portion of the molecule explained the peak at 280 *M*, but two other fragments (524 *M* and 222 *M*) were also observed. The loss of a second portion of the molecule, with a mass of 58 *M*, would explain both these fragments. It was hypothesised that this second portion could be the ring oxygen and neighbouring geminal dimethyl carbon, OC(CH<sub>3</sub>)<sub>2</sub>, from the A ring. Analysis of the methyl ester, NAD<sub>4</sub>-OMe, showed that only one of the fragments as 524 *M* was replaced by 542 *M*. This was consistent with the proposed fragmentation pattern of the molecule as shown in figure S1. NAD, NAD<sub>1</sub>, and NAD<sub>2</sub> all showed MS<sup>2</sup> spectra consistent with the fragmentation pattern observed for NAD<sub>4</sub>.



**Figure S1.** Proposed fragmentation of nodulisporic acids, NAD<sub>4</sub> and NAD<sub>4</sub>-OMe

The major fragments in the HR-ESI-MS<sup>2</sup> spectra of DH-NAC<sub>4</sub> and NAC were consistent with successive loss of the eastern terpenoid skeleton and OC(CH<sub>3</sub>)<sub>2</sub> of the A ring, indicating the same fragmentation pattern as for the D-series metabolites. An additional fragment for C-series compounds, suggesting a loss of *M* 68, was attributed to the C-26 prenyl group. Further confirmation was found in the fact that this fragment was not observed for NAB and NAB<sub>4</sub> in which the prenyl group is cyclised and therefore less readily lost during CID. The HR-ESI-MS<sup>2</sup> spectra of

## SUPPORTING INFORMATION

---

DH-NAA<sub>4</sub> and NAA<sub>1</sub> were also consistent with the fragmentation patterns observed for all other nodulisporic acids analysed.

Given the consistent and predictable way in which the nodulisporic acids were observed to behave when analysed by HR-ESI-MS<sup>2</sup> it was possible to predict fragmentation patterns for biosynthetic intermediates. This allowed for rapid and accurate identification of nodulisporic acids in crude extracts where purification was not possible due to instability or low abundance. High resolution masses, key fragments, and annotated HR-ESI-MS<sup>2</sup> spectra for all nodulisporic acids identified are reported below.

## SUPPORTING INFORMATION



Table S3: HR-ESI-MS<sup>2</sup> analysis of nodulisporic acids

Name	Formula	Exact Mass	Calc. for [M+H] <sup>+</sup>	HRMS Obs. (Δppm)	MS <sup>2</sup> Fragments (%relative intensity)
Emindole SB	C <sub>28</sub> H <sub>39</sub> NO	405.3032	406.3104	406.3093 (2.81)	130 (100)
NAF	C <sub>28</sub> H <sub>37</sub> NO <sub>3</sub>	435.2773	436.2846	436.2856 (-2.25)	130 (100)
NAE	C <sub>38</sub> H <sub>53</sub> NO <sub>3</sub>	571.4025	572.4098	572.4098 (0.91)	266 (100)
NAD	C <sub>38</sub> H <sub>49</sub> NO <sub>4</sub>	583.3662	584.3734	584.3743 (-1.48)	526 (60), 280 (40), 222 (100)
NAD <sub>1</sub>	C <sub>38</sub> H <sub>49</sub> NO <sub>5</sub>	599.3611	600.3684	600.3685 (-0.25)	542 (60), 280 (60), 222 (100)
NAD <sub>2</sub>	C <sub>38</sub> H <sub>51</sub> NO <sub>6</sub>	617.3716	618.3789	618.3799 (-1.59)	560 (70), 280 (30), 222 (100)
NAD <sub>4</sub>	C <sub>38</sub> H <sub>51</sub> NO <sub>4</sub>	585.3818	586.3891	586.3887 (0.66)	528 (70), 280 (40), 222 (100)
NAD <sub>4</sub> -OMe	C <sub>39</sub> H <sub>53</sub> NO <sub>4</sub>	599.3975	600.4047	600.4064 (-2.77)	542 (100), 280 (65), 222 (40)
NAD <sub>5</sub>	C <sub>38</sub> H <sub>49</sub> NO <sub>4</sub>	583.3662	584.3734	584.3737 (-0.45)	526 (70), 280 (30), 222 (100)
NAD <sub>6</sub> *	C <sub>38</sub> H <sub>51</sub> NO <sub>5</sub>	601.3767	602.3840	602.3829 (-1.83)	544 (60), 280 (45), 222 (100)
DH-NAC	C <sub>43</sub> H <sub>57</sub> NO <sub>4</sub>	651.4288	652.4360	652.4346 (2.2)	594 (70), 348 (90), 290 (100)
DH-NAC <sub>1</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>5</sub>	667.4237	668.4310	668.4311 (-0.22)	610 (60), 348 (100), 290 (95), 222 (15)
DH-NAC <sub>2</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>6</sub>	685.4342	686.4415	686.4415 (0.0)	628 (40), 348 (100), 290 (80), 222 (5)
DH-NAC <sub>4</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>4</sub>	653.4444	654.4517	654.4516 (0.13)	596 (85), 348 (90), 290 (100), 222 (10)
DH-NAC <sub>5</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>4</sub>	651.4288	652.4360	652.4373 (-1.94)	594 (90), 348 (70), 290 (100), 222 (10)
DH-NAC <sub>6</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>5</sub>	669.4393	670.4466	670.4452 (2.09)	612 (70), 348 (80), 290 (100), 222 (20)
NAC	C <sub>43</sub> H <sub>57</sub> NO <sub>5</sub>	667.4237	668.4310	668.4328 (-2.77)	610 (20), 364 (100), 306 (50), 288 (30)
NAC <sub>1</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>6</sub>	683.4186	684.4259	668.4259 (2.29)	626 (20), 364 (100), 306 (40), 288 (25)
NAC <sub>2</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>7</sub>	701.4292	702.4364	702.4346 (2.6)	644 (30), 364 (100), 306 (40), 288 (30)
NAC <sub>4</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>5</sub>	669.4393	670.4466	670.4466 (0.3)	612 (30), 364 (100), 306 (50), 288 (30)
NAC <sub>5</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>5</sub>	667.4237	668.4310	668.4324 (-2.17)	610 (40), 364 (70), 306 (100), 288 (30)
NAC <sub>6</sub>	C <sub>43</sub> H <sub>59</sub> NO <sub>6</sub>	685.4342	686.4416	686.4424 (-1.29)	628 (15), 364 (100), 306 (70), 288 (50)
DH-NAB	C <sub>43</sub> H <sub>55</sub> NO <sub>4</sub>	649.4131	650.4204	650.4208 (-0.64)	592 (20), 346 (100), 288 (40)
DH-NAB <sub>1</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>5</sub>	665.4080	666.4153	666.4137 (2.4)	608 (20), 346 (100), 288 (35)
DH-NAB <sub>2</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>6</sub>	683.4186	684.4259	684.4259 (2.29)	626 (15), 346 (100), 288 (30)
DH-NAB <sub>4</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>4</sub>	651.4288	652.4360	652.4368 (-1.17)	594 (30), 346 (100), 288 (40)
DH-NAB <sub>5</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>4</sub>	649.4131	650.4204	650.4192 (1.82)	592 (30), 346 (100), 288 (50)
NAB	C <sub>43</sub> H <sub>55</sub> NO <sub>5</sub>	665.4080	666.4153	666.4163 (-1.5)	608 (40), 362 (85), 304 (100)
NAB <sub>1</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>6</sub>	681.4029	682.4103	682.4102 (0.02)	624 (30), 362 (100), 304 (90)
NAB <sub>2</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>7</sub>	699.4135	700.4208	700.4208 (-0.17)	642 (50), 362 (100), 304 (75)
NAB <sub>4</sub>	C <sub>43</sub> H <sub>57</sub> NO <sub>5</sub>	667.4237	668.4310	668.4300 (1.42)	610 (40), 362 (95), 304 (100)
NAB <sub>5</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>5</sub>	665.4080	666.4153	666.4163 (-1.5)	608 (10), 362 (100), 304 (20)
DH-NAA	C <sub>43</sub> H <sub>53</sub> NO <sub>5</sub>	663.3924	664.3997	664.3977 (2.94)	606 (100), 360 (70), 302 (40)
DH-NAA <sub>1</sub>	C <sub>43</sub> H <sub>53</sub> NO <sub>6</sub>	679.3873	680.3946	680.3940 (0.83)	622 (90), 360 (100), 302 (70)
DH-NAA <sub>4</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>5</sub>	665.4080	666.4153	666.4155 (-0.3)	608 (100), 360 (100), 302 (50)
NAA	C <sub>43</sub> H <sub>53</sub> NO <sub>6</sub>	679.3873	680.3946	680.3946 (-0.35)	622 (70), 604 (65), 564 (60), 376 (100), 318 (60), 290 (60)
NAA <sub>1</sub>	C <sub>43</sub> H <sub>53</sub> NO <sub>7</sub>	695.3822	696.3895	696.3882 (1.84)	638 (50), 620 (100), 376 (80), 318 (45), 290 (30)
NAA <sub>2</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>8</sub>	713.3928	714.4001	714.3998 (0.34)	656 (60), 638 (100), 376 (40), 318 (45), 290 (30)
NAA <sub>4</sub>	C <sub>43</sub> H <sub>55</sub> NO <sub>6</sub>	681.4029	682.4102	682.4117 (-2.18)	624 (70), 606 (100), 376 (90), 318 (35), 290 (40)



\*As noted in Figure 3 of the manuscript an EIC-MS<sup>2</sup> trace for NAD<sub>6</sub> (602 M → 280 M, 222 M) will also show a peak for NAD<sub>1</sub>, given <sup>13</sup>C isotopes of NAD<sub>1</sub> (i.e. 600.36 + 2) will closely match the parent mass of NAD<sub>6</sub> and also give the diagnostic 280, 222 M fragments which are common to both NAD<sub>1</sub> and NAD<sub>6</sub>.

## SUPPORTING INFORMATION

## Emindole SB





## NAF





## SUPPORTING INFORMATION





NAE



NAD







## SUPPORTING INFORMATION





NAD<sub>1</sub>NAD<sub>2</sub>



## SUPPORTING INFORMATION



NAD<sub>4</sub>NAD<sub>4</sub>-OMe

## SUPPORTING INFORMATION



NAD<sub>5</sub>NAD<sub>6</sub>

## SUPPORTING INFORMATION





## DH-NAC







## NAC







## SUPPORTING INFORMATION

DH-NAC<sub>1</sub>NAC<sub>1</sub>





## SUPPORTING INFORMATION

DH-NAC<sub>2</sub>NAC<sub>2</sub>





## SUPPORTING INFORMATION

DH-NAC<sub>4</sub>NAC<sub>4</sub>

## SUPPORTING INFORMATION

DH-NAC<sub>5</sub>NAC<sub>5</sub>



## SUPPORTING INFORMATION

DH-NAC<sub>6</sub>NAC<sub>6</sub>





## SUPPORTING INFORMATION





## DH-NAB







## NAB







## SUPPORTING INFORMATION

DH-NAB<sub>1</sub>NAB<sub>1</sub>





## SUPPORTING INFORMATION

DH-NAB<sub>2</sub>NAB<sub>2</sub>





## SUPPORTING INFORMATION

DH-NAB<sub>4</sub>NAB<sub>4</sub>





## SUPPORTING INFORMATION

DH-NAB<sub>5</sub>NAB<sub>5</sub>

## SUPPORTING INFORMATION



DH-NAA<sub>4</sub>NAA<sub>4</sub>

## SUPPORTING INFORMATION



DH-NAA<sub>1</sub>NAA<sub>1</sub>

## SUPPORTING INFORMATION

## DH-NAA





## NAA





## SUPPORTING INFORMATION

NAA<sub>2</sub>

SUPPORTING INFORMATION

---

**Isolation of Nodulisporic Acids**

Isolation of nodulisporic acids was carried out following procedures adapted from those described in the literature.<sup>[3]</sup> To provide sufficient structural evidence for the nodulisporic acids identified, an example of each major series (main-series, 1-series, 2-series, 4-series) and each biosynthetic step (D, C, B, and A) was isolated and characterised. These metabolites were either known compounds or closely related to those previously reported allowing for assignment of NMR data to be confirmed by comparison to the literature.<sup>[3]</sup> Analysis of these purified nodulisporic acids by HR-ESI-MS<sup>2</sup> provided further evidence for their identity and allowed for related intermediates to be identified as described above (pg 43).

## SUPPORTING INFORMATION

Isolation of NAD<sub>4</sub>


Mycelia from an NAD<sub>4</sub> producing strain (230 g) was extracted with MeOH (2 × 250 mL). The second, then first extracts were passed through a column of HP-20 (80 mL, pre-equilibrated in MeOH). The combined eluents were diluted with H<sub>2</sub>O (500 mL) and recycled back through the same column. The loaded column was washed with H<sub>2</sub>O (250 mL) and eluted with 250 mL portions of i) 60% acetone/ H<sub>2</sub>O (fraction A), ii) 80% acetone/ H<sub>2</sub>O (fraction B), and iii) acetone (fraction C). One-third (approx. 200 mg) of fraction B (606.7 mg) was chromatographed on silica gel (40 g, eluting with 3 CV each of 9:1 PE/DCM, 20:1 DCM/EtOAc, EtOAc, 5:1 EtOAc/MeOH, MeOH), from which fractions eluting from EtOAc afforded two samples (13.0 mg and 2.4 mg) enriched in NAD<sub>4</sub>.

NMR data see Table S4; HR-ESI-MS see Table S3.

NAD<sub>4</sub>-OMe

A sample enriched in NAD<sub>4</sub> (13 mg) was dissolved in 2 mL 1:1 MeOH/DCM, and cooled to 0 °C. To this, 300 μL TMSCHN<sub>2</sub> (2 M in Et<sub>2</sub>O) was added and stirred for at 0 °C for 1 h. The reaction mixture was quenched with 2% AcOH<sub>(aq)</sub> and warmed to room temperature over 30 min. The resulting DCM layer was separated by microextraction, dried *in vacuo* and purified by semi-preparative HPLC (C18, 100% MeCN, *t<sub>R</sub>* = 9.8 min; then 90% MeCN/H<sub>2</sub>O, *t<sub>R</sub>* = 17.2–18.5 min) to produce NAD<sub>4</sub>-OMe (2.2 mg). Evidence of O-methylation at the C-5'' carboxyl terminus was confirmed by HR-ESI-MS<sup>2</sup> and 2D-NMR experiments.

NMR data see Table S4; HR-ESI-MS see Table S3



R = H = NAD<sub>4</sub>  
R = Me = NAD<sub>4</sub>-OMe

## SUPPORTING INFORMATION

Table S4. NMR Data for NAD<sub>4</sub> and NAD<sub>4</sub>-OMe, CDCl<sub>3</sub>

Position	NAD <sub>4</sub>					NAD <sub>4</sub> -OMe	
	<sup>13</sup> C	<sup>1</sup> H (int., mult., J)	COSY	HMBC	NOESY <sup>a</sup>	<sup>13</sup> C	<sup>1</sup> H (int., mult., J)
NH-1	-	7.59 (1H, s)	-	2, 14, 15, 27	28(w)	-	7.59 (1H, s)
2	151.2	-	-	-	-	151.2	-
3	53.4	-	-	-	-	53.5	-
4	39.4	-	-	-	-	39.4	-
5	33.6	1.55 (1H, m) 1.90 (1H, m)	5b, 6 5a, 6, 7(w)	-	5b 5a, 28	33.6	1.56 <sup>c</sup> (1H, m) 1.91 <sup>c</sup> (1H, m)
6	27.9	1.84 (2H, m)	5a, 5b, 7	-	7, 29, 30	27.9	1.84 (2H, m)
7	73.5	3.56 (1H, dd, J = 6.9, 6.9 Hz)	5b(w), 7	30	6, 9, 2 <sup>b</sup>	73.5	3.55 (1H, appt t, J = 7.4 Hz)
8	41.4	-	-	-	-	41.4	-
9	40.2	1.70 (1H, m)	10a, 10b	-	7, 28	40.2	1.71 (1H, m)
10	22.9	1.46 (1H, m) 1.61 (1H, m)	9, 10b 9, 10a	-	-	22.9 <sup>b</sup>	1.45 <sup>c</sup> (1H, m) 1.60 <sup>c</sup> (1H, m)
11	25.2	1.61 (1H, m) 1.80 (1H, m)	11b, 12 11a, 12	-	-	25.2	1.59 <sup>c</sup> (1H, m) 1.79 <sup>c</sup> (1H, m)
12	48.6	2.74 (1H, m)	11a, 11b, 13a, 13b	-	29	48.7	2.74 (1H, m)
13	27.6	2.31 (1H, dd, J = 13.3, 10.7 Hz) 2.66 (1H, dd, J = 13.4, 6.5 Hz)	12, 13b 12, 13a	2(w), 12(w), 14 2, 3, 12, 14	28 -	27.6	2.30 <sup>c</sup> (1H, dd, J = 12.9, 10.4 Hz) 2.66 <sup>c</sup> (1H, dd, J = 13.3, 6.4 Hz)
14	118.6	-	-	-	-	118.7	-
15	125.0	-	-	-	-	124.8	-
16	109.8	7.49 (1H, s)	26	14, 17, 25, 27	-	109.8	7.49 (1H, s)
17	139.2	-	-	-	-	139.1 <sup>d</sup>	-
18	132.8	-	-	-	-	132.6 <sup>d</sup>	-
19	119.8	5.95 (1H, d, J = 3.0 Hz)	23	18, 20, 23	31, 32	119.6 <sup>c</sup>	5.95 (1H, d, J = 3.0 Hz)
20	72.8	-	-	-	-	72.8	-
O-21	-	-	-	-	-	-	-
22	74.6	-	-	-	-	74.6	-
23	48.7	2.92 (1H, ddd, J = 10.7, 7.8, 3.0 Hz)	19, 24a, 24b	17, 22	33	48.6	2.93 (1H, m)
24	33.5	2.69 (1H, dd, J = 16.0, 8.4 Hz) 3.13 (1H, dd, J = 16.0, 9.3 Hz)	23, 24b, 26 23, 24a, 26	22, 23(w), 25 17, 18, 23, 25, 26(w)	24b, 34 24a	33.5	2.68 <sup>c</sup> (1H, dd, J = 16.2, 8.0 Hz) 3.13 <sup>c</sup> (1H, dd, J = 16.0, 9.1 Hz)
25	138.2	-	-	-	-	138.0 <sup>d</sup>	-
26	107.6	7.14 (1H, s)	16, 24a, 24b	15, 18, 24	-	107.6	7.13 (1H, s)
27	141.4	-	-	-	-	141.5	-
28	14.6	0.99 (3H, s)	-	2, 3, 4, 12	NH-1(w), 5b, 9, 13a	14.6	0.99 (3H, s)
29	19.4	1.12 (3H, s)	-	3, 4, 5, 9	6, 12	19.3	1.12 (3H, s)
30	16.4	0.85 (3H, s)	-	7, 8, 9, 1 <sup>"</sup>	6, 1 <sup>"</sup> a	16.4	0.85 (3H, s)
31	30.1 <sup>b</sup>	1.35 <sup>b</sup> (3H, s)	-	19, 20, 32	19	30.1 <sup>b</sup>	1.35 <sup>b</sup> (3H, s)
32	30.2 <sup>b</sup>	1.33 <sup>b</sup> (3H, s)	-	19, 20, 31	19	30.2 <sup>b</sup>	1.34 <sup>b</sup> (3H, s)
33	32.1	1.34 (3H, s)	34	22, 23, 34	23	32.1	1.33 (3H, s)
34	22.3	1.09 (3H, s)	33	22, 23, 33	24a	22.3 <sup>b</sup>	1.09 (3H, s)
1 <sup>"</sup>	36.0	1.41 (1H, m) 1.70 (1H, m)	1 <sup>"</sup> b, 2 <sup>"</sup> a, 2 <sup>"</sup> b 1 <sup>"</sup> a, 2 <sup>"</sup> a, 2 <sup>"</sup> b	-	30, 3 <sup>"</sup> (w) 3 <sup>"</sup> (w)	36.1	1.41 (1H, m) 1.69 (1H, m)
2 <sup>"</sup>	22.7	2.10 (1H, m) 2.20 (1H, m)	1 <sup>"</sup> a, 1 <sup>"</sup> b, 2 <sup>"</sup> b, 3 <sup>"</sup> 1 <sup>"</sup> a, 1 <sup>"</sup> b, 2 <sup>"</sup> a, 3 <sup>"</sup>	-	- 7	22.5 <sup>b</sup>	2.06 <sup>c</sup> (1H, m) 2.16 <sup>c</sup> (1H, m)
3 <sup>"</sup>	144.9	6.90 (1H, tq, J = 7.4, 1.6 Hz)	2 <sup>"</sup> a, 2 <sup>"</sup> b, 6 <sup>"</sup>	5 <sup>"</sup> , 6 <sup>"</sup>	1 <sup>"</sup> a(w), 1 <sup>"</sup> b(w)	142.7	6.78 (1H, tq, J = 7.4, 1.3 Hz)
4 <sup>"</sup>	126.8	-	-	-	-	127.6	-
5 <sup>"</sup>	170.9	-	-	-	-	168.7 <sup>d</sup>	-
6 <sup>"</sup>	12.3	1.88 (3H, s)	3 <sup>"</sup>	3 <sup>"</sup> , 4 <sup>"</sup> , 5 <sup>"</sup>	-	12.5	1.87 (3H, s)
OMe	-	-	-	-	-	51.9	3.74 (3H, s)



<sup>a</sup>Mixing time = 0.5 s. Selected correlations. <sup>b</sup>Interchangeable within column. <sup>c</sup>obtained from HSQC experiment <sup>d</sup>obtained from HMBC experiment

## SUPPORTING INFORMATION

Isolation of NAD & NAD<sub>1</sub>

Mycelia from an NAD producing strain (320 g wet weight approx.) was extracted with EtOAc (500 mL approx.) overnight, filtered, and extracted for a second time overnight. The combined extracts were washed with brine and solvent removed in vacuo to give a crude brown oil (3.6 g) which was dissolved in DCM:MeOH (9:1) and fractionated using flash chromatography. Fraction B (15 mg) was further purified by semi-preparative HPLC (column#2, 80% B, isocratic, 3.0 mL/min) which afforded NAD (0.8 mg) as a white solid. Fractions D and E were combined and purified by semi-preparative HPLC using the same conditions as described for NAD, this yielded NAD<sub>1</sub> (1.1 mg) as a white powder.

NMR Data see Tables S5 and S6, HR-ESI-MS Data see Table S3



## SUPPORTING INFORMATION

Table S5: NMR Data for NAD, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
<b>1 (N)</b>	-	7.60 (1H, s)	-	27
<b>2</b>	150.7	-	-	-
<b>3</b>	53.2	-	-	-
<b>4</b>	38.9	-	-	-
<b>5a</b>	33.2	n.o.	-	-
<b>5b</b>		n.o.	-	-
<b>6a</b>	25.7	1.86 (1H, m)	7	-
<b>6b</b>		1.86 (1H, m)	7	-
<b>7</b>	76.6	3.44 (1H, dd, J = 11.3, 4.6 Hz)	6a, 6b	-
<b>8</b>	47.2	-	-	-
<b>9</b>	44.5	1.68 (1H, m)	-	-
<b>10a</b>		n.o.	-	-
<b>10b</b>		n.o.	-	-
<b>11a</b>		n.o.	-	-
<b>11b</b>		n.o.	-	-
<b>12</b>	48.7	2.73 (1H, m)	-	13a, 13b
<b>13a</b>	27.3	2.65 (1H, dd, J = 13.3, 6.4 Hz)	13b	2, 3, 12, 14
<b>13b</b>		2.30 (1H, dd, J = 13.3, 10.6 Hz)	13a	12
<b>14</b>	118.5	-	-	-
<b>15</b>	124.8	-	-	-
<b>16</b>	109.6	7.49 (1H, s)	-	14, 17, 18, 27
<b>17</b>	138.0	-	-	-
<b>18</b>	139.2	-	-	-
<b>19</b>	119.7	5.95 (1H, d, J = 3 Hz)	23	-
<b>20</b>	72.7	-	-	-
<b>21 (O)</b>		-	-	-
<b>22</b>	74.4	-	-	-
<b>23</b>	48.5	2.93 (1H, m)	19, 24a, 24b	-
<b>24a</b>	33.2	3.13 (1H, dd, J = 15.9, 9.3 Hz)	23, 24b	-
<b>24b</b>		2.69 (1H, dd, J = 15.9, 7.8 Hz)	23, 24a	-
<b>25</b>	132.7	-	-	-
<b>26</b>	107.5	7.14 (1H, s)	-	25, 15
<b>27</b>	141.5	-	-	-
<b>28</b>	14.4	1.01 (3H, s)	-	2, 3, 4, 12
<b>29</b>	19.2	1.16 (3H, s)	-	3, 9, 4, 5
<b>30</b>	10.9	1.09 (3H, s)	-	1", 7, 8, 9
<b>31</b>	29.9	1.35 (3H, s)	-	19, 20, 32
<b>32</b>	31.8	1.33 (3H, s)	-	19, 20, 31
<b>33</b>	22.1	1.09 (3H, s)	-	22, 23, 34
<b>34</b>	30.9	1.34 (3H, s)	-	22, 23, 33
<b>1"</b>	153.4	5.92 (1H, d, J = 15.4 Hz)	2"	-
<b>2"</b>	125.6	6.40 (1H, dd, J = 15.4, 11.2 Hz)	1", 3"	-
<b>3"</b>	139.9	7.32 (1H, d, J = 11.2 Hz)	2"	-
<b>4"</b>	124.8	-	-	-
<b>5"</b>	169.9	-	-	-
<b>6"</b>	12.7	1.98 (3H, s)	-	3", 4", 5"

n.o. = not observed, signal obscured or not resolved. \*Chemical shift obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

Table S6: NMR Data for NAD<sub>1</sub>, CDCl<sub>3</sub>.

Position	<sup>13</sup> C	<sup>1</sup> H	COSY	HMBC
<b>1 (N)</b>	-	7.61 (1H, s)	-	-
<b>2</b>	150.9	-	-	-
<b>3</b>	52.7	-	-	-
<b>4</b>	39.4	-	-	-
<b>5a</b>	30.1	2.04 (1H, m)	5b	-
<b>5b</b>		1.94 (1H, m)	5a	-
<b>6a</b>	30.6	2.07 (1H, m)	-	-
<b>6b</b>		2.10 (1H, m)	-	-
<b>7</b>	106.5	-	-	-
<b>8</b>	49.2	-	-	-
<b>9</b>	40.4	n.o.	-	-
<b>10a</b>	25.7	1.83 (1H, m)	11b, 10b	-
<b>10b</b>		1.76 (1H, m)	11b, 10a	-
<b>11a</b>	24.9	1.66 (1H, m)	12, 11b	-
<b>11b</b>		1.50 (1H, m)	11a, 10a, 10b	-
<b>12</b>	48.7	2.80 (1H, m)	13a, 13b, 11a	13
<b>13a</b>	27.5	2.33 (1H, m)	12, 13b	2, 14
<b>13b</b>		2.68 (1H, m)	12, 13a	2, 3, 12, 14
<b>14</b>	118.3	-	-	-
<b>15</b>	124.9	-	-	-
<b>16</b>	109.7	7.50 (1H, s)	-	26, 27, 17, 18, 14, 15
<b>17</b>	138.2	-	-	-
<b>18</b>	139.1	-	-	-
<b>19</b>	119.7	5.95 (1H, d, J = 3.0 Hz)	23	23, 25, 20, 31
<b>20</b>	72.6	-	-	-
<b>21 (O)</b>	-	-	-	-
<b>22</b>	74.5	-	-	-
<b>23</b>	48.9	2.93 (1H, ddd, J = 9.2, 8.6, 3.0 Hz)	19, 24a, 24b	18, 19, 22, 24, 33, 34
<b>24a</b>	33.3	2.68 (1H, m)	23, 24b, 26	17, 23, 22
<b>24b</b>		3.13 (1H, dd, J = 15.9, 9.2 Hz)	23, 24a, 26	17, 18, 23, 25, 26
<b>25</b>	132.7	-	-	-
<b>26</b>	107.8	7.14 (1H, s)	24a, 24b	25, 24, 15
<b>27</b>	141.3	-	-	-
<b>28</b>	14.5	0.99 (3H, s)	-	12, 2, 3, 4
<b>29</b>	17.6	1.15 (3H, s)	-	3, 4, 5, 9
<b>30</b>	16.4	1.08 (3H, s)	-	7, 1", 8, 9
<b>31</b>	29.9	1.35 (3H, s)	-	20, 32
<b>32</b>	31.8	1.34 (3H, s)	-	20, 31
<b>33</b>	22.0	1.09 (3H, s)	-	22, 23, 34
<b>34</b>	30.1	1.34 (3H, s)	-	22, 23, 33
<b>1" a</b>	44.1	1.77 (1H, m)	2", 1" b	-
<b>1" b</b>		2.33 (1H, m)	2", 1" a	7
<b>2"</b>	72.7	4.88 (1H, ddd, J = 8.1, 8.1, 8.1 Hz)	3", 1" a, 1" b	-
<b>3"</b>	146.3	6.95 (1H, d, J = 8.1 Hz)	2"	-
<b>4"</b>	126.8	-	-	-
<b>5"</b>	170.9	-	-	-
<b>6"</b>	12.7	1.89 (3H, s)	-	3", 4", 5"



n.o. = not observed, signal obscured or not resolved.

## SUPPORTING INFORMATION

Isolation of NAD<sub>2</sub>

Mycelia from an NAD<sub>2</sub> producing strain (380 g wet weight approx.) was extracted with EtOAc (750 mL approx.) overnight, filtered, and extracted for a second time overnight. The combined extracts were washed with brine and solvent removed in vacuo to give a dark brown oil (3.6 g) which was dissolved in DCM: MeOH (9:1) and fractionated using flash chromatography. Fractions containing NAD<sub>2</sub> were identified by LC-MS and TLC, combined (60 mg approx.) and purified by semi-preparative HPLC (column#1, 90% B, isocratic, 3.5 mL/min). Collections of the major peak were freeze dried to give a white powder (4.9 mg). Analysis of this sample by NMR spectroscopy showed the major product contained an eastern hemisphere consistent with that of a 2-series nodulisporic acid. The characteristic H-19 signal was not present in the spectrum and further analysis identified the metabolite as an isomerised product of NAD<sub>2</sub> containing an 18-23 alkene instead of the expected 18-19-alkene. The migration of this double bond has been reported in previous isolations of nodulisporic acids and is a product of degradation during workup rather than an alternative biosynthetic product.<sup>[3a]</sup>

NMR Data see Table S7. HR-ESI-MS see Table S3.





## SUPPORTING INFORMATION

**Table S7:** NMR Data for 18-23 alkene-NAD<sub>2</sub>, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)	-	7.66 (1H, s)	26	14, 2, 15, 17
2	149.6	-	-	-
3	52.3	-	-	-
4	39.5	-	-	-
5a	31.6	1.58 (1H, m)	5b	-
5b		2.20 (1H, m)	5a	-
6	n.o.	n.o.	-	-
7	112.9	-	-	-
8	48.8	-	-	-
9	46.5	1.80 (1H, m)	10a, 10b	3, 8, 10, 30, 1"
10a	23.2	1.49 (1H, m)	9, 10b, 11a, 11b	8, 9
10b		1.41 (1H, m)	9, 10a, 11a, 11b	-
11a	25.3	1.79 (1H, m)	11b, 12, 10a, 10b	-
11b		1.59 (1H, m)	11a, 12, 10a, 10b	3, 12
12	49.0	2.77 (1H, m)	13a, 13b, 11a, 11b	-
13a	27.5	2.34 (1H, m)	13b, 12	2, 3, 11, 12, 14
13b		2.69 (1H, m)	13a, 12	2, 3, 12, 14
14	118.2	-	-	-
15	123.7	-	-	-
16	107.4	7.35 (1H, s)	26, 19	26, 15, 17, 19, 27
17	138.3	-	-	-
18	141.7	-	-	-
19	36.4	3.37 (2H, m)	16, 24	18, 17, 25, 23
20	73.5	-	-	-
21 (O)	-	-	-	-
22	71.4	-	-	-
23	136.2	-	-	-
24	34.3	2.45 (2H, m)	19	18, 17, 25
25	131.8	-	-	-
26	107.2	7.22 (1H, s)	1, 16	16, 14, 15, 17, 25, 23
27	143.0	-	-	-
28	14.4	1.00 (3H, s)	-	2, 3, 4, 12
29	17.4	1.10 (3H, s)	-	3, 4, 5, 9
30	16.4	1.12 (3H, s)	-	7, 8, 9, 1"
31/32	30.4	1.42 (6H, s)	-	18, 20, 31/32
33/34	29.6	1.32 (6H, s)	-	22, 24, 33/34
1"a	40.0	1.74 (1H, m)	1"b, 2"	2", 3", 8, 9
1"b		1.49 (1H, m)	1"a	3", 7, 8, 30, 9
2"	78.4	4.60 (1H, dd, J = 5.5, 3.1 Hz)	3", 1"a, 6"	3", 8, 7
3"	80.6	4.03 (1H, m)	2", 6", 4"	5", 2", 4"
4"	40.2	2.70 (1H, m)	3", 6"	5", 6", 3"
5"	176.8	-	-	-
6"	13.2	1.13 (1H, m)	4", 2", 3"	3", 4", 5"


n.o. = not observed, signal obscured or not resolved. \*Chemical shift obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

Isolation of DH-NAA<sub>4</sub> & DH-NAC<sub>4</sub>

Mycelia from a DH-NAA<sub>4</sub> producing strain (260 g wet weight approx.) was extracted with EtOAc (500 mL approx.) overnight, filtered, and extracted for a second time overnight. The combined extracts were washed with brine and solvent removed in vacuo to give a buttery yellow solid (2.1 g) which was dissolved in DCM: MeOH (9:1) and fractionated using flash chromatography. Fractions containing the target nodulisporic acids were identified by LC-MS and TLC, combined (250 mg) and purified by semi-preparative HPLC (column#1, 95% B, isocratic, 3.5 mL/min). Collections of the two major peaks were freeze dried and analysed by NMR identifying them as DH-NAA<sub>4</sub> (0.2 mg) and DH-NAC<sub>4</sub> (0.1 mg).

NMR Data see Tables S8 and S9, HR-ESI-MS see Table S3



## SUPPORTING INFORMATION

**Table S8:** NMR Data for DH-NAA<sub>4</sub>, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)	-	-	-	-
2	153	-	-	-
3	55.8	-	-	-
4	39.1	-	-	-
5a	32.2	1.86 (1H, m)	5b	-
5b		1.68 (1H, m)	5a	-
6a	27.5	1.70 (1H, m)	6b, 7	-
6b		1.75 (1H, m)	6a, 7	-
7	73.4	3.53 (1H, dd, J = 9.6, 5.8 Hz)	6a, 6b	8
8	46.9	-	-	-
9	41.3	1.62 (1H, m)	-	-
10	n.o.	n.o.	-	-
11	25.3	n.o.	-	-
12	47.4	2.84 (1H, m)	13a	-
13a	27.6	2.30 (1H, dd, J = 13.8, 10.7 Hz)	13b, 12	2
13b		2.74 (1H, dd, J = 13.8, 6.5 Hz)	13a	2, 3, 15
14	121.7	-	-	-
15	122	-	-	-
16	116.3	7.70 (1H, s)	-	25, 27, 18, 14
17	n.o.	-	-	-
18	136.1	-	-	-
19	120.8	6.01 (1H, d, J = 3.0 Hz)	23	18, 20
20	72.6	-	-	-
21 (O)	-	-	-	-
22	74.4	-	-	-
23	49.2	3.00 (1H, ddd, J = 9.3, 7.7, 3.0 Hz)	19, 24a, 24b	-
24a	31.8	2.8 (1H, dd, J = 17.6, 7.7 Hz)	24b, 23	18, 22, 26
24b		3.41 (1H, dd, J = 17.6, 9.3 Hz)	24a, 23	18
25	138.5	-	-	-
26	113.3	-	-	-
27	161.6	-	-	-
28	15	0.91 (3H, s)	-	2, 3, 4, 12
29	19.4	1.10 (3H, s)	-	3, 4, 5, 9
30	16.6	0.84 (3H, s)	-	7, 9, 1"
31	29.9	1.36 (3H, s)	-	32, 19, 20
32	31.9	1.34 (3H, s)	-	31, 19, 20
33	22.2	1.08 (3H, s)	-	23, 34, 22
34	30	1.36 (3H, s)	-	23, 33, 22
1'	197.3	-	-	-
2'	75.9	4.97 (1H, s)	-	27, 1', 3'
3'	140	-	-	-
4'a	122.3	4.93 (s, br)	-	-
4'b		5.15 (s, br)	-	-
5'	n.o.	n.o.	-	-
1''a	35.9	1.44 (1H, m)	-	8
1''b		1.71 (1H, m)	-	-
2''a	22.8	2.09 (1H, m)	3'', 2''b	-
2''b		2.19 (1H, m)	3'', 2''a	-
3''	144.9	6.89 (1H, dd, J = 6.4, 6.4 Hz)	2''a, 2''b, 6''	-
4''	126.4	-	-	-
5''	169.6	-	-	-
6''	12.2	1.87 (3H, s)	3''	4'', 5''

n.o. = not observed, signal obscured or not resolved. \*Chemical shift obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

**Table S9:** NMR Data of DH-NAC<sub>4</sub>, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)	-	7.69 (1H, brs)	-	-
2	150.7	-	-	-
3	53.0	-	-	-
4	39.2	-	-	-
5	33.4	n.o.	-	-
6	n.o.	n.o.	-	-
7	73.4	3.51 (1H, m)	-	-
8	35.8	-	-	-
9	40.0	1.68 (1H, m)	-	-
10	n.o.	n.o.	-	-
11	n.o.	1.61 (2H, m)	12	-
12	48.7	2.71 (1H, m)	13a, 13b	-
13a	n.o.	2.30 (1H, dd, J = 13.2, 10.7 Hz)	12, 13b	-
13b		2.65 (1H, dd, J = 13.2, 6.4 Hz)	12, 13a	-
14	n.o.	-	-	-
15	n.o.	-	-	-
16	107.8	7.39 (1H, s)	-	-
17	n.o.	-	-	-
18	n.o.	-	-	-
19	119.5	5.93 (1H, d, J = 3.0 Hz)	23	-
20	72.7	-	-	-
21 (O)	-	-	-	-
22	74.4	-	-	-
23	48.5	2.92 (1H, ddd, J = 9.4, 7.5, 3.0 Hz)	19, 24a, 24b	-
24a	31.6	3.13 (1H, dd, J = 15.8, 9.4 Hz)	23, 24b	-
24b		2.57 (1H, dd, J = 15.8, 7.5 Hz)	23, 24a	-
25	n.o.	-	-	-
26	n.o.	-	-	-
27	n.o.	-	-	-
28	14.5	0.99 (3H, s)	-	2, 3, 4, 12
29	19.2	1.11 (3H, s)	-	3, 4, 5, 9
30	16.3	0.86 (3H, s)	-	7, 8, 9, 1"
31	30.1	1.35 (3H, s)	-	19, 20, 32
32	31.9	1.33 (3H, s)	-	19, 20, 31
33	30.0	1.35 (3H, s)	-	34, 22
34	22.1	1.09 (3H, s)	-	22, 23, 33
1'a	28.2	3.55 (1H, m)	5', 1'b	-
1'b		3.51 (1H, m)	1'a, 2', 4'	-
2'	122.5	5.35 (1H, m)	4', 5', 1'b	-
3'	132.7	-	-	-
4'	25.6	1.76 (3H, s)	2'	2', 3', 5'
5'	18.1	1.86 (3H, s)	1'a, 2'	2', 3', 4'
1''a	41.2	1.71 (1H, m)	1''b, 2''a, 2''b	-
1''b		1.45 (1H, m)	1''a, 2''a, 2''b	-
2''a	n.o.	2.19 (1H, m)	1''a, 1''b, 2''b, 3''	-
2''b		2.10 (1H, m)	1''a, 1''b, 2''a, 3''	-
3''	144.7	6.89 (1H, dd, J = 6.4, 6.4 Hz)	2''a, 2''b, 6''	-
4''	126.2	-	-	-
5''	168.9	-	-	-
6''	12.2	1.88 (3H, s)	3''	3'', 4'', 5''

n.o. = not observed, signal obscured or not resolved. \*Chemical shift obtained from HSQC and HMBC experiments


## SUPPORTING INFORMATION

## Isolation of NAC

Mycelia from an NAC producing strain (120 g) was extracted with MeOH (2 × 250 mL). The second, then first extracts were passed through a bed of HP-20 beads (80 mL, pre-equilibrated in MeOH). The combined eluents were diluted with 750 mL of H<sub>2</sub>O to a final concentration of 40% MeOH/ H<sub>2</sub>O and cycled back through the same HP-20 column. The loaded beads were washed with H<sub>2</sub>O (250 mL) and then eluted with 250 mL portions of i) 50% acetone/ H<sub>2</sub>O (fraction A), ii) 80% acetone/ H<sub>2</sub>O (fraction B) and iii) acetone (fraction C). Fractions B and C, verified by TLC and LC-MS analysis to contain nodulisporic acid compounds, were combined (667 mg) and chromatographed over silica gel (40 g, MeOH/CHCl<sub>3</sub>, 1–100%, fractions D–H). Fraction E (5–6% MeOH/CHCl<sub>3</sub>, 378 mg) was further chromatographed over silica gel (24 g, EtOAc/*n*-hexane, 0–100%, 17 CV; EtOAc, 7 CV, fractions I–L). The MeOH-soluble portion of fraction L (EtOAc, 32.4 mg) was purified using semipreparative HPLC (column#1, 85% acetonitrile/ H<sub>2</sub>O, 3.3 mL/min) to give NAC (*t<sub>R</sub>* = 5.9 min).

Fraction F (6–7% MeOH/CHCl<sub>3</sub>) from the first silica column was purified by semipreparative HPLC (C18, 80% acetonitrile/H<sub>2</sub>O, 3.3 mL/min) to afford NAC (*t<sub>R</sub>* = 9.7 min) and combined with the earlier HPLC fraction to give a total yield of 0.6 mg. NMR spectra of our sample of NAC recorded in CDCl<sub>3</sub> were consistent with literature data.<sup>[3b]</sup>

NMR data see Table S10; HR-ESI-MS see Table S3



NAC

## SUPPORTING INFORMATION

Table S10. NMR Data for NAC, CDCl<sub>3</sub>.


Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)		7.81 (1H, br s)	-	2, 14, 15, 27
2	152.0	-	-	-
3	53.1	-	-	-
4	39.1	-	-	-
5a	33.2	1.52 (1H, m)	5b, 6a	-
5b		1.99 (1H, m)	5a	-
6a	25.6	1.86 (1H, m)	5a, 6b, 7	-
6b		1.90 (1H, m)	6a, 7	-
7	76.5	3.44 (1H, dd, <i>J</i> = 10.8, 4.2 Hz)	6a, 6b	-
8	47.4	-	-	-
9	44.5	1.68 (1H, m)	-	-
10	24.8	1.46 (2H, m)	11a, 11b	-
11a	25.1	1.57 (1H, m)	10, 11b, 12(w)	-
11b		1.72 (1H, m)	10, 11a	-
12	48.9	2.72 (1H, m)	11a(w), 13a, 13b	-
13a	27.4	2.30 (1H, dd, <i>J</i> = 13.3, 10.8 Hz)	12, 13b	-
13b		2.65 (1H, dd, <i>J</i> = 13.3, 6.4 Hz)	12, 13a	2, 3, 14
14	118.7	-	-	-
15	126.7	-	-	-
16	107.4	7.40 (1H, s)	-	14, 15, 17, 25, 26, 27
17	135.4	-	-	-
18	131.9	-	-	-
19	120.2	5.96 (1H, d, <i>J</i> = 2.8 Hz)	23	18, 20, 23
20	72.7	-	-	-
21 (O)	-	-	-	-
22	73.9	-	-	-
23	60.1	2.69 (1H, dd, <i>J</i> = 4.6, 2.8 Hz)	19, 24	-
24	76.5	5.08 (1H, d, <i>J</i> = 4.6 Hz)	23	22, 25
25	136.1	-	-	-
26	121.9	-	-	-
27	141.1	-	-	-
28	14.4	1.02 (3H, s)	-	2, 3, 4, 12
29	19.1	1.14 (3H, s)	-	3, 4, 5, 9
30	11.0	1.09 (3H, s)	-	7, 8, 9, 1''
31	32.0	1.34 (3H, s)	-	19, 20, 32
32	29.85	1.32 (3H, s)	-	19, 20, 31
33	29.85	1.50 (3H, s)	-	22, 23, 34
34	22.6	1.07 (3H, s)	-	22, 23, 33
1'	27.0	3.79 (2H, m)	2'	-
2'	123.1	5.38 (1H, br t, <i>J</i> = 6.7 Hz)	1', 4', 5'	-
3'	133.0	-	-	-
4'	25.6	1.76 (3H, s)	2', 5'	2', 3', 5'
5'	18.1	1.90 (3H, s)	2', 4'	2', 3', 4'
1''	153.5	5.91 (1H, d, <i>J</i> = 15.3 Hz)	2''	-
2''	125.9	6.39 (1H, dd, <i>J</i> = 15.3, 11.5 Hz)	1'', 3''	-
3''	139.9	7.33 (1H, d, <i>J</i> = 11.5 Hz)	2'', 6''	-
4''	125.2	-	-	-
5''	171.1	-	-	-
6''	12.6	1.98 (3H, br s)	3''	3'', 4'', 5''

n.o. = not observed, signal obscured or not resolved. \*Chemical shifts obtained from HSQC and HMBC experiments.

## SUPPORTING INFORMATION

Isolation of NAB<sub>4</sub>

Mycelia from an NAB<sub>4</sub> producing strain (240 g wet weight approx.) was extracted with EtOAc (500 mL approx.) overnight filtered and extracted for a second time overnight. The combined extracts were washed with brine and solvent removed in vacuo to give a buttery yellow solid (2.8 g) which was dissolved in DCM: MeOH (9:1) and fractionated using flash chromatography. Fractions containing indole diterpenes were identified by TLC, combined, and subjected to a second round of flash chromatography. Fractions containing NAB<sub>4</sub> were identified by LC-MS and combined (200 mg). Semi-preparative HPLC (column#1, 95% B, isocratic, 3.5 mL/min) was used to purify the major peak which was freeze dried to give a white powder (12 mg). 2D NMR Showed that this sample contained two indole diterpene products which had signals consistent with 2' epimers of NAB<sub>4</sub> which are known to be common breakdown products of nodulisporic acids.<sup>[4]</sup> Further purification of this sample led to degradation of the target metabolites.



**Table S11:** NMR Data for NAB<sub>4</sub> and its 2'-epimer, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
<i>Epimer 1</i>				
1'a	n.o.	3.30 (1H, d, J = 15.8 Hz)	1'b, 2'	26, 3', 27
1'b		4.06 (1H, m)	1'a, 2'	2', 26, 3', 27
2'	68.6	5.20 (1H, d, J = 7.0 Hz)	1'a, 1'b	5', 4', 27
3'	146.3	-	-	-
4'	112.3	4.76 (m)	5'	16.7
5'	16.7	1.22 (3H, s)	4'	4', 3'
26	115.3	-	-	-
27	153.8	-	-	-
<i>Epimer 2</i>				
1'a	n.o.	3.47 (1H, d, J = 17.6 Hz)	1'b, 2'	26, 3', 27
1'b		4.04 (1H, m)	1'a, 2'	2', 26, 3', 27
2'	68.6	5.20 (1H, d, J = 7.0 Hz)	1'a, 1'b	5', 4', 27
3'	145.0	-	-	-
4'	113.6	4.85 (m)	5'	16.7
5'	16.7	1.29 (3H, s)	4'	4', 3'
26	123.9	-	-	-
27	152.5	-	-	-

n.o. = not observed, signal obscured or not resolved.


\*Chemical shift obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

Isolation of NAA<sub>1</sub> and NAB

Mycelia from an NAA<sub>1</sub> producing strain (500 g wet weight approx.) was extracted with MeOH (1 L). The extract was passed through a bed of HP-20 beads (250 mL, pre-equilibrated in MeOH). The eluent was diluted with H<sub>2</sub>O (1:1) and cycled back through the same HP-20 beads. The loaded beads were washed with 500 mL portions of i) H<sub>2</sub>O, ii) 50% acetone/H<sub>2</sub>O, iii) 80% acetone/H<sub>2</sub>O, and iv) acetone. Target nodulisporic acids were identified by LC-MS in the 50% and 80% fractions which were subsequently combined and subjected to silica gel chromatography (CHCl<sub>3</sub>: MeOH). Fractions containing NAA<sub>1</sub> were identified by LC-MS and the target purified using semi-preparative HPLC (Column#1, 80–90% B over 20 min, 3.5 mL/min) to give NAA<sub>1</sub> as a yellow powder (2.8 mg) and NAB as a white powder (0.1 mg).

NMR data see Table S12 and S13; HR-ESI-MS see Table S3.





## SUPPORTING INFORMATION

Table S12: NMR Data for NAA<sub>1</sub>, CD<sub>3</sub>OD.

Position	<sup>13</sup> C	<sup>1</sup> H	COSY	HMBC
1 (N)	-	-	-	-
2	155.7	-	-	-
3	56.5	-	-	-
4	40.3	-	-	-
5a	31.1	1.73 (1H, m)	6, 5b	-
5b		1.91 (1H, m)	5a, 6	4
6	30.0	1.86 (2H, m)	5a, 5b	4
7	107.5	-	-	-
8	50.3	-	-	-
9	42.1	1.81 (1H, dd, J = 2.6, 12.8 Hz)	10a, 10b	29, 30
10a	25.7	1.58 (1H, m)	9, 10b, 11a, 11b	-
10b		1.72 (1H, m)	9, 10a, 11b	12, 9
11a	26.6	1.71 (1H, m)	12, 11b, 10a	12, 9
11b		1.88 (1H, m)	12, 11a, 10a, 10b	3
12	49.0	2.96 (1H, m)	13a, 13b, 11a, 11b	-
13a	28.2	2.37 (1H, m)	12, 13b	12, 2, 14
13b		2.77 (1H, dd, J = 13.8, 6.5 Hz)	12, 13a	12, 2, 14
14	123.0	-	-	-
15	123.1	-	-	-
16	117.0	7.76 (1H, s)	24	27, 26, 17, 25, 18, 14, 15
17	137.0	-	-	-
18	135.2	-	-	-
19	121.9	6.12 (1H, d, J = 3.0 Hz)	23	18, 20, 23, 31
20	74.1	-	-	-
21 (O)	-	-	-	-
22	75.7	-	-	-
23	60.2	2.76 (1H, m)	19, 24	18
24	75.4	5.16 (1H, d, J = 5.9 Hz)	23, 16	22, 23, 18, 25, 26
25	138.4	-	-	-
26	114.6	-	-	-
27	163.2	-	-	-
28	15.2	1.00 (3H, s)	-	12, 2, 3, 4
29	18.1	1.15 (3H, s)	-	2, 3, 4, 9, 5
30	17.1	1.05 (3H, s)	-	7, 9, 1", 8
31	29.9	1.36 (3H, s)	-	19, 20, 32
32	32.0	1.34 (3H, s)	-	19, 20, 31
33	23.2	1.13 (3H, s)	-	22, 23, 34
34	30.2	1.45 (3H, s)	-	33, 23, 22
1'	197.7	-	-	-
2'	77.2	5.22 (1H, s)	-	1', 3', 4', 5', 27
3'	141.6	-	-	-
4'a	117.4	5.18 (1H, m)	4'b, 5'	1', 3', 5'
4'b		5.00 (1H, m)	4'a	-
5'	18.3	1.48 (3H, s)	4'a	-
1''a	45.3	1.69 (1H, m)	2'', 1''b	8, 9, 30, 2'', 3''
1''b		2.35 (1H, m)	2'', 1''a	8, 9, 7
2''	74.0	4.9 (1H, m)	3'', 1''a, 1''b	7
3''	146.1	6.90 (1H, dq, J = 8.0, 1.4 Hz)	2'', 6''	6'', 5''
4''	128.7	-	-	-
5''	171.8	-	-	-
6''	12.7	1.83 (3H, d, J = 1.4 Hz)	3''	5'', 3'', 4''

n.o. = not observed, signal obscured or not resolved.

## SUPPORTING INFORMATION

Table S13: NMR Data for NAB, CDCl<sub>3</sub>.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)	-	-	-	-
2	151.3	-	-	-
3	55.3	-	-	-
4	38.5	-	-	-
5	31.8	n.o.	-	-
6	25.5	1.77 (2H, m)	7	-
7	76.6	3.41 (1H, m)	6	-
8	47.5	-	-	-
9	44.9	n.o.	-	-
10	n.o.	n.o.	-	-
11	n.o.	n.o.	-	-
12	47.0	2.73 (1H, m)	13a, 13b	-
13a	28.0	2.23 (1H, dd, J = 13.6, 2.8 Hz)	13b, 12	-
13b		2.65 (1H, dd, J = 13.6, 6.3 Hz)	13a, 12	3
14	n.o.	-	-	-
15	n.o.	-	-	-
16	107.4	7.31 (1H, s)	-	27, 17, 18
17	133.2	-	-	-
18	135.4	-	-	-
19	119.9	5.96 (1H, d, J = 2.8 Hz)	23	20
20	72.5	-	-	-
21 (O)	-	-	-	-
22	73.6	-	-	-
23	60.4	2.69 (1H, dd, J = 5.7, 2.8 Hz)	19, 24	-
24	75.9	4.98 (1H, d, J = 5.7 Hz)	23	-
25	n.o.	-	-	-
26	n.o.	-	-	-
27	154.6	-	-	-
28	15.0	0.91 (3H, s)	-	2, 3, 4, 12
29	19.3	1.09 (3H, s)	-	3, 4, 5, 9
30	11.0	1.06 (3H, s)	-	7, 8, 9, 1"
31	32.0	1.32 (3H, s)	-	32, 20
32	29.8	1.33 (3H, s)	-	31, 20, 19
33	23.1	1.12 (3H, s)	-	22, 23, 34
34	30.1	1.48 (3H, s)	-	22, 23, 33
1'a	40.6	3.50 (1H, s, J = 16.4 Hz)	1'b, 2'	-
1'b		4.07 (1H, dd, J = 16.4, 8.0 Hz)	1'a, 2'	-
2'	69.0	5.24 (1H, d, J = 8.0 Hz)	1'a, 1'b	-
3'		-	-	-
4'a	112.9	4.8 (1H, s br)	4'b, 5'	-
4'b		4.72 (1H, s br)	4'a	-
5'	17.0	1.25 (3H, s)	4'a	-
1"	153.8	5.91 (1H, d, J = 15.3 Hz)	2"	-
2"	125.7	6.38 (1H, dd, J = 15.3, 13.0 Hz)	1", 3"	-
3"	n.o.	7.31 (1H, m)	2", 6"	-
4"	n.o.	-	-	-
5"	n.o.	-	-	-
6"	12.7	1.98 (3H, s)	3"	-


n.o. = signal not observed or obscured. \*Signals obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

Isolation of NAD<sub>6</sub>

Mycelia from an NAD<sub>6</sub> producing strain (264 g wet weight) was extracted with EtOAc (500 mL approx.) overnight filtered and extracted for a second time overnight. The combined extracts were washed with brine and solvent removed in vacuo to give a brown solid (2.0 g) which was dissolved in CHCl<sub>3</sub> and fractionated using flash chromatography. Fractions containing NAD<sub>6</sub> were identified by TLC and LC-MS and combined (40 mg). Semi-preparative HPLC (column#1, 70% B, isocratic, 3.5 mL/min) was used to purify the major peak which was freeze dried to give NAD<sub>6</sub> as a white powder (1.6 mg).

NMR data see Table S14; HR-ESI-MS see Table S3.

NAD<sub>6</sub>

## SUPPORTING INFORMATION

**Table S14:** NMR Data for NAD<sub>6</sub>, (CD<sub>3</sub>)<sub>2</sub>CO.

Position	<sup>13</sup> C*	<sup>1</sup> H	COSY	HMBC
1 (N)	-	9.67 (1H, s br)	-	-
2	152.4	-	-	-
3	54.2	-	-	-
4	40.3	-	-	-
5a	33.5	1.86 (1H, m)		
5b		1.82 (1H, m)		
6a	27.6	1.70 (1H, m)	7	
6b		1.85 (1H, m)	7	
7	74.4	3.90 (1H, dd, J = 10.8, 3.8 Hz)	6a, 6b	
8	42.0	-	-	-
9	42.9	n.o.		
10a	n.o.	1.51 (1H, m)		
10b		1.62 (1H, m)	11b	
11a	25.6	1.66 (1H, m)	12, 11b	
11b		1.77 (1H, m)	11a, 10b	
12	49.6	2.76 (1H, obscured)	11a, 13a, 13b	
13a	27.8	2.29 (1H, dd, J = 13.0, 10.9 Hz)	12, 13b	
13b		2.65 (1H, m)	12, 13a	14
14	118.2	-	-	-
15	n.o.	-	-	-
16	109.9	7.43 (1H, s)	26	14, 17, 18
17	138.2	-	-	-
18	143.0	-	-	-
19	119.3	5.98 (1H, d, J = 3.0 Hz)	23	
20	72.9	-	-	-
21 (O)	-	-	-	-
22	74.6	-	-	-
23	49.7	2.83 (1H, obscured)	19, 24a, 24b	
24a	33.6	2.65 (1H, m)	23, 24b, 26	
24b		3.09 (1H, dd, J = 15.8, 9.3 Hz)	23, 24a, 26	
25	132.7	-	-	-
26	108.2	7.18 (1H, s)	16, 24a, 24b	25
27	n.o.	-	-	-
28	14.6	1.04 (3H, s)		2, 3, 4, 12
29	19.5	1.14 (3H, s)		3, 4, 5, 9
30	16.7	0.88 (3H, s)		7, 8, 9, 1"
31	30.4	1.31 (3H, s)		19, 20, 32
32	32.1	1.26 (3H, s)		19, 20, 31
33	30.0	1.27 (3H, s)		22, 23, 34
34	22.2	1.05 (3H, s)		22, 23, 33
1"a	45.5	1.49 (1H, m)	1"b, 2"	
1"b		1.89 (1H, m)	1"a, 2"	
2"	65.3	4.77 (1H, td, J = 8.4, 4.6 Hz)	1"a, 1"b, 3"	
3"	145.8	6.75 (1H, d, J = 8.8 Hz)	2", 6"	
4"	126.6	-	-	-
5"	169.4	-	-	-
6"	12.5	1.89 (3H, s)	3", 2"	3", 4", 5"


n.o. = signal not observed or obscured. \*Signals obtained from HSQC and HMBC experiments

## SUPPORTING INFORMATION

Isolation of NAD<sub>5</sub>

Mycelia from an NAD<sub>5</sub> producing strain (208 g wet weight) was extracted with EtOAc (500 mL approx.) overnight filtered and extracted for a second time overnight. The extracts were combined, and solvent removed in vacuo to give a brown-yellow oil (1.05 g) which was dissolved in CHCl<sub>3</sub> and fractionated using flash chromatography. Fractions containing NAD<sub>5</sub> were identified by TLC and LC-MS and combined (67 mg). Preparative HPLC (column#1, 85–100% B over 20 min, 5 mL/min) was used to purify NAD<sub>5</sub> which was freeze dried to give a white powder (<0.1 mg).

NMR data see Table S15; HR-ESI-MS see Table S3.

NAD<sub>5</sub>


## SUPPORTING INFORMATION

**Table S15:** NMR Data for NAD<sub>5</sub>, (CD<sub>3</sub>)<sub>2</sub>CO


Position	<sup>13</sup> C*	<sup>1</sup> H	COSY**	HMBC
1 (N)	-	9.82 (1H, s)		
2	151.9	-	-	-
3	53.3	-	-	-
4	39.6	-	-	-
5a	33.2	2.11 (1H, m)	5b, 6a, 6b	
5b		2.25 (1H, dd, J = 15.0, 6.8 Hz)	5a, 6a, 6b	
6a	n.o.	2.47 (1H, ddd, J = 16.4, 6.8, 3.3 Hz)	5a, 5b, 6b	
6b		2.67 (1H, m)	5a, 5b, 6a	
7	214.9	-	-	-
8	51.8	-	-	-
9	43.0	n.o.	-	-
10	n.o.	n.o.	-	-
11	n.o.	n.o.	-	-
12	49.7	2.85 (obscured)	13a, 13b	
13a	n.o.	2.70 (1H, dd, J = 13.2, 6.0 Hz)	13b, 12	
13b		2.35 (1H, dd, J = 13.2, 10.7 Hz)	13a, 12	
14	n.o.	-	-	-
15	n.o.	-	-	-
16	109.9	7.45 (1H, s)		
17	n.o.	-	-	-
18	n.o.	-	-	-
19	119.4	5.99 (1H, d, J = 3 Hz)	23	
20	72.9	-	-	-
21 (O)	-	-	-	-
22	74.6	-	-	-
23	49.5	2.81 (obscured)	19, 24a, 24b	
24a	n.o.	2.66 (1H, dd, J = 16.0, 7.5 Hz)	23, 24b	
24b		3.09 (1H, dd, J = 16.0, 9.6 Hz)	23, 24a	
25	n.o.	-	-	-
26	108.2	7.18 (1H, s)		
27	n.o.	-	-	-
28	14.7	1.07 (3H, s)		2, 3, 4, 12
29	17.7	1.25 (3H, s)		3, 4, 5, 9
30	21.2	1.07 (3H, s)		7, 8, 9, 1"
31	30.3	1.31 (3H, s)		19, 20, 32
32	32.1	1.26 (3H, s)		19, 20, 31
33	30.1	1.27 (3H, s)		22, 23, 34
34	22.2	1.05 (3H, s)		22, 23, 34
1"a	38.0	1.87 (1H, m)	1"b, 2"	
1"b		1.51 (1H, m)	1"a, 2"	
2"	n.o.	2.05 (2H, obscured)	1"a, 1"b, 3"	
3"	142.7	6.76 (1H, td, J = 7.6, 1.7 Hz)	2", 6"	
4"	128.6	-	-	-
5"	169.4	-	-	-
6"	12.3	1.81 (3H, d, J = 1.7 Hz)	3"	3", 4", 5"

n.o. = signal not observed or obscured. \*Signals obtained from HSQC and HMBC experiments

\*\*Some correlations confirmed using selective 1D TOCSY (mixing time 50 ms)

**NMR Spectra****NAD NMR Spectra****Figure S2.**  $^1\text{H}$  NMR spectrum of NAD

## SUPPORTING INFORMATION

**Figure S3.** HSQC Spectrum of NAD



## SUPPORTING INFORMATION







Figure S4. COSY Spectrum of NAD

## SUPPORTING INFORMATION

**Figure S5.** HMBC Spectrum of NAD


## SUPPORTING INFORMATION

NAD<sub>1</sub> NMR Spectra**Figure S6.** <sup>1</sup>H NMR Spectrum of NAD<sub>1</sub>




**Figure S7.**  $^{13}\text{C}$  NMR Spectrum of  $\text{NAD}_1$


## SUPPORTING INFORMATION

**Figure S8.** COSY Spectrum of NAD<sub>1</sub>


## SUPPORTING INFORMATION

Figure S9. HSQC Spectrum of NAD<sub>1</sub>

## SUPPORTING INFORMATION

**Figure S10.** HMBC Spectrum of NAD<sub>1</sub>

## SUPPORTING INFORMATION

NAD<sub>4</sub> NMR SpectraFigure S11. <sup>1</sup>H NMR Spectrum of NAD<sub>4</sub>



## SUPPORTING INFORMATION





Figure S12.  $^{13}\text{C}$  NMR Spectrum of  $\text{NAD}_4$

## SUPPORTING INFORMATION

**Figure S13.** COSY Spectrum of NAD<sub>4</sub>




Figure S14. HSQC Spectrum of NAD<sub>4</sub>






Figure S15. HMBC Spectrum of NAD<sub>4</sub>




**Figure S16.** NOESY (mixing time = 0.5 s) NMR Spectrum of NAD<sub>4</sub>

## SUPPORTING INFORMATION

NAD<sub>4</sub>-OMe NMR SpectraFigure S17. <sup>1</sup>H NMR Spectrum of NAD<sub>4</sub>-OMe

## SUPPORTING INFORMATION

**Figure S18.**  $^{13}\text{C}$  NMR Spectrum of NAD<sub>4</sub>-OMe





Figure S19. COSY Spectrum of NAD<sub>4</sub>-OMe



**Figure S20.** HSQC Spectrum of NAD<sub>4</sub>-OMe






Figure S21. HMBC Spectrum of NAD<sub>4</sub>-OMe


## SUPPORTING INFORMATION

NAD<sub>2</sub> NMR Spectra**Figure S22.** <sup>1</sup>H NMR Spectrum of NAD<sub>2</sub>


## SUPPORTING INFORMATION

**Figure S23.** HSQC Spectrum of NAD<sub>2</sub>


## SUPPORTING INFORMATION

**Figure S24.** COSY Spectrum of NAD<sub>2</sub>

## SUPPORTING INFORMATION


**Figure S25.** HMBC Spectrum of NAD<sub>2</sub>




**Figure S27.** COSY Spectrum of NAC




## SUPPORTING INFORMATION

**Figure S28.** HSQC Spectrum of NAC


## SUPPORTING INFORMATION

**Figure S29.** HMBC Spectrum of NAC


## SUPPORTING INFORMATION

DH-NAC<sub>4</sub> NMR Spectra**Figure S30.** <sup>1</sup>H NMR Spectrum of DH-NAC<sub>4</sub>


## SUPPORTING INFORMATION

**Figure S31.** COSY Spectrum of DH-NAC<sub>4</sub>

## SUPPORTING INFORMATION


**Figure S32.** HSQC Spectrum of DH-NAC<sub>4</sub>

## SUPPORTING INFORMATION



**Figure S33.** HMBC Spectrum of DH-NAC<sub>4</sub>

## SUPPORTING INFORMATION

NAB<sub>4</sub> NMR Spectra**Figure S34.** <sup>1</sup>H NMR Spectrum of NAB<sub>4</sub>

## SUPPORTING INFORMATION






Figure S35. COSY NMR Spectrum of NAB<sub>4</sub>




## SUPPORTING INFORMATION

**Figure S36.** COSY NMR Spectrum of NAB<sub>4</sub>


## SUPPORTING INFORMATION

DH-NAA<sub>4</sub> NMR Spectra**Figure S37.** <sup>1</sup>H NMR Spectrum of DH-NAA<sub>4</sub>

## SUPPORTING INFORMATION


**Figure S38.** COSY Spectrum of DH-NAA<sub>4</sub>

## SUPPORTING INFORMATION




**Figure S39.** HSQC Spectrum of DH-NAA<sub>4</sub>


## SUPPORTING INFORMATION




**Figure S40.** HMBC Spectrum of DH-NAA<sub>4</sub>

## SUPPORTING INFORMATION

NAA<sub>1</sub> NMR Spectra**Figure S41.** <sup>1</sup>H NMR spectrum of NAA<sub>1</sub>




**Figure S42.**  $^{13}\text{C}$  NMR spectrum of NAA<sub>1</sub>



**Figure S43.** COSY spectrum of NAA<sub>1</sub>





**Figure S44.** HSQC Spectrum of NAA<sub>1</sub>






Figure S45. HMBC Spectrum of NAA<sub>1</sub>


## SUPPORTING INFORMATION

## NAB NMR Spectra


**Figure S46.**  $^1\text{H}$  NMR Spectrum of NAB

**Figure S47.** COSY Spectrum of NAB

## SUPPORTING INFORMATION

**Figure S48.** HSQC Spectrum of NAB

## SUPPORTING INFORMATION

**Figure S49.** HMBC Spectrum of NAB

## SUPPORTING INFORMATION


NAD<sub>6</sub> NMR Spectra

Figure S50. <sup>1</sup>H NMR Spectrum of NAD<sub>6</sub>





Figure S51. COSY Spectrum of NAD<sub>6</sub>



## SUPPORTING INFORMATION

**Figure S52.** HSQC Spectrum of NAD<sub>6</sub>

## SUPPORTING INFORMATION





Figure S53. HMBC Spectrum of NAD<sub>6</sub>

## SUPPORTING INFORMATION

NAD<sub>5</sub> NMR Spectra**Figure S54.** <sup>1</sup>H NMR Spectrum of NAD<sub>5</sub>






Figure S55. COSY Spectrum of NAD<sub>5</sub>

## SUPPORTING INFORMATION

**Figure S56.** HSQC Spectrum of NAD<sub>5</sub>

## SUPPORTING INFORMATION

**Figure S57.** HMBC Spectrum of NAD<sub>5</sub>

## SUPPORTING INFORMATION

**In Vivo Feeding Studies**

To determine whether NAD<sub>5</sub> and NAD<sub>6</sub> were substrates for NodJ, and consequently whether they are precursors for the main and 1-series, *in vivo* feeding studies were undertaken. To conduct these experiments *nodJ* was added to the CY2 strain of *P. paxilli*, in which the entire paxilline biosynthetic gene cluster has been deleted, and the CY2 strain without *nodJ* was used as a control.

Fungi were grown using standard conditions (Pg 5) and nodulisporic acid substrates were provided to the culture on days 0 and 4 as MeOH aliquots (100  $\mu$ L, 1–2 mg/mL substrate). The substrates included NAD<sub>4</sub>, NAD<sub>5</sub>, NAD<sub>6</sub> and a MeOH blank as a control (Table S16). Cultures were harvested after 10 days and mycelia were extracted and analysed following standard procedures (Pg 5).

**Table S16.** NodJ *in vivo* feeding studies

Experiment*	Strain	Substrate provided
A	CY2	MeOH (control)
B	LS29 (CY2 + <i>nodJ</i> )	MeOH (control)
C	CY2	NAD <sub>4</sub>
D	LS29 (CY2 + <i>nodJ</i> )	NAD <sub>4</sub>
E	CY2	NAD <sub>6</sub>
F	LS29 (CY2 + <i>nodJ</i> )	NAD <sub>6</sub>
G	CY2	NAD <sub>5/1</sub> **
H	LS29 (CY2 + <i>nodJ</i> )	NAD <sub>5/1</sub> **

\*All experiments were conducted in triplicate


\*\*Insufficient NAD<sub>5</sub> was available to conduct the experiment therefore a sample containing both NAD<sub>1</sub> and NAD<sub>5</sub> was used.

Analysis of experiments A and B did not show the presence of any nodulisporic acids (Figure S58) and culture growth appeared unaffected by addition of MeOH aliquots. Mycelia from experiment C showed the presence of the substrate, NAD<sub>4</sub>, but no other nodulisporic acids, confirming CY2 does not contain proteins capable of producing additional nodulisporic acids. Experiment D produced NAD, NAD<sub>1</sub>, NAD<sub>5</sub>, and NAD<sub>6</sub>, which are the expected products of NodJ when provided with NAD<sub>4</sub> as seen in heterologous reconstruction of the biosynthetic pathway (Figure S58). This result confirms both the expression of *nodJ* in this strain and its ability to access substrate provided via spiking the culture.

Singh *et al* predicted that NAD was formed via an enzyme catalysed elimination of 2"-OH from NAD<sub>6</sub>, therefore experiments E and F were conducted to test this hypothesis.<sup>[3a]</sup> However, when NAD<sub>6</sub> was provided as a substrate NAD was not detected (Figure S58), indicating an alternative explanation for the production of main series nodulisporic acids was required. We propose that hydrogen abstraction at C-2" of NAD<sub>4</sub> gives an allylic radical intermediate which partitions either to NAD through the loss of hydrogen or to NAD<sub>6</sub> through reaction with an iron-bound hydroxyl radical (Scheme 2, Manuscript). Such bifurcation of a radical intermediate has been reported for other P450 oxidases and is consistent with the experimental data obtained through feeding studies.<sup>[5]</sup> NAD<sub>1</sub> was also not detected in these experiments confirming the inability of NAD<sub>6</sub> to be utilised as a substrate by NodJ to produce any other nodulisporic acids and therefore the 6-series is a shunt pathway.

The final two experiments were conducted to establish whether NAD<sub>5</sub> was a substrate for NodJ and therefore a precursor for NAD<sub>1</sub>. Since insufficient NAD<sub>5</sub> could be purified for feeding studies a sample containing both NAD<sub>5</sub> and NAD<sub>1</sub> was used as the substrate. When this substrate was provided to CY2 in experiment G the ratio of NAD<sub>5</sub> to NAD<sub>1</sub> remained unchanged after the 10 days in culture (Figure S59). However, with NodJ present (experiment H) the NAD<sub>5</sub> decreased and NAD<sub>1</sub> increased. This result provides evidence to suggest that NAD<sub>5</sub> can be converted to NAD<sub>1</sub> by NodJ and is therefore an intermediate and not a shunt product. Interestingly no evidence for production of NAD<sub>3</sub>, a metabolite characterised by Merck, was observed in this experiment despite the obvious biosynthetic relationship to NAD<sub>5</sub>.<sup>[3a]</sup>

## SUPPORTING INFORMATION




**Figure S58.** LC-MS analysis of in vivo feeding studies.

LC-MS analysis of in vivo feeding studies leading to the assignment of NAD<sub>6</sub> as a shunt product and NAD<sub>5</sub> as a precursor for NAD<sub>1</sub>. Traces are EICs of HR-ESI-MS2 analysis and letter codes refer to experiment details in Table S16. \*Since NAD and NAD<sub>5</sub> are isomeric a single trace has been provided and NAD peaks distinguished by an asterix (\*).



## SUPPORTING INFORMATION



**Figure S59.** NAD<sub>5/1</sub> feeding study

Analysis of NAD<sub>1</sub> and NAD<sub>5</sub>, and comparison to substrate, in experiments G and H (-1, -2, -3 refer to replicate cultures). Result presented as relative (left) and absolute (right) values.

### Non-enzymatic NAD<sub>6</sub> elimination

To determine whether elimination of the 2''-OH of NAD<sub>6</sub> could proceed non-enzymatically a sample of NAD<sub>6</sub> was treated with formic acid and analysed by LC-MS over a period of 12 h. No evidence of NAD production was observed over this time and higher concentrations of acid led to degradation of the metabolite.

## SUPPORTING INFORMATION

## Proposed NodJ P450 Monooxygenase Bifurcation Mechanism




Figure S60. Proposed mechanism for NodJ

Top – Proposed mechanism for NodJ in the bifurcation of nodulisporic acid biosynthesis to produce both NAD and NAD<sub>6</sub> via oxidation at C-2".

Bottom – NodJ mechanism in the context of the cytochrome P450 catalytic cycle.



## SUPPORTING INFORMATION

## Nodulisporic Acid Biosynthesis Scheme




Figure S62. Nodulisporic acid biosynthesis

## Author Contributions

Research was conducted in equal parts by lead authors Dr. A. T. Richardson, Dr. R. C. Cameron, and Dr L. J. Stevenson with assistance and contributions from supporting authors Dr A. J. Singh, Dr Y. Lukito, Dr D. Berry and Dr M. J. Nicholson. Prof E. J. Parker and Dr M. J. Nicholson conceived the study and were responsible for funding acquisition, project oversight and administration, and assisted with preparation of the manuscript.

## References

- [1] C. J. van Dolleweerd, S. A. Kessans, K. C. Van de Bittner, L. Y. Bustamante, R. Bundela, B. Scott, M. J. Nicholson, E. J. Parker, *ACS Synth. Biol.* **2018**, *7*, 1018-1029.
- [2] K. C. Van de Bittner, M. J. Nicholson, L. Y. Bustamante, S. A. Kessans, A. Ram, C. J. van Dolleweerd, B. Scott, E. J. Parker, *J. Am. Chem. Soc.* **2018**, *140*, 582-585.
- [3] a) S. B. Singh, J. G. Ondeyka, H. Jayasuriya, D. L. Zink, S. N. Ha, A. Dahl-Roshak, J. Greene, J. A. Kim, M. M. Smith, W. Shoop, J. S. Tkacz, *J. Nat. Prod.* **2004**, *67*, 1496-1506; b) J. G. Ondeyka, K. Byrne, D. Vesey, D. L. Zink, W. L. Shoop, M. A. Goetz, S. B. Singh, *J. Nat. Prod.* **2003**, *66*, 121-124; c) J. G. Ondeyka, A. M. Dahl-Roshak, J. S. Tkacz, D. L. Zink, M. Zakson-Aiken, W. L. Shoop, M. A. Goetz, S. B. Singh, *Bioorganic Med. Chem. Lett.* **2002**, *12*, 2941-2944; d) O. D. Hensens, J. G. Ondeyka, A. W. Dombrowski, D. A. Ostlind, D. L. Zink, *Tetrahedron Lett.* **1999**, *40*, 5455-5458; e) J. G. Ondeyka, G. L. Helms, O. D. Hensens, M. A. Goetz, D. L. Zink, A. Tspouras, W. L. Shoop, L. Slayton, A. W. Dombrowski, J. D. Polishook, D. A. Ostlind, N. N. Tsou, R. G. Ball, S. B. Singh, *J. Am. Chem. Soc.* **1997**, *119*, 8809-8816.
- [4] Y. Zou, X. Li, Y. Yang, S. Berritt, J. Melvin, S. Gonzales, M. Spafford, A. B. Smith, *J. Am. Chem. Soc.* **2018**, *140*, 9502-9511.
- [5] a) F. P. Guengerich, *ACS Catal.* **2018**, *8*, 10964-10976; b) F. P. Guengerich, *Chem. Res. Toxicol.* **2001**, *14*, 611-650; c) A. E. Rettie, A. W. Rettenmeier, W. N. Howald, T. A. Baillie, *Science* **1987**, *235*, 890-893.
- [6] T. Hackmann, *Prot. Sci.* **2022**, *31*, 864-881.
- [7] a) A. Stamatakis, *Bionformatics* **2014**, *30*, 1312-1313; b) F. Sievers, A. Wilm, D. Dineen, *Mol. Syst. Biol.* **2011**, *7*, 539.